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ABSTRACT
Activities associated with, or interacting with, leukaemic cell
populations were assayed for the ability to influence in vitro
haematopoiesis.
The first of these, the glycoprotein leukaemia inhibitory factor 
(LIF), has a role in aspects of murine, non human primate and 
human haematopoiesis. It is thought to be particularly 
important in the development of megakaryocytes and is also 
known to induce the terminal differentiation of certain 
leukaemic cell lines.
LIF was assayed both for direct and indirect effects on the 
proliferation of haematopoietic precursor cell populations i n 
vitro. As a direct acting agent in semi-solid agar culture of 
haematopoietic cell populations derived from normal bone 
marrow or 15 day foetal liver, LIF was unable to support 
colony formation. In cultures of cells derived from normal bone 
marrow stimulated with single, or combinations of, growth 
factors, the addition of LIF had no statistically significant effect 
on the level of colony formation. In cultures of cells derived 
from foetal liver, stimulated with particular growth factor 
combinations (medium conditioned by the Wehi3B leukaemic 
cell line + medium conditioned by the lung fibroblast cell line, 
L929); GM-CSF + M-CSF; IL-la 4- IL-3 + M-CSF), LIF, was shown 
to decrease the level of colony formation.
LIF did not directly alter the proportion of the population in 
DNA synthesis in cell populations derived from normal femoral 
marrow, 15 day foetal liver or y- irradiated femoral marrow.
Abstract
As an indirect acting agent LIF failed to block the synthesis of a 
stem cell stimulator, or it's action, on a population of high 
proliferative potential colony forming cells derived from
normal femoral marrow, cloned in the presence of 
Wehicm+L929cm. (HPP-CFC (Wehicm + L929cm))
LIF's actions on clones of a murine myeloid leukaemia 
(SA2JMB1) were also assessed. LIF had no statistically 
significant effect on colony formation or the level of DNA 
synthesis in populations of SA2JMB1 leukaemic cells.
A second group of associated activities was produced by the X- 
irradiation induced murine myeloid leukaemia (SA2JMB1). 
Medium conditioned by the leukaemic cells was assayed i n 
vitro both for direct and indirect effects on the proliferation of 
haematopoietic cells derived from femoral marrow.
As a direct acting agent in 7 and 14-day semi-solid agar 
culture of femoral marrow, leukaemic conditioned medium 
alone stimulated limited colony formation. In 7 and 14 day 
cultures stimulated with single and combinations of specific 
colony stimulating factors: (rmGM-CSF, rhM-CSF, rhIL-la) a 
significant increase in colony number was noted in all cases 
when cultures were supplemented with leukaemic conditioned 
medium.
SA2JMBlcm was shown to support the proliferation of an IL-3 
dependent cell line (FDCP-A4 cells). The colony enhancing 
ability of SA2JMBlcm was shown to be blocked by pre­
treatment with antibodies to IL-3. This suggested that 
SA2JMB1 conditioned medium contained IL-3 or an IL-3 like
activity, as one of its components.
Abstract
Tte encOiiinceO meOium fsileO lo Otgefilc slleg lte level of 
DNA iccitesis ic s oooulhiioc of HPP-CFC (Wetifm+L929fm) 
OegtveO fgom cogmsl boce mhggnw og y- igghOthieO boce
mhggnw.
As sc icOigefl hfiica haeci lte eocOiiiocgO meOium OiO blofa 
lte hfiioc of s slem fell ognlifeghiioc siimulhing oc cogmsl 
boce msggow OegiveO HPP-CFC (Wettem+L929fm).
Ttis leuahemih hSsnfihieO heiiviic wss stowc lo be lsgaeg ltsc 
50KD, secsilive lo tesl igehimeci scO sble lo sfl ic s Oiffegecl 
mscceg lo lte slem fell ictibting MIF-l-s.
Ttus ltis covel hfiiviiy msy be tmongihci ic blofaico 
siimulhing hfiioc ic themhinooieite slem fells scO ltus 
fncigtbuie lo lte themhinonieiif icsuffifiecfy sem ic
lruaarmts.
CHAPTER 1: Introduction
1.1 Haematopoiesis
1.1.1 General
The process of haematopoiesis, or blood cell formation, has to 
be continuous throughout the life-span of an individual-most 
blood cells have a limited life-span, from hours (neutrophilic 
granulocytes) to upwards of one hundred days (erythrocytes), 
thus they need to lee consaanlly replenished . The symtem thus 
must be able to produce an output, but at the same time, 
maintain the cellular integrity necessary to generate that 
output. It must be spccifi c eet daaptable, taat it: ii muss be 
able to pprc^duu^^ a given quantity of each of the eight types of 
blood cell but at the same time be able to selectively alter the 
level of production with demand. 1991; Metcalf, 1992;
Ogawa, 1993; Ogawa, 1994). When we condeler ahat the 
average daily turnover of blood cells in a 70kg man is thought 
to be approximately 1 trilllon (Ogawa, 1999), hhe need for 
precise regulation within this system becomes obvious.
The first pare of hlise sheliy wlH aake a brife ooeeview of 
haematopoiesii looking at the dlCCerret categories of 
haematopoietic cells. It will examine the assays used to study 
them and the manner in which early haematopoietic cells are 
regulated, with particular reference to inhibitory activities. The 
second part focuses on factors associated with leukaemic cell 
populations, examining their actions on various aspects of in
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vitro haematopoiesis. The first of these is the haematopoietic 
growth factor: Leukaemia inhibitory factor. The second, an 
unknown activity(ies) produced by a cloned leukaemic cell line.
1.1.2 The haematopoietic tissues
These tissues are essentially haematopoietic factories in which 
blood cells are formed, undergo differentiation and maturation 
before migrating into the circulation, and, in some cases, on into 
other tissues (Ogawa, 1994). The tissue is made up of cells at 
progressive levels of differentiation, the organisation of which 
is not completely random, (Schofield et al 1979; Spangrude et 
al 1991; Trentin, 1970 ), but equally is not neatly arranged into 
anatomical compartments in the way of dynamic systems such 
as the skin or intestinal wall. It has thus been with the 
development of techniques such as the purification of growth 
factors (Review Nicola, 1989; Arai et al ,1990; St Georgiev and 
Albright, 1993), in vitro clonogenic assays (Review Testa and 
Molineux, 1993), recognition of specific cell surface markers 
(Review Moore, 1991) and cell sorting (Review Lord and Marsh, 
1993; Visser and Bekkum, 1990) that a picture of 
haematopoietic tissue as three sequential yet continuous cell 
compartments has emerged (Tubiana et al, 1993).
The first compartment ,the most primitive, consists of 
pluripotent quiescent stem cells (Lajtha et al, 1969 ). In 
normal steady state haematopoiesis the size of the stem cell 
pool is maintained by a balance between self-renewal and 
differentiation. The next compartment consists of so called
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committed progenitor cells. These are restricted to 
development along one or more lineages and respond to a 
range of regulators known as cytokines. The stem cell 
compartment is essentially a continuum of cells whose 
maturation is characterised by decreasing pluripotency and an 
increased likelihood of proliferation. These feed into the 
progenitor cell compartment where proliferation and 
amplification occurs. Derived from these is the third 
compartment, the end cell compartment, made up of cells 
which have differentiated along a given lineage and have lost 
their capacity for proliferation. (Lajtha, 1979; Dexter, 1987;
Brown et al, 1985) .(Diagram 1)
NORMAL BLOOD CELL FORMATION (Haematopoiesis)
STEM CELLS PROGENITOR CELLS FUNCTIONAL END CELLS
-The majority -Transitional cell type. -Red and white blood cells 
are quiescent
bathed in a stem
cell inhibitor.
This is the case in normal healthy individuals
DIAGRAM 1 SCHEMATIC APPRECIATION OF NORMAL
BLOOD CELL FORMATION
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The nature of the progression of a daughter stem cell from a 
point of maximal self-renewal and pluripotency towards 
commitment to a particular cell lineage may occur randomly 
(stochastic) (Ogawa , 1983), may be rigidly determined (Nicola 
and Johnson, 1982) or might be influenced by growth factor 
and micro-environmental cues (Trentin, 1970).
This is an idealised but helpful picture of the balance that 
exists in normal haematopoiesis. Should the system be 
perturbed the level of proliferation within compartments one 
and two can alter by a series of subtle cellular and humoral 
regulatory cues to accommodate increased needs. (Moore, 1991; 
Ogawa, 1993; Ogawa, 1994; Ali et al, 1989; Dawood et al, 1990; 
Robinson and Riches, 1991) (Diagram 2)
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HAEMATOPOIESIS AFTER STRESS TO THE SYSTEM
STEM CELLS 
-More of these 
come into cycle
switched on by
a stem cell 
stimulator .
PROGENITOR CELLS 
-Get greater numbers 
of this transitional 
cell type.
FUNCTIONAL END CELLS 
-The result is greater 
numbers of these end 
cells thus replenishing 
the system.
DIAGRAM 2 BLOOD CELL FORMATION IN INDIVIDUALS SUFFERING 
LONG-TERM ILLNESS OR RECOVERING FROM HAEMATOPOIETIC 
STRESS (mild irradiation or chemotoxicity.)
1.1.3 Studying Haematopoiesis-Assaying Stem
cells and progenitor cells
Stem cells are few in number and difficult to distinguish 
morphologically. The ultimate definition of a stem cell is "that 
cell in a tissue which under normal circumstances, maintains its 
own population-, undiminished in function and size, and 
furnishes daughters to provide new functionaL-cells of that 
tissue ." (Schofield, 1983) These can only be truly identified by 
their ability to reconstitute all blood cells (both myeloid and 
lymphoid) in irradiated animals .
1.1.3.1 The spleen col^^^ny assay-(CFU-S)
Introduction £
In 1961 Till and McCulloch (in work fundamental to the study 
of haematopoiesis) demonstrated that mouse haematopoietic 
tissues contained cells (colony forming unit-spleen (CFU-S)) at a 
frequency of about 1 in 104 cells which when injected into a 
lethally irradiated syngeneic recipient could give rise to splenic 
colonies of haematopoietic cells. Each colony was composed of 
multiple end-cell lineages as well as cells capable of generating 
more spleen colonies when injected into new recipients. Thus 
CFU-S not only showed multi-potency and an ability for 
extensive proliferation but also an ability to self-renew. 
(Siminovitch et al 1963; Becker et al, 1963; Vogel et al, 1968; 
Schofield et al, 1980 ). With the observation that some colonies 
were transient it became clear that the CFU-S was a 
heterogenous age-structured cell compartment. The so called 
early CFU-S (day 7-10) (CFU-SII) were apparently more 
mature progenitor cells and gave rise to colonies containing 
cells of mainly one lineage with little or no ability to self­
renew. Late CFU-S(day 12) (CFU-S I) appeared to be more 
primitive, giving rise to colonies containing cells of more than 
the one lineage along with cells which showed a self-renewal 
ability in secondary assays. (Worten et al, 1969; Schofield and 
Lajtha, 1973; Morley and Blake, 1974; Morley et al, 1975; Magli 
et al, 1982; Johnston and Nicola, 1984). The nature of the 
ageing associated with the CFU-S heterogeneity was explained 
in the Niche hypothesis (Schofield, 1978; Schofield, 1983). This 
hypothesis not only addressed many of the anomalies 
associated with CFU-S ageing but also importantly proposed
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that they were not totipotent haematopoietic stem cells. In 
essence it states that the CFU-S can be thought of as part of a 
stem cell pool, internally heterogeneous, hierarchically 
arranged according to self-renewal ability. At the head of this 
pool is a stem cell whose defining characteristic is it's 
totipotency and its ability for maximum self-renewal.
This notion is confirmed by various lines of evidence including 
the lack of lymphoid cells found in CFU-S colonies (Paige et al, 
1979), the emergence of a pre-CFU-S (Hodgson and Bradley, 
1979) and the ability of cells not forming spleen colonies to 
facilitate long term marrow re-population. (Ploechmacher et al, 
1989; Bertoncello et al 1992). The Pre-CFU-S population is 
thought to be that population from which CFU-S are derived. 
They are also thought to be the cells responsible for recovery 
of the haematopoietic system following X-irradiation, this 
property being referred to as a radio protective ability (RPA). 
In fractionation studies of haematopoietic tissue, a cell 
population consisting of populations of day 12 CFU-S and pre- 
CFU-S could be separated from other cells by virtue of their 
wheat germ agglutinin f fluorscien isothiocyanate binding. The 
injection of 80 of these enriched cells, per animal, to a group of 
lethally irradiated mice resulted in. 50% survival. 104 whole 
bone marrow cells would be required in injection to attain the 
same result (Ploechmacher and Brons, 1989 ). RH123 is a vital 
dye which was initially thought to stain mitochondria 
preferentially and therefore be a marker for metabollicaly 
active cells. However it has been shown that low levels of
RH123 staining of human haematopoietic progenitor cells may
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be the result of the expression of P-glycoprotein which confers 
the multidrug resistance phenotype. Although the mechanism 
of low level RH123 staining in these cells is not known it is 
apparent that RH123 permits separation of the primitive cell 
population into two subsets: RH123high and RH1231ow 
(Fleming, 1993). Fractionation of this cell population along 
these lines yields two fractions: RH1231ow with a high preCFU- 
S/low CFU-S 12 content and RH123high with a higher CFU-S 
12/low pre-CFU-S content. It is the RH1231ow fraction which is 
responsible for the recovery seen in these animals. Other 
separation techniques provide similar evidence for the 
existence of a pre-CFU-S population. (Bertoncello et al 1992; 
Wright and Pragnell, 1992)
The work on CFU-S should not be dismissed however, it was 
fundamental in establishing a picture of a stem cell pool, a 
possible hierarchy and ultimately still represents a valuable in 
vivo tool for examining early haematopoietic cells.
1.1.3.2 In vitro Colony Assays
In vitro colony assays of progenitor cells (colony forming cells) 
able to proliferate, differentiate and mature in semi-solid agar 
culture were first reported by Pluznik and Sachs (1965) and 
Bradley and Metcalf (1966). Initially only cells of the 
granulocyte and macrophage lineage were seen. The cells 
giving rise to these were termed granulocyte-macrophage 
colony forming cells (GM-CFC) In later work colonies with 
granulocutes, erythrocytes, eosinophils, macrophages and
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megakaryocytes (GEMM-CFC/MIX-CFC) were demonstrated. 
(Johnston and Metcalf, 1977; Fuasser and Messner, 1978; 
Metcalf, 1988). Stimulation of colony formation in these assays 
was produced by media conditioned by the growth of another 
tissue. As the factors responsible for this stimulation were 
identified an explosion in in vitro colony assays took place.
Colony stimulating factors-a class of
haematopoietic growth factor
Haematopoietic growth factors are a gro up of acidic 
glycoproteins (collectively known as cytokines ) which play a 
crucial role in the survival and development of haematopoietic 
cells through interaction with specific receptors on target cells. 
(Kaushansky and Karplus, 1999 ) . Originally known as the 
colony stimulating factors, to date at least 20 factors ( each 
encoded by it's own unique gene ) with proliferative effects on 
haematopoietic cell populations have been produced in 
recombinant form. (Moore, 1991; Metcalf, 1992; Metcalf, 1993; 
Adamson, 1993). Although they show little amino acid 
sequence homology structurally they have a similar molecular 
weight of 13-21KD (this can vary however due to high 
glycosylatim variabililyy adopting a four helix bundle tertiary 
fold structure. Most exist as monomers (IL-la and (3, IL-3 ,LIF) 
although there are dimers (IL-8) and trimers TNF a and p. 
Several cytokines exist both as soluble and membrane bound 
forms which may reflect the paracrine and autocrine nature of 
their actions. They are also often highly conserved between
Introduction
species (Nicola, 1989; Bazan, 1990 ). They interact with specific 
high affinity receptors which may exist as more than the one 
sub-unit and exhibit homology in their extracellular domains. 
(Hirano et al, 1994; Gearing , 1993) Frequently there appears to 
be co-evolution of cytokines and receptors in more than the 
one system. (Bazan, 1991; Yamamori and Sarai, 1992).
Curiously cytokines can show different activities (they are 
plieotropic) on cells of different lineages or on cells of the same 
lineage at different points in maturation, with expression of 
relevant receptors on both cell types (Nicola, 1989). This is 
compounded by the fact that many of the cytokines appear to 
have overlapping functions, a phenomenon known as 
redundancy. (Metcalf, 1992; Metcalf, 1993; Chiarugi et al, 
1993). In essence the principle of redundancy refers to the fact 
that there appear to be more regulators with similar or 
overlapping functions than would seem necessary to achieve 
cell proliferation (Metcalf, 1993). In support of this observation 
are several strands of evidence including: common proliferative 
actions; common biological actions; shared receptor sub-units 
and co-expression of receptors on the same cell type. (Metcalf 
1992, Metcalf 1993). Careful interpretation of this evidence, 
however, suggests that the relationship between these factors 
may be more complicated than it first appears. An insight into 
the potentially subtle relationship that exists between factors 
comes from studies using gene knockout mice. In these mice 
genes for haematopoietic regulators known to share functions 
with other cytokines can be deleted, and the effects of this 
deletion studied. Results show that such deletions result in
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mice unable to develop normally. (Escary et al, 1993; Metcalf, 
1993; Dumenil et al, 1993). This suggests that although, in 
vitro, many cytokines may appear identical in terms of 
function, in the finely balanced in vivo environment they may 
have a role which is far more subtle than previously noted. 
This principle has been termed growth factor " subtlety". The 
principle of subtlety is further substantiated by the 
observation that growth factors "synergise". That is: growth 
factors able to stimulate a proliferative response in a cell 
population are able to stimulate a more than additive response 
when used together. The fact that such a response is more than 
merely the sum of the parts strongly suggests that there is 
some subtle interplay between growth factors. In later 
discussions on LIF the phenomena of redundancy and subtlety 
are considered more fully.
For the purposes of this introduction it is sufficient to 
appreciate that the use of growth factors in assays has made 
comprehensive in vitro studies of progenitor and more 
primitive haematopoietic cells possible.
Several reviews of haematopoietic growth factors are available 
(Nicola, 1989; Arai et al, 1990; Devalia and Linch, 1991).
Introduction 12
Colony Forming Cells with differing proliferative 
potentials.
Low proliferative potential colony forming cells 
(LPP-CFC)
Several of the cytokines which have been molecula^y cloned 
and purified to homogeneity (e.g GM-CSF, G-CSF, M-CSF (CSF-1), 
lL-3 (MULTI-CSF), EPO ) have direct stimulatory effects on 
colony forming progenitor cells with a limited lineage 
developmental potential and a low proliferative potential. 
These are low proliferative potential colony forming ceUs (LPP- 
CFC) e.g GM-CFC/MIX-CFC. (Metcalf, 1989)
However, more cytokines have emerged, in particular several 
of the interleukins (Heyworth et al, 1990; Moore, 1991) which 
acting alone have only a very limited effect on progenitor cells 
but in association with other factors exert a synergistic 
stimulatory effect on the proliferation of multi-potent 
progenitor cells.
High proliferative potential colony forming cells
(HPP-CFC)
The High proliferative potential colony forming cell (HPP- 
CFC) was originally reported in cultures of murine bone 
marrow by Bradley and Hodgson (1979). They demonstrated a 
relatively primitive, quiescent population with a resistance to 5
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fluorouracil (5FU) (a cytotoxic agent which targets more mature 
cycling progenitors ) higher than that seen in LPP-CFC. These 
cells required more than the one growth factor in order to 
proliferate, and gave rise to colonies made up of more than 
50,000 cells per colony.
The HPP-CFC surviving 5 fluorouracil (5FU) treatment were 
rare with a frequency of 1 in 400 NBM cells. They showed a 
pattern of regeneration similar to pre-CFU-S, were present in 
low density RH123 dull fractions of normal bone marrow and 
could be detected in clonal agar culture only in the presence of 
IL-la + IL-3 + M-CSF. HPP-CFC shared many phenotypic 
characteristics with early haematopoietic cells. These HPP-CFC 
could give rise to CFU-S day 13, cells with short term Marrow 
repopulating ability, erythroid and megakaryocyte progenitors 
as well a second class of HPP-CFC which require only IL-3 + M- 
CSF to proliferate in culture. (Bradley et al, 1980; Bradley et al, 
1985; Bertoncello et al, 1985; Mcniece et al, 1987; Bartelmez et 
al, 1989; Bertoncello, 1992).
The second class of HPP-CFC is postulated to be a more mature 
cycling population on the basis of it's sensitivity to 5FU 
treatment (99% depletion) (Bradley et al, 1985). They are 
found in the RH123 bright fraction of low density bone marrow 
(Hodgson et al, 1989; Bertoncello et al, 1991). In replating 
experiments they generated only LPP-CFC cells, which, as 
outlined in 1.3.2.3, respond to lineage specific single factors 
(Mcniece et al, 1990). This suggested a hierarchical scheme of 
progressively maturing progenitor populations, from HPP-CFC 
stimulated with IL-l-ct+IL-3+M-CSF to HPP-CFC stimulated
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with IL-3 + M-CSF to CFC stimulated with lineage restricted 
factors (LPP-CFC). These were designated HPP-CFC1, 2 and 3 
(LPP-CFC) (Bertoncello, 1992) (Diagrams 3 and 4 show the 
heterogenous HPP-CFC pool and how it relates to other 
haematopoietic cell types .Some of the markers used to detect 
cell populations are also indicated).
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In querying the validity of this scheme it is worth noting that 
Fleming et al, (1993) equates heterogeneity within early 
progenitor cell populations with cell cycle status. Using 
propidium iodide staining, Hoeschst dye and tritiated 
thymidine labelling they determined the fraction of 
phenotypically defined murine stem cells (Thy 1.1 lo, LIN-/lo, 
SCA-1+) which were in DNA synthesis. The fraction was 
estimated to be 18-22%. Further they used RH123 to 
fractionate this stem cell population. RH123 permits separation 
of the primitive cell population into two subsets: RH123high
and RH1231ow. Of these cells only 2.9% of RH123 lo are in 
S/G2/M where 30% RH123high are in S/G2/M. These cell
fractions were separated, injected into lethally irradiated
recipients and survival monitored over thirty days. The
injection of 100 G0/G1 cells (RH1231ow) rescued 90% of lethally 
irradiated mice in contrast to 100S/G2/M cells(RH123high) 
which rescued only 25% of lethally irradiated recipients. Long 
term donor derived multi-lineage reconstitution of the 
peripheral blood was observed in recipients of RH1231ow but 
not RH123high. The data not only confirm heterogeneity within 
a stem cell pool but also confirm that with active proliferation 
comes a reduced stem cell activity. This data is in agreement 
with the 5FU and other findings for HPP-CFC.
A variety of other growth factor combinations which 
stimulated HPP-CFC and were ablated by 5FU treatment 
emerged (Falk and Vogel, 1988; Bertoncello, 1992). A study by 
Kriegler et al (1994) set out to define the inter-relationship of 
these and various other HPP-CFC populations. Their conclusions
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are complex but in brief they state that the HPP-CFC 
compartment is extremely heterogenous, both in terms of 
consisting of five major HPP populations, but also within those 
populations themselves. They envisage a complicated cell 
compartment in which gradual changes in growth factor 
requirements occur as HPP-CFC mature. At the head of the pool 
is a primitive HPP-CFC (more primitive than HPP-CFCl) 
stimulated by at least two combinations of four factors. (Other 
work by Lowry et al (1991) suggested possibly up to six factor 
combinations but Kriegler could not repeat this work) 
Bertoncello (1992) quotes two other examples of work in which 
four factors stimuluta morr RH113 dulL-cells than three factor 
combinations but anly .peculates as to theia place nr the HPP- 
CFC hierarchy.
According to the model proposed by Kriegler et al (1994), as 
the compartment progresses we find HPP-CFCl a heterogenous 
sub-pool stimulated by IL-la+Il-3+M-CSF. However they also 
suggest several other three factor combinations able to 
stimulate HPP-CFCl, but which do not produce the same levels 
of self renewal as seen with the IL-la + IL-3 + M-CSF
combination. This leads them to conclude that these 
combinations stimmlate more mature HPP-CFCl. Two two factor 
combinations aae akss proposed to tiimulata theea huer HPP- 
CFCl.
Next is the similarly heterogenous HPP-CFC 2, in which earlier 
cells are stimulated by IL-3 - M-CSF, and later by other two 
factor combinations which may overlap with the single factor 
combinations stimulating LPP-CFC or HPP-CFC 3. To an extent
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this work is supported by the findings of Yoder et al (1993) 
who confirm an increased growth factor requirement in earlier 
HPP-CFC. Using counterflow centrifugal elutriation they report 
that HPP-CFC are heterogenously elutriated on the basis of 
differences in size or density. They separate HPP-CFC into six 
subsets differing in growth factor responsiveness. HPP-CFC 
elutriated at the lower flow rates (lower density) differ in their 
growth factor requirement for cloning as compared to HPP-CFC 
elutriated at higher flow rates (higher density). Lower density 
fractions require more growth factors. The lower density 
fraction contained no CFU-S day 12 where the higher density 
fraction did. This further suggests that the low densityfraction 
consists of cells more primitive than those in the high density 
fraction. These could possibly be developmentally linked to the 
pre-CFU-S which were found in a similar fraction. This confirms 
the notion of a highly heterogenous stem cell compartment. 
Interestingly Han (1994) reports a new HPP-CFC sub­
population able to form colonies containing HPP-CFC 2, GEMM- 
CFC and megakaryocytes. They term it HPP-mCFU-MK and 
postulate that it may in fact be HPP-CFCl expressing its 
potential to develop magakaryocytes in the presence of correct 
levels of the relevant factor. This contributes to the notion of 
heterogeneity existing within the overall heterogeneity of the 
cell pool.
It is clear that the HPP-CFC compartment is heterogenous and 
that sub-populations can be identified by analyzing the kinetics 
of cell regeneration and the specific cellular requirements for 
cytokines. (Diagram. 5 summarises this complex compartment).
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DECREASING PROLIFERATIVE POTENTIAL
CFU-A
CFU-BL
DIAGRAM 5 SCHEMATIC SHOWING THE EXCESSIVE HETEROGENEITY 
WITHIN THE HPP-CFC POOL .
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From the above it would seem that there was evidence relating
CFU-S to HPP-CFC, however the exact relationship can at 
present remain only largely anecdotal. Interestingly 
Bertoncello (1992) notes that HPP-CFCl do not form an 
accurate index of Long term marrow repopulating ability in 
haematopoietic tissue suggesting that they may not be pre- 
CFU-S noted to have this ability. It may be that one of the more 
primitive combinations Kriegler et al (1994) report will emerge 
with this ability.
Importantly these studies confirm that a very primitive 
heterogenous cell population with a reported human 
counterpart (Gordon, 1993) can be studied m vitro.
Other early progenitor cells in vitro
HPP-CFC do not represent the only in vitro assay for early 
haematopoietic progenitor cells. Nakahata and Ogawa identified 
a population present in both human and mouse, producing 
undifferentiated blast cell colonies at 16 days in culture. 
(Nakatha and Ogawa, 1982) A human counterpart is also 
reported (Leary et al, 1988). Replating of these cells revealed 
colonies containing secondary blasts and GEMM-CFC. This 
suggests that CFU-BL are more primitive than the late GEMM- 
CFC. There is considerable evidence including the above 
observation (Suda et al 1983; Ikebuchi et al, 1988; Wong et al, 
1988; Bertoncello, 1992) that CFU-BL may well be closely 
related to HPP-CFCl.
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Similarly Pragnell et al (1988) describe an early progenitor 
named the CFU-A. Stimulated to colony formation with 10% 
L929cm (as a source of M-CSF) and 10% AFl-19Tcm (a erurce 
of GM-CSF) and incubated at 37°C for 11 days these ceUs bear 
many similarities to HPP-CFC-1. Not least of these is the 
difficulty in separating one cell type from the other in enriched 
bone marrow populations. (Graham et al, 1990; Kriegler et al 
1994; BertonceUo, 1992).
Other early populations reported include the CRU(competitive 
^population unit) and the CAFC(Crbbleetrge area forming cell) 
(Review Wright and Pragnell, 1992)
As yet the cell populations discussed above have not been 
integrated into one model and although evidence infers that 
they may be clorety related, an accurate plcauya o. how one 
may relate to another woufd require more data.
S u m m a r y
In vitro prrggyiior ccU alsedc haav etlablithed several 
potentially overlapping cell populations which are comparable 
in organisation and developmental potential to the CFU-S 
assayed in vivo. These are potentially the members of the stem 
cell pool responsible for haematopoietic homrotlesi s and as 
such these assays provide an excellent crntroCCyd medium in 
which to examine the effects of exogenous factors on early 
haematopoietic events.
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1.2 PROLIFERATION REGULATION
1.2.4 Proliferation regulation within the stem 
cell pool
Haematopoiesis can be viewed as a complex multi-stage 
process with haematopoietic tissue broadly divided into several 
compartments of progressively more mature cell types. (Moore, 
1991; Wright and Lord, 1992) The manner in which normal 
haematopoiesis is regulated has recently been elucidated and it 
has become clear that it is controlled by a balance between 
positive and negative regulators. (Lord, 1986; Lord 1988; 
Axelraad, 1990; Han and Caen, 1994)
Haematopoietic stem cells (as represented by CFU-S) have long 
been considered to be quiescent with regard to proliferation 
with 85-95% of the population in the GO phase of the cell cycle. 
(Lajtha et al 1969; Becker et al 1965). CFU-S derived from 
normal non-stressed foetal liver tissue show a high proportion 
in S-phase (30-40%) (Riches et al, 1981; Dawood et al, 1989). 
Following depletion of CFU-S from normal marrow by 
physiological insult the proportion of CFU-S in S-phase is 
increased to 30-50%. (Lahiri and Van Putten, 1972; Byron, 
1975).
Local variations in the proliferative status of CFU-S suggested 
that this alteration in proliferative status was under the control 
of locally produced factors. (Gidali and Lajtha, 1972; Rencricca 
et al 1970; Wright and Lord, 1977; Ali et al, 1989) which act 
specifically on CFU-S as opposed to later progenitors (Tarejo et
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al, 1984) and were non-species specific in their action (Wright 
et al, 1980; Cork et al, 1986).
A stem cell inhibitor associated with normal bone marrow 
tissue (Lord et al, 1977; Wright et al, 1980; Cork et al, 1981) 
and a stem cell ' associated with bone marrow recovering from 
physiological stress or foetal liver tissue (Lord et al, 1977; 
Croizat and Frindell, 1980; Dawood et al, 1990) were 
demonstrated. These activities were shown to be different in 
terms of molecular weight with the stimulator in a 30-50KD 
banding, the inhibitor in a 50-100KD banding and no opposing 
activity in either banding.(Lord et al, 1977; Graham et al,
1990) . They were shown to be produced by separate 
populations of cells within the monocyte-macrophage lineage 
(Wright et al 1980; Wright et al 1982; Simmons and Lord, 
1985; Wright and Lorrimore, 1987; Ali et al , 1989; Robinson 
and Riches, 1991) whose distribution within the marrow was 
different and which could be separated by virtue of theur 
different densities (Wright and Lord, 1979; c^l^im^cn et al
1991) Regardless of the proliferative status of the tissue both 
producer cell populations were present. (Wright and Lord, 
1979; Lord, 1986). A variety of macrophage cell lines were 
screened and an activity derived from medium conditioned by 
J774.2 macrophages shown to act in the same way as the stem 
cell inhibitor. The activity was subsequentty shown to be a 
protein species that migrated as a doublet on SDS PAGE gel 
electrophoresis. The doublet was found to be two previously 
described cytokines macrophage inflammatory protein -1-p 
(MIP-l-P) and macrophage inflammatory protein-1-a (MIP-1-
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a). By using antibodies directed against MIP-1-a the inhibitory 
activity was subsequently shown to reside with this part of the 
doublet. (Graham et al, 1990; Wright and Pragnell, 1992) One of 
a family of at least ten basic heparin binding polypeptides 
sometimes referred to as chymrkinee, it is a peptide of 694 
amino acids with a molecular weight of 8-lOKd which was 
originally identified by its pro-inflammatory capacity after 
injection into the footpads of C3H/HeJ mice. (Moore, 1991; 
BroKmeyer et al, 1993; Lord et al, 1993) It has an identified 
human counterpart " LD78". (Lord et al, 1993)
1.2.4.1 Macrophage inflammatory protein-l-a
With the finding that MIP-1-a corresponded to the normal 
bone marrow associated stem cell inhibitor came much interest 
in its actirge within aaematopriesis. The picture which has 
emerged demrgstrdtys a molecule which is part of a family of 
chymokigee with a crgOueigg array of functions. (Broxmeyer et 
al, 1993)
Broxmecyr et al (1989) showed that MIP-1 (containing both 1- 
a and 1-p) was synergistic with certain colony stimulating 
factors (GM-CSF and M-CSF but not G-CSF) for the promotion of 
enhanced GM-CFC colony formation in vitro. Whilst MIP-1 was 
shown to have no significant effect on erythroid progenitor ceB 
colony formation, MlP-1-a alone was shown to inhibit colony 
formation by the erythroid burst forming unit. Interestingly 
this inhibition could be removed by the addition of MIP-1-p, 
implying that MIP-1-p is antagonistic to the effects of MIP-1-a.
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Work on CFU-A, an in vitro colony assay similar to the HPP-CFC 
assay and thought to be representative of the in vivo CFU-S cell 
population (Dunlop et al, 1992; Maltman et al, 1993), showed 
that MIP-1-a could inhibit the formation of CFU-A colonies 
whilst MIP-1-p, at least at the concentrations tested, was 
ineffective in this respect. (Pragnell et al, 1988; Lorrimore et al 
1990; Wright and Pragnell 1992; Lord et al, 1993; Broxmeyer 
et al, 1993). This finding is further complicated by the fact that 
there is evidence to suggest that both molecules act through 
the same receptor .(Graham and Pragnell 1992). Graham et al 
(1990 ) have shown that MIP-1-a was effective in reversibly 
inhibiting the cycling of CFU-A with regenerating marrow as a 
source of these stem cells. Both in vitro liquid suspension 
culture of factor stimulated immature stem cell populations 
supplemented with MlP-1-a (Bodine et al, 1991) and in vivo 
administration of MIP-1-a to mice (Dunlop et al, 1992; Lord et 
al, 1992) demonstrated MIP-1 -a's ability to suppress 
proliferation within, and, consequently be haemoprotective for, 
early stem cell populations (Broxmeyer et al, 1993). Mayani et 
al (1995) confirm, this finding, testing MIP-1-a on populations 
of highly purified cord blood cells. MIP-1-ta is also known to 
show an inhibitory activity for non haematopoietic cells. It is 
active in inhibiting the proliferation of epidermal keratinocytes 
and may be produced locally within the epidermis from 
epidermal Langerhans cells (Graham and Pragnell, 1992; 
Graham et al, 1994).
As will be subsequently discussed other haemoregulatory 
inhibitory activities exist one of which is Transforming growth
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factor beta (TGF-J3). This inhibitor appears to have similar 
functions to MIP-1-a. (Maltman et al, 1993), and it is noted 
that both inhibitors are able to decrease proliferation within 
CFU-A populations to the same extent. Interestingly they find 
that TGF-p can down-regulate expression of the MIP-1-a gene 
in bone marrow derived macrophages. The expression of MIP- 
1-p is inhibited in a similar manner. In the murine macrophage 
cell line RAW264.7, 24hrs after treatment with TGF-P western 
blotting showed that there was a reduction in the level of MIP- 
1-a protein production. On FDCP-mix cells TGF-p can down 
regulate MIP-1-a receptor expression. Although based on in 
vitro findings the extent of this down regulation is such that 
they question the significance of MIP-1-a in the presence of 
TGF-P in vivo. Several points are worth considering here. 
Firstly the work of Mayani et al (1995) suggests that the mode 
of action of MIP-1-a and TGF-p is perhaps more subtle than 
this finding suggests with each molecule acting in a slightly 
different way on different but overlapping primitive cell 
populations. Secondly problems such as the aggregation of 
MIP-1-a which pose a significant problem in vitro, leading to 
loss of inhibitory activity, are far less problematic in vivo. 
(Lord et al, 1993; Graham et al, 1994). Indeed the fact that the 
molecular weight of the originally described NBM associated 
inhibitor was 5O-1OOKD is probably attributable to the 
aggregation of MIP-1-a and may be necessary for localising in 
viv9 activity or ligand-receptor interaction. ((Graham and 
Pragnell, 1992; Graham et al, 1994). The precise relationship 
between these inhibitors remains to be elucidated. A report by
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VerfaiHie et al (1994) discusses the effect of MIP-1-a addition 
to a unique LTBMc set-up. They conclude firstly that the 
addition of MIP-1-a alone to cultures has no significant effect 
on the number of primitive cells in culture after eight weeks. 
They suggest that this may indicate that MIP-1~a does not 
have a direct action and that for inhibitory action MIP-1-a 
requires interaction with other cytokines. Interestingly when 
they co-culture IL-3 and MIP-1-a they find that cultures 
produce more primitive progenitors capable of initiating long­
term cultures than with either molecule alone. This is in 
contrast to findings for IL3+TGF-P where cultures showed 
reduced numbers of long term culture initiating cells. They 
hypothesize that the IL-3+MIP-l-a result may be attributable 
to an increased proliferation without differentiation. MIP-1-a 
may act as a survival agent here rather than an inhibitory 
signal. They demonstrate that the action of MIP-1-a and IL-3 
requires the release of undefined diffusible factors from 
stroma but that the two molecules interact directly with 
primitive progenitor cells and not the stroma. A system such as 
this whose dynamics are not fully defined is a vivid example of 
the complex interplay that exists between cytokines "in vivo". 
The strength of the TGF-p data above is surely open to debate. 
In summary members of the MIP family show a range of 
haematopoietic effects with MIP-1-a showing direct
suppressing activities and a possible role as a survival agent 
for immature progenitors.
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1.2.4.2 The interaction of stimulator and 
i n h ibitor
The nature of the interaction between stimulator and inhibitor 
providing the balance of haematopoiesis is thought to be 
governed by a number of parameters. Firstly it has been 
demonstrated that the two factors do not interact with one 
another in a simple on-off switching mechanism but that they 
interact with the other's producer cell to regulate the level of 
production. (Lord and Wright, 1982; Riches and Cork, 1987). 
Further, there is a differential sensitivity to these factors 
within the stem cell pool. The earlier (more primitive ) a cell 
the greater it's sensitivity to inhibitor the later the greater it’s 
sensitivity to stimulator. (Wright et al, 1985). This could be a 
consequence of stem cell pool heterogeneity or indeed it's 
cause. Fleming et al (1993) note that stem cell heterogeneity is 
well correlated with cell cycle status suggesting that more 
quiescent cells exhibit greater stem cellness, as judged by their 
marrow reconstituting ability. It may be that a greater 
sensitivity to stimulator and a consequential movement into 
cycle represents stem cell ageing.
The balance between stimulator or inhibitor production has 
also been proposed to be a consequence of the size of the CFU-S 
pool. It is postulated that CFU-S themselves produce a feedback 
signal to producer cells which effectively prevents the 
production of stimulator. The isolation from stem cell 
conditioned medium of a 30-50KD fraction termed 'stem cell
feedback factor' able to actively suppress stimulator production
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seemed to be confirmation of this hypothesis. (Lord, 1986) 
However there are situations where stem cell numbers are high 
but stimulator is still being produced such as foetal al liver 
(Dawood et al, 1989). This forces a reassesment of the system 
proposed by Lord. It may well be that the production of stem 
cell regulators is not only related to the size of the CFU-S pool.
I.2.4.3. A variety of negative haemoregulatory 
activities.
Besides those discussed above other negative and positive 
haemoregulatory activities exist (review Guigon and Najman ,
1988; Axelraad, 1990; Moore, 1991; Wright and Pragnell, 1992; 
Mayani et al, 1995). Recently with the desire for 
haemoprotection an integral consideration in cancer therapy 
(Moser and Paukovits, 1991; Tubiana et al, 1993; Guigon and 
Bonnet, 1995) there has been much interest in negative 
regulators which act in a reversible way to arrest DNA 
synthesis or to prevent entry into S-phase, in early stem cells. 
Several inhibitory molecules other than MIP-1-a have emerged 
(again raising Metcalf's (1993 ) question of redundancy in 
growth factors) (Guigon and Bonnet, 1995).
These include the large molecules Transforming growth factor 
beta (TGF-P) and TNF-a (Ruscetti et al, 1991; Moore 1991; 
Maltman et al, 1993) Leukaemia associate d inhibitor s LAI 
(Olofsson anal (Dlssse, 1980 a ,b add c. ) and Leukaemia 
associated inhiniiort^ aatti^vite^^ LAIA (acidic raoferratia) 
(Bognacki et aa 1981; Broxmeyer et al( 1981) and two small
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chemically unrelated peptides: the penta peptide PEEDCK 
(HP5B) and the tetrapyptide AcSDKP (Axelraad, 1990; Lord and 
Dexter, 1992; Moser and Paukovits, 1991; Wright and Pngnell, 
1992; Robinson et al, 1993; Tubiana et al 1993; Guigon and 
Bonnet, 1995). The majority of these have an often confusing 
array of pliyotropaic and overlapping functions with some e.g. 
TNF-a and PEEDCK exhibiting both positive and negative 
activities. The effects of many of these inhibitors are to be 
found at the level of progenitor cells however at least one of 
these the tetrapeptide ACSDKP has been shown to be a 
proliferation inhibitor for haematopoietic stem cells.
I.2.4.4. The haematopoietic inhibitory peptide 
ACSDKP
GENERAL BIOLOGY
The tetrdpeptidy AcSDKP was first isolated as a crude extract 
from foetal calf bone marrow (Frindel and Guigon, 1977) and 
foetal calf liver (Guigon et al, 1984 ). It was purified as a 487 
dalton peptide which was grg-species specific, being active in 
both human and mouse, and could be chemically synthesized 
(Termed "Seras pen i de"). (Legfagt et al, 1989; Guigon et al, 
1990). AcSDKP is degraded by the enzyme plasma angiotensin- 
1 converting enzyme (ACE) in a reaction mediated in vivo by 
the N-terminal end of the enzyme. (Rousseau et al, 1995). Both 
native and synthetic peptide inhibit the entry into S-phase of 
CFU-S following haematopoietic stress. (Frindel and Guigon
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1977,; Lenfant et al 1989\ Guigon et al, 1990). In contrast to 
MIP-1-a the tetrapeptide is thought only to be active at the 
Go/Gl point in the cell cycle i.e it does not alter the cycling 
status of cells already in the cell cycle. (Monpezat and Frindell, 
1989; Wright and Pragnell, 1992). In vitro work by Robinson et 
al (1993) demonstrated the ability of AcSDKP to inhibit the 
cycling of a murine HPP-CFC population induced by a stem cell 
stimulator. They attribute the inhibitory activity to the SDK 
sequence of the molecule. Godden et al (1993) showed the 
same effect on murine CFU-A induced to enter S-phase in 
response to a stimulator. On enriched populations of human 
stem cells (CD34+HLA-DRlow) thought to contain the primitive 
stem cells capable of initiating long term culture, AcSDKP 
reversibly inhibited proliferation and colony generation. 
(Bonnet et al, 1992) The molecule is also active on some later 
progenitor populations (Guigon et al, 1990). They report that 
24hr incubation of human mono-nuclear cells with seraspenide 
induces growth inhibition in GM-CFC, BFU-E and CFU-E. Unlike 
MIP-1-a, TNF-a and TGF-p AcSDKP has never exhibited 
stimulatory activity, and importantly, for a role in cancer 
therapy, it does not act on leukaemic cells. (Guigon and .Bonnet, 
1995). The peptide sequence is found in TNF-a and thymosin- 
p-4 where it represents the N-terminal sequence (Lenfant et al, 
1989). Speculation that AcSDKP may exist as a latent part of a 
higher molecular weight molecule cleaved to release the active 
tetrapeptide was given credence by the finding that thymosin- 
p-4 could be enzymatically cleaved to release AcSDKP. (Grillon 
et al, 1990). However Pradelles et al (1990) note that the
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distribution of thymosin-p^ and AcSDKP in mouse tissue did 
not support this theory. (Guigon and Bonnet, 1995)
The inhibitory ability of AcSDKP appears not to be limited to 
the haematopoietic system. Adult rat hepatocytes are normally 
quiescent being triggered into cycle only in response to partial 
hepatectomy. Tub'iana et al (1333) report work by Lombard et 
al (1990) in which AcSDKP significantly reduced hepatocyte 
proliferation following partial hepatectomy. The fact that 
AcSDKP prevents the cycling of a aoa-haematopoietrc cell 
population suggests that it may act by interfering with a 
general growth regulatory mechanism rather than a process 
associated with one cell type.
Mechanism of action
The mechanisms of action by which an inhibitor exerts its 
activity include blocking or down regulating receptors for 
positive stimulatory factors; interfering with the actions of 
genes activated by positive regulators or blocking the synthesis 
of positive regulators (Moore, 1991). In the case of AcSDKP the 
mechanism of action is unclear. (Tu0iaaa et al, 1993; Guigon 
and Bonnet, 1995).
Robinson et al (1993) showed the ability of AcSDKP to block the 
action of a stem cell stimulator on an HPP-CFC sub-population. 
Since the stimulator had already been synthesized this would 
imply a role in either stimulator destruction, some form of 
receptor down-regulation or active blocking/interference with 
the normal intracellular signaling pathway. The fact that
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receptors for AcSDKP itself have not yet been identified 
(Guigon and Bonnet, 1995) may add weight to the first of these 
suppositions
Tubiana (1993 ) and Obiigon and Bonnet, (1995 ) review data 
from Aizawa et al (1992) and Lenfant et al (1991) on the role 
of AcSDKP in stem cell to stromaL-cell adherence. They note 
that the peptide enhanced the adherence of CFU-S to stromaL- 
cyCls and that binding of this nature could be lost in the 
presence of anti-AcSDKP antibodies. With the assumption being 
that haematopoietic cells bound to the stroma respond to 
stromaL-cell produced factors does this suggest that AcSDKP 
interacts to alter the micro-egvirogment. If this is the case
then how does this relate to the observation that AcSDKP 
directly interacts with CD34+ cells? (Bonnet et al, 1993) It is 
perhaps worth considering the work of Verfaillie et al (1994) 
in which it was demonstrated that stromal released soluble
factors were essential for the IL3+MIP LTBMC maintenance but 
that these molecules themselves directly interacted with early 
progenitor cells. AcSDKP could be altering properties of the 
microenvironment by interacting with factors produced by it 
whilst not itself stimulating the microenvironment to produce 
such factors.
An engaging report on the protection of normal human 
haematopoietic progygitrre against photoforin-11 mediated 
phototherapy suggests several possible mechanisms of 
protective action (Cutton et al, 1994). The killing effect itself 
relies on the 0^'^ of a sensitizer (partrfrrin 11) to induce the 
oxidation of biological material within a cell in response to
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light. Although the mechanisms by which the cell killing is 
induced are not fully understood it is clear that AcSDKP 
prevents the effect on progenitor cells in this instance. This is 
particularly interesting as AcSDKP's protective effect is not 
extended to either of the leukaemic cell populations tested. 
They discuss four possible explanations for this finding. Firstly 
they postulate that AcSDKP may maintain some progenitors 
within the target population out of DNA synthesis thus 
preventing the initial uptake of the killing agent. They are 
reluctant to believe that this alone could account for the
reduced killing effect. Unlike the work of Robinson et al (1993) 
discussed earlier, peptidic analogues have not been tested in
these systems and thus the activity cannot be attributed to the 
SDK sequence. Secondly they discuss the possibility that 
AcSDKP actively dissociates the 'billing agen t but add that their
methods should discount this possibility. Their final two
proposals are linked in that they suggest the effect of AcSDKP 
is mediated through the production of other factors. Firstly in 
inhibiting apoptosis, but no relevant cytokines could be found, 
and secondly in producing cytokines which in turn cause the 
release of anti-oxidative enzymes, again no relevant cytokines 
could be found. Both of these findings concur with work by 
Bonnet el al (1992) which showed no cytokine induction by 
AcSDKP in human long-term bone marrow cultures.
Recently work on inh'iibitory cytokine. hag focussed on 
comparing their actions with the iatenttnn of elusadating some 
general, inhibitory mechanism.
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Bonnet et al (1995) in studies which assayed and compared the 
effects of AcSDKP, MIP-l-a, TNF-a and TGF-p on in vitro 
populations of purified CD34+ cells conclude that the 
mechanism of action of these molecules is likely to be different. 
Differential inhibrtory responses illicited from varying CD34+ 
cell subsets suggest that these four molecules may target 
different but overlapping cell populations within the CD34+ cell 
population. Such a subtle regulatory mechanism would in some 
way address Metcalf's question of redundancy. The 
heterogeneity of the cell pool may require several activities to 
succes^Ey regulate itself. Most interestingly their work 
indicates that although TNF-a contains the SDK pepticHc 
sequence its effects are different to that of AcSDKP. TNF-a 
induced a large reduction in CFU-GM(GM-CFC) numbers from 
the CD34+HLA-DRhigh cell fraction. It was shown to act in a 
dose dependant fashion where AcSDKP was only moderately 
inhibitory for this cell fraction and was completely ineffective 
at higher and lower concentrations. This bell shaped response 
curve for ACSDKP is similar to that seen for the pentapeptide 
pEEDCK (GiEgon and Bonnet, 1995; Mouser and Paukovits, 
1991). The reason for the pattern of this response is unclear. 
Earlier studies which demonstrated that TNF-a but not AcSDKP 
acted by modulating cytokine receptor expression (Bonnet et al, 
1993; Khoury et al, 1994) further suggest that these molecules 
act in a different way. This begs the question "What is the 
significance of the SDK sequence in TNF-a ?".
In comparing AcSDKP to MIP-l-a Bonnet et al note a similarity 
in that both molecules require daily addition to cultures to
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remain effective. However rather than a genuine functional 
overlap related to some common structural or genetic target 
this finding is likely to be explained in terms of small peptide 
degradation (AcSDKP) (Roseau et al, 1995) and possible 
polymerisation with consequential lack of function (MIP-l-a) 
(Graham et al, 1992; Graham et al, 1994). Of greater interest 
here are the differences between the two molecules. 
Specifically there is the fact that they operate differently in 
their inhibition of stem cell cycling. There is also MIP's greater 
ability to slow down differentiation in the CD34+HLA-DRlow 
cell sub-set (could this relate to Verfaide's theory that MIP-l-a 
may be a survival factor in certain instances?). As touched on 
above it could be argued here that AcSDKP may prove to have 
a similar action on another cell-subset in which MIP-1-a would 
be less active. A case for subtlety over redundancy? The 
possibility that AcSDKP acts to induce MIP-l-a (based on its 
antagonism by MIP-l-3) (Cashman et al 1994) seems 
discountable given that MIP-l-a and AcSDKP act differently 
and that levels of MIP-l-a found in experimental systems did 
not support this theory. Again this ties up with observations 
discussed above on cytokine induction by AcSDKP.
In summary the mecaagism(s) of action of AcSDKP cannot be 
fully elucidated and indeed the molecule may operate through 
several different mecaagisme. The importance of a small 
sequence within the peptide has been demonstrated although 
the mechanism by which it executes its function is not 
understood nor is its relevance in explaining the effects of 
AcSDKP in other systems.
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The physiological significance of AcSDKP
In attempting to define the physiological significance of AcSDKP 
as an inhibitor of haematopoietic stem cells, strategies have
been to either look (Both in vivo and in vitro) for its synthesis 
or to examine the effects of its withdrawal. Several delicate 
experiments along these lines have been undertaken. Perhaps 
the most convincing evidence for a physiological role rests with 
the fact that AcSDKP is synthesized both in vitro and in vivo. 
Wdzieczak-Bakala el al (1990) demonstrated the formation of 
AcSDKP both in vitro, in LTBMC's, and in vivo, following 
injection of mice with radio-labelled precursors (tritiated 
proline). Work initially by Lau ret et al (1989) using an anti­
serum with cross-reactivity for AcSDKP results in an increase 
in the percentage of CFU-S in S-Phase with the total number of 
CFU-S unchanged. (Frindel et al, 1992; Tubiana et al, 1993). 
Using an enzyme immunoassay to show the distribution of 
AcSDKP in man it was demonstrated that red-blood cells and 
granulocytes possessed only low levels whereas lymphocytes, 
plasma and serum appeared to possess high levels. (Pradelles 
et al, 1990; Loizon et at, 1993).
There does appear therefore to be significant evidence for a
physiological role for AcSDKP.
S u 111 m a r y
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In summary, it is the possibility of reversibiy blocking the 
cycling of normal stem cells which presents an enticing 
prospect for chemotherapy. Guigon and Bonnet (1995) report 
the ability of AcSDKP to protect haematopoietic stem cells 
against a variety of cytotoxic chemicals. Protection against 
photopurging has also been demonstrated (Coutton et al, 1994). 
Unlike many of the other inhibitory activities, AcSDKP has a 
limited range of actions and would seem a good candidate for a 
haemoprotective agent which does not cause many other sree- 
effects.
It was primarily the potential of AcSDKP to regulate 
haematopoietic stem cells and the finding that the SDK 
sequence conferred this ability on the molecule which 
stimulated interest in Leukaemia inhibitory factor (a cytokine 
known to contain the -SDK-sequence) in this lab.
1.3: LEUKAEMIA INHIBITORY FACTOR
1.3.5 LEUKAEMIA INHIBITORY FACTOR: GENERAL
Since cytokines became available in recombinant form, it has 
become obvious that few are specific to one target cell and 
fewer still are unique in function (Gearing, 1993). The 
plieotropy associated with the molecule leukaemia rnniOrtory 
factor exemplifies this perhaps better than any other cytokine. 
(Review Gough and Williams, 1989; Metcalf, 1991; Vrllrger et al, 
1992; Hilton, 1992; Gearing, 1993; Metcalf, 1994).
Introduction 4_fi
Biology of LIF
As an agent effective on leukaemic cell populations LIF was 
initially characterised as a factor associated with Krebs 11 
Ascites tumour conditioned medium able to induce the 
differentiation of a mouse leukaemic cell line Ml (Metcalf et al, 
1988). It was purified to homogeneity (Hilton et al, 1988) and a 
cDNA encoding active LIF was isolated (Gearing et al, 1987) A 
human genomic clone encoding LIF was subsequently 
identified (Gough et al, 1988). The Ml cell line can be induced 
to differentiate by a variety of agents among them G-CSF, a 
differentiation factor (D factor) (Tomida et al, 1984) purified 
from L-cell conditioned medium and a differentiation inducing 
factor (DIF-A) from human monocytic cells (Abe et al, 1989). It 
was subsequently shown by Lowe et al (1989) that D-factor, 
DIF A and LIF were all identical. Other similar factors such as 
the macrophage-granulocyte inducer MG1-2B showed 
similarities to LIF but on sequencing were shown to be other 
molecules(lL-6). (Hilton et al, 1988; Metcalf, 1991).
Many of LIF’s activities were similar to molecules which had 
been independently purified and cloned by a variety of groups 
working in other fields (Hilton, 1992). It emerged that these 
molecules were all identical to LIF and as a consequence LIF is 
known under a variety of names often reflecting the variety of 
its functions. These are summarised in table Il.
NAME ACRONYM
DIFFERENTIATION 
INDUCING FACTOR
D-FACTOR
DIF
LOWE ET AL 1989 
TOMIDA ET AL 1984
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DIFFERENTIATION
INHIBITING
ACTIVITY
DIA SMITH ET AL 1988
HUMAN
INTERLEUKIN FOR 
DA CELLS
HILDA MOUREAU ET AL 
1988
HEPATOCYTE 
STIMULATING 
FACTOR 111
HSF1B BAUMANN AND 
WONG 1989 ;
CHOLINERGIC
NEURONAL
DIFFERENTIATION
FACTOR
CNDF YAMAMORI ET AL 
1989
MELANOMA-
DERIVED
LIPO-PROTEIN
LIPASE
INHIBITOR
MLPLl MORI ET AL 1989
TABLE II: Other names for LIE.
Perhaps most notable are DIA (Smith et al, 1987; Smith et al, 
1988; Williams et al, 1988) where LIF actually shows an ability 
to INHIBIT differentiation and HSF-111 where LIF stimulates 
the release of acute phase proteins from hepatocytes (Metcalf, 
1991). (Review diagram 6)
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INDUCED BY INDUCES
IL-1 a 
TNF a
ES CELL
PROLIFERATION
WITHOUT
DIFFERENTIATION
(DIA
/DRF)
$ ::
LJUFw -
RELEASE OF 
ACUTE-PHASE 
PROTEINS FROM 
HEPATOCYTES 
(HSF 111)
ADRENERGIC TO 
CHOLINERGIC 
NEURONAL SWITCHING 
(CNDF)
MEGAKARYOCYTE
PROLIFERATION
DIFFERENTIATES 
M1 LEUKEMIC 
CELLS TO 
MACROPHAGES 
(LIF/DIF/
D FACTOR)
MYOBLAST
PROLIFERATION
PROLIFERATION OF 
DA-1A MYELOID CELL 
LINE
(HILDA)
LIPOPROTEIN 
LIPASE INHIBITOR 
IN ADIPOCYTES 
(MLPLl)
DIAGRAM 6 SUMMARY SCHEMATIC OF LIES ACTIONS ON VARIOUS 
TYPES OF TISSUE
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Molecular biology of LIF
Human and murine LIF exhibit 78% sequence homology within 
the 179 residues making up the molecule (Gough et al, 1988) 
and in both cases LIF is a highly glycosylated single chain 
(monomeric) polypeptide, a glycoprotein. It has a molecular 
weight of 58KD (Hilton et al, 1988) (although other sources 
quote 45-52KD(Melcalf 1991) and 38-67KD (Gough and 
Williams, 1989)) and de-glycosylated of 20-30KD(Hilton, 1992; 
Gearing, 1993) concurring with the size predicted from the 
cDNA by Gearing et al (1987). The variability noted in size is 
due to differential glycosylation associated with tissue source 
of LIF (Metcalf, 1991). It appears that in in vitro the level of 
glycosylation does not relate to function. ( Hilton, 1992; 
Gearing, 1993). It may be that in vivo LIF is vulnerable to 
catabolism and heavy glycosylation may act to prevent this. 
Disulphide bridging of cysteine residues within the molecule is 
necessary for activity .(Metcalf, 1991). In both human and 
mouse, LIF appears to be encoded by a unique gene located at 
chromosome 22q 12 in human (Sutherland et al, 1989) and 11 
in mouse (Gough and Williams, 1989; Gearing, 1993). In mouse 
LIF exists in two forms (Gearing et al, 1987; Estrov et al, 1992; 
Hilton 1992; Gearing, 1993). The LIF gene is composed of three 
exons, in mouse an alternative LIF transcript arises due to their 
being an alternative copy of the first exon associated with a 
distinct promoter region. The two resultant LIF proteins, one 
diffusible another membrane bound, differ only in their amino
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terminal portion of the leader sequence ie they have a variant 
signal peptide but identical mature proteins. This difference 
results in a form of LIF which is incorporated into the 
extracellular matrix (Rath-en et al, 1990). In other species no 
analogous protein has been found.
The SDK sequence and LIF
The importance of the SDK sequence in AcSDKP biology has 
been suggested. A study by Wilson et al (1992) to define 
structural and Oagctiogallc important regions of the LIF gene 
and protein revealed regions of conserved sequence in the LIF 
protein from Marigy, rat, human ^vine and porcine species. 
They conclude that LIF is a highly conserved molecule from 
74% sequence armrlogc between mouse and sheep to 92% 
between rat and mouse. Importantly examination of the cross­
species comparison of protein sequence revealed large areas of 
the molecule which are completely conserved suggesting the 
sequence arrangement to be of fundamental importance. They 
further note that all six cysteine residues found in murine LIF 
are crgeyrvyd at identical positions in the four other species. 
This further suggests that intramolecular ^sulphate bonds are 
vital to the molecule (Gough et al, 1992). Of interest here is the 
observation that the sequence SDK appears in the murine LIF 
protein sequence. Comparison with the other species reveals 
that in all cases the ser and lys ends of this short sequence are 
always conserved whilst the asp residue appears only in the 
murine form. In the case of human, ovine and porcine LIF it
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has been substituted with 'gly'. With such emphasis given to 
those sequences which are preserved the fact that this 
sequence is not would imply that its functional significance is 
not great. However two questions arise from ihis finding. 
Firstly the SDK sequence is present in the mouse is it thus able 
to give murine LIF an inhibitory role like that associated with 
AcSDKP ? Perhaps this role is fulfilled by another molecule in 
the other species. Secondly i s the subsitteiesl residue 
significant ? In three cases the substitute is 'gly' why is this 
particular sequence conserved in three species ? Robinson et al 
(1993) showed that SDK was iihyln to bn hen ilgniaiannt 
component of the AcSDKP molecule. Is it that this substitute 
sequence could show a similar role ?
Sources of LIF
As with many cytokines the cell types which have the potential 
to produce LIF are many and varied. However the in vivo
significance of an inducible in vitro response must always be 
questioned.
It is thus with some caution that LIF has been noted to be a 
potential product of many cell types including: T lymphocytes 
(Gearing et al, 1987) activated monocytes (A-negon et al, 1990) 
human lung fibroblasts and human umbilical vein endotheliaL- 
cells (Lubbert et al, 1991) Buffalo rat liver cells (Smith and 
Hooper, 1987) Krebs 11 ascites cells (Hilton et al, 1988) the 
melanocyte cell line THP-1 (Abe et al 1989)Human bone 
marrow stromaL-cells (Wetzler et al, 1991; Derigs and Boswell,
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1993; Wetzler et al, 1994) human carcinoma cell lines 
(Kamohara et al, 1994) peripheral blood monrnaclear cells in 
anaemia (Bagnara et al, 1993)huolan j^:riK^uaar chondrocytes
and cartilage (Campbell et al, 1993) human synovial fibroblasts 
(Hamilton et al, 1993) ^mrann dermal fibroblast cultures
(Lorenzo et al, 1994) embryonic blastocyst cells (Metcalf, 
1991).
Work by Brown et al (1994) in which the in vivo expression of 
LIF is assayed in 221 normal adidl mouse tissues revealed that 
LIF was expressed u! low levels in most tissues. They postulate 
that such low levels of LIF expression suggest either that this 
finding is not biologically significant or represents the subtle 
paracrine nature of LlF's action. Such a scheme would sit well 
with the problem of containing a molecule exhibiting such a 
high degree of pliyotropc. This work taken in crnjanctirn with 
the work of Weztlyr el al above is important in suggesting that 
LIF may have a role to play in normal haematopoiesis.
The pattern of induction of LIF expression suggests some 
factors which may p!ay a commo rrol in stimulating LIF 
production. Campbell et al (1993) note that LIF production by 
human adiinulal arnndlochtes nnd arrtilgye Is induced by IL- 
la and TNF-a. The same factors induce LIF expression in 
human synovial fibrobbasts (Hamilton et al, 199S^^)). IL-lcr Is 
noted to ignaoe substance P in sympathetic ganglia through the 
induction of LlF(Scaadiack et al, 1993). This latter example 
highlights not only the induction of LIF by cytokines but also 
the importance of cot0ldnet in ttih nervour syseem
(For review consult Bazan, 1991; Yamamori et al 1992). TNF-a
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stimulates LIF production in human dermal fibroblast cultures 
(Lorenzo et al, 1994). TNF-ex has also been shown to sttimuhtto 
proliferation of mouse primoediaS germ ceUs m culture. In the 
presence of LIF this stimulatory action is enhanced (Kawase et 
al, 1994) It may be that TNF-a acts to produce auO-optrmal 
levels of LIF here and although it is noted that TNF-a is more 
effective in inducing proliferation than the soluble form of LIF 
the possibility that TNF-a acts indirectly through a fibroblastic 
feeder layer is worth considering. It has been demonstrated by 
Hamilton et al (1993) andl Lubbert et at (1991) that fibroblasts
can produce LIF. Are they producing a matrix associated form
in this instance ? Further studies by Dolci et al (1994) looking 
at the effects of LIF on the proliferation and survival of 
primordial germ cells concluded that this is governed both by 
contact dependent mechanisms and diffusible factors. Other 
evidence to confirm this exists (Yoahrda et al, 1994). Alexander 
et al (1992) showed that a single dose of human LIF completely 
protected mice from E coli endotoxin (lipopolysaccneride) with 
only a short pre-treatment interval. TNF-a and IL-l-a have 
been shown to provide similar protection but only after a 
longer pre-treatment interval suggesting that they may 
mediate this response through LIF.
IL-1 a,,p,TNF-a and TGF-p have all been shown to increase the 
expression of LIF by both human and murine bone marrow
stromaL-cell cultures. (Wetzler et al, 1331; Derigs and Boswell, 
1993) Given the importance of TGF-p as a potential 
haematopoietic inhibitor this observation may be extremely 
important in implicating LIF in naematopoeitic regulation. IL-4
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has been demodstrathd to reduce LIF protein levels in human 
stromaL-celi cultures. (Wetzler et al, 1994). Interestingly IL-4 
also inhibits the LIF induced differentiation of Ml cells 
(Kasukabe et al, 199 1) which wrnId suggesS than IL-4 acted 
both on LIF (or its action) and its manufacture. The fact that 
Kasukabe et al (1994) report that IL-4 interferes with a LIF 
activated target gene, c-myc, suggests that IL-4 is at least 
capable of acting on the target.
LIF as an inducer of other cytokines
Since the biological effects of cytokines are determined by their 
interactions with other cytokines. It is important to consider 
not only those cytokines which induce LIF production but also 
those which are induced by LIF. A common pattern of cytokine 
induction in various tissue types emerges. Human articular 
chondrocytes express IL-ip, IL-6 and IL-8 mrna. It is worth 
noting that IL-8 can be induced by IL-la (Villiger et al, 1993). 
Is this secondary activation through LIF? A similar pattern of 
cytokine induction by LIF is found in human blood monocytes, 
synovocytei and both epithelial and neuronaL-cell lines 
(Villiger et al, 1993). II ii proposed by Abdollahi et al (1991) in 
studies looking at the expression oS IRF1I , a positive 
transcription factor for expression of the IFN-P gene, that LIF 
acts (in differentiating Ml cells) to induce the expression of 
IFN-p. During an acute inflammatory response cytokines 
released by different cell types (monocytes I fibroblasts / 
endotheliaL-cells) stimulate the synthesis and secretion of a set
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of plasma prrteigs-acale phase proteins by the liver. Mayer et 
a I (1993) note that LIF can induce the production of acute 
phase proteins in gog-aaman primates. Although uncertain as 
to whether this is an instance where LIF acts directly it is 
worth noting that Wegenka et al (1993) discuss the finding that 
a factor essential to the action of acute phase proteins is known 
to be activated by IL-6 a molecule with an ever growing list of 
similarities to LIF. As nleoueeed above LIF can induce the 
expression of IL-6 mRNA. Is this a further example of LIF 
stimulating the release of a eycogddrc cytokine ?
In summary LIF has the potential to modulate inflammatory 
and immune responses through its pattern of induction and the 
pattern of eyoogdary cytokines it can induce. (Diagram 6)
LIF and its receptor: An explanation of LIF’s 
functional similarity to other cytokines
Perhaps one of the most significant developments in LIF 
biology over the past five years has been the observation that 
it possesses many Oagctiogal similarities to other cytokines. IL- 
6, Oncost-at-in M (OSM), and to a lesser extent , Ciliary 
neutroph^ic factor (CNTF) and IL-11 share similarities with LIF 
(Hilton 1992; Metcalf, 1993; Robinson et al, 1994). All of these 
exhibit over lapping functions in the immune response, 
haematopoiesis, the gyivoae system and acute phase protein 
regulation (H ira no et al, 1994), A point has been reached where 
attention has focussed on whether LIF and related cytokines 
are functionally equivalent and thus a classic example of the
Imroduclion
redundancy postulated by Metcalf. In order to address tnra 
question it is first necessary to consider the LIF receptor.
Two LIF receptor types have been identified, one a high 
affinity receptor the other a low affinity receptor. (Metcalf, 
1991; Hilton, 1992 ; Gearing et al, 1331 ; Gearing, 1993; 
Robinson et al, 1994). The difference between the two has been 
shown to be due to the rates of dissociation, which is much 
higher from the low affinity receptor. (Hilton and Nicola, 1992). 
A human low affinity receptor has been cloned (Gearing et al, 
1991) and found to be a 200KD glycoprotein. It is a member of 
the cytokine binding family of receptors characterised by a 
conserved pattern of cysteine residues and a "trp-sex-x-trp-sex 
" amino acid motif in the extracellular 200 amino acres unit of 
the structure. (Co.sman D, 1993; Robinson et al, 1994). Receptors 
for IL 2, 3, 4, 5, 6, 7, 9, GM-CSF, G-CSF and CNTF have all been 
shown to be members of this family (Gearing, 1993). Murine 
cDNA's encoding soluble LIF receptors and showing 70% 
sequence homology with the human sequenoe(Geering et al, 
1991) were detected. This soluble form was demonstrated at 
high levels in the serum of mice and rats but no equivalent was 
detected in humans. (Layton et al, 1992). Importantly tnra 
soluble LIF can block the binding of LIF to its membrane bound 
receptor in vitro suggesting perhaps a role for the receptor in 
localising LIF. The consequences of LIF binding to its receptor 
have been noted for various cell types with the majority of 
data derived from Ml. These include phosphorylation of heat 
shock protein 1-1SP27, induction of INF-1 and tyrosine 
phosphorylation of of a 160KD protein. (Abdollahi et al, 1991
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;.Lord et al, 1991; Michishita et al, 1991; Gearing 1993).
Feldman et al (1994) report that LIF binding to its receptor 
induces the tyrosine phosphorylation of p91, a tradrcriptifd 
factor which leads to the assembly of protein complexes
essential for the function of the enhancers of two genes. It is 
noted (Yamamori et al, 1991) that LIF binding does lead to
enhanced transcription of genes such as c-fos and jun-b. Yin et
al (1994) identify a 130KD tyrosine phosphorylated protein 
induced by LIF in 3T3 cells as JAK 2 tyrosine kinase which is 
intimately associated with the signal transducing region of the 
LIF receptor. Similarly Ernst et al (1994) show that a tyrosine 
kinase HCK in FS cells was associated with the signal 
transducing region of the LIF receptor and showed increased 
activity in response to LIF binding. Studies by Boulton et al 
(1994) on a variety of cell lines conclude that LIF binding to its 
receptor results in tyrosine kinase phosphorylation and 
ultimately in the triggering of genes within the cell. (Hirano et 
a/, 1994).
The receptor itself has been found to be related structurally to 
the G-CSF receptor as well as to gp 130, the transmembrane 
signal transducing region of the IL-6 protein. Gp 130 associates 
with lL-6ra, an 80KD membrane bound molecule, when IL-6 
binds to IL-6r<a. (Gearing et al, 1991; Hirano et al, 1994). At a 
glance this similarity immediately suggests an explanation for 
the large functional overlap seen between IL-6 and LIF. (For a 
review see Gearing, 1993; I-Frano et al, 1994). However the 
observation that there were both high and low affinity 
receptors could not be explained by this model. The picture
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which emerged revealed the LIF receptor as consisting of at 
least two subunits (Gearing and Bruce, 1992). A low affinity 
LIF receptor, designated LIFrp, forms functional high affinity 
receptors in combination, i.e. by heterodimerization, with gp 
130. (Davis et al, 1993) It is envisaged that LIF may interact 
with an a sub-unit, like that for IL-6, with which the (3 unit 
may be associated and the gp 130 would come to be associated. 
Gp 130 is a common receptor subunit shared between IL-6 and 
LIF suggesting a common signal transduction pathway between 
these two receptors. Through this work and other studies it 
emerged that other members of this cytokine family had 
receptors which shared the gp 130 molecule and were 
essentially variations on a theme. Most notably amongst these 
was OSM. This is a 28 KD glycoprotein produced by activated 
monocyte and T lymphocytes known to be linked to LIF in 
terms of primary amino acid sequence and predicted secondary 
structures (Rose and Bruce, 1991; Robinson et al, 1994) the 
location of their genes on human chromosone 22 within 19 kbp 
of each other (Jeffrey et al, 1993) and the ability of both to 
differentiate Ml cells at similar concentrations .(Gearing, 1993). 
Gpl30 could bind OSM' probably after the binding of OSM to an 
a sub-unit with low affinity (Gearing and Bruce, 1992). In the 
presence of the LIFr3 sub-unit a high affinity receptor emerged 
(Hirano et al, 1^94). In the case of CNTF a 22KD glycoprotein 
with structural similarities to LIF and IL-6 (Richardson, 1994) 
the receptor complex is composed of an 80KD CNTFra, receptor 
sub-unit (with 30%sequence homology to the IL-6ra) anchored 
to the cell surface. This becomes associated with LIFrb and
Introduction
gpl30 sub-units for biological action. (Richardson, 1994; Hirano 
et al, 1994; Gearing, 1993; Davis et al, 1993). (These receptor 
subunits are summarised in diagram 7.)
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DIAGRAM 7 SCHEMATIC REPRESENTATION OF THE HIGH AND LOW 
AFFINITY LIF RECEPTOR AND THEIR RELATIONSHIP WITH GP130 . 
OSM AND CNTF RECEPTORS ARE THOUGHT TO BE BASED ON SIMILAR 
SUB-UNIT PAIRING WITH FRACTIONS OF THE HIGH AFFINITY LIF 
RECEPTOR POSSIBL YINVOL VED IN THE CONSTRUCTION OF EACH OF 
THE OTHER TYPES OF RECEPTOR.
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Functional similarity: subtlety or redundancy?
The question of redundancy or subtlety remains difficult to 
resolve. The shared receptor structure discussed for the above 
cytokines appears to offer an explanation as to how the 
cytokines induce similar functions. However it does not answer 
the question WHY? Perhaps a clue as to the solution may lie in 
considering not those functions which cytokines have in 
common but those which they do not.
For example in the case of LIF and IL-6 where there is 
significant functional overlap in more than the one cell type 
(Review Gearing, 1993 ) it is known that some actions common 
to both, such as the activation of a gene in the H35 rat 
hepatoma cell line, can be modified independently and 
differentially for each cytokine. (Bauman et al, 1992) This 
suggests that there is a genuine subtlety in the way in which 
these cytokines are involved in regulating this gene. Although 
at face value it appears that the gene is activated by both, the 
control of that activation appears subtly different -perhaps 
modified by the specific receptor subunit? An equally 
illuminating example of this can be found in work by Pellorce 
et al (1994) in which LIF and IL-6 were shown to stimulate 
heptaglobin and fibrinogen production in HEPG2 hepatoma 
cells. Although both stimulate production the dose response 
curves for the two are radically different. The same is true for 
the differentiation of Ml leukaemic cells. (Metcalf and Gearing, 
1989).
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Oncostatin M is known to share a variety of functions with LIF 
(Gearing, 1993; Jeffrey et al, 1993; Thoma et al, 1994). Scrutiny 
of these shared responses occasionally reveals a differential 
nature within an apparently identical response. For example 
LIF and OSM both stimulate the release of acute phase proteins 
from hepatocytes however the response is larger with OSM 
than LIF(Richards et al, 1992). Of greater importance is the 
observation that OSM has functions not shared with LIF. These 
include inhibition of growth of A375 melanoma cells (Zarling et 
al, 1986) stimulation of plasminogen activity in aortic 
endotheliaL-cells. (Gearing, 1993). These findings also suggest 
the presence of a unique non-LIF binding OSM receptor. As yet 
no murine OSM has been detected . The discovery of this would 
strengthen the case for subtlety over redundancy. A report by 
Tanigawa et al (1995) looking at the macrophage 
differentiation of Ml cells in response to LIF, OSM and IL-6 
concludes that these factors induce a differential pattern of 
differentiation. The gp 130 heterodimers LIF and OSM are 
shown to decrease levels of a transcription factor from a gene 
(SCL) which is a crucial step in the differentiation process. IL-6, 
a gpl30 heterodimer, appears to act differently, as, although 
equally capable of decreasing the levels of the transcription 
factor from the SCL gene, enforced SCL expression does not 
inhibit IL-6 induced differentiation of Ml cells. Differentiation
with OSM and LIP is inhibited .
CNTF and IL-11 both exhibit examples of functions shared with 
LIF but regulated in different ways and functions not shared 
with LIF. (Review Pellorce et al, 1994; Davis et al, 1993;
Introduction 5-6
Richardson, 1994; Robinson 1994; Gearing 1993; Hilton, 1992; 
Gough and Williams, 1989; Metcalf, 1991).
It seems logical to deduce from these few examples that the 
apparent redundancy in cytokine action may represent an in 
vivo subtlety which is not obvious within the relatively crude 
restrictions of in vitro assay. Gearing argues that this 
functional overlap represents a synergistic mechanism which 
protects against toxicity. The fact that a molecule such as LIF 
has been conserved in so many systems shows significant 
physiological economy. If this is possible why would there be 
such a wasteful dynamic as so many identical molecules ? 
Despite the advances in in vitro culture techniques and the 
ability to use panels of anti-bodies against possible secondary 
cytokines the in vivo environment represents a delicate 
signalling network which may well be regulated in a manner 
which simply precludes the problem of redundancy. It may 
well be an in vitro artefact. The homology seen between these 
molecules may represent a common ancestor which has 
diversified to perform specific functions with suitable 
alterations to the molecular structure. It is worth noting that in 
the case of other related molecules showing high sequence 
homology, e.g. MlP-1-a and p, this does not itself guarantee 
functional similarity. MlP-1-a is a potent stem cell inhibitor, 
MIP-l-p, which shares 67% sequence homology with the 
former, is not. Identification of the functionally relevant 
regions of each of the above cytokines could resolve the 
redundancy question revealing that far from wasteful, the
Introduction £7
system exhibits great economy.with fine tuning of a core 
molecule for specific tasks.
LIF in haematopoiesis.
As outlined in the early part of this introduction 
haematopoiesis is a balance between differentiation and self­
renewal (proliferat ion and survival). The success of 
haematopoiesis relies on maintenance of this delicate balance. 
The importance of a molecule which can induce differentiation 
in one system (Ml leukaemic cells) and promote proliferation 
in another (ES cells (Smith et al, 1988) as a potential regulator 
in haematopoiesis is considerable. With the discovery that the 
SDK sequence was present in murine LIF, elucidating a role for 
LIF within haematopoiesis became important. Noting its 
relevance in AcSDKP function and the importance of other 
tetrapeptides such as AGR-GLY-ASP(RGD) (the sequence within 
fibronectin which mediates attachment (D'souza et al, 1991 ) it 
seemed possible that murine LIF could interact with stem cell 
stimulator.
LIF has been shown to induce the differentiation of Ml 
leukaemic cells to macrophage like cells as has IL-6 (although 
LIF is 16-25 times more effective) (Metcalf and Gearing, 1989). 
IL-6 is constitutivcly expressed by Ml cells and this expression 
increases in the presence of LIF. It is unlikely however that LIF 
acts through IL-6 as the increase is slight and the factors 
inducing lL-6 do not induce a response like that seen for LIF. 
Interestingly macrophages are known to express IL-6 so this
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may be a consequence of the cells differentiating rather than 
the cause. The LIF induced differentiation could be enhanced 
by addition of G-CSF or M-CSF to cultures but not by GM-CSF or 
IL-3. (Metcalf et al, 1988; Metcalf, 1989) Work by Maekawa et 
al (1990) notes that human myeloid leukaemic cell lines (HL60 
and U937) showed reduced clonogenicity in the presence of 
combinations of L1F/IL-6/G-CSF and GM-CSF but not to LIF 
alone. LIF was synergistic in this respect with G-CSF and GM- 
CSF. Wang et al (1990) report that LIF prolongs the doubling 
time of a clonogenic population of newly established acute 
myeloblastic cell lines in liquid culture. In normal 
haematopoiesis lL-6 and IL-3 act synergistically to support the 
proliferation of haematopoietic cells by decreasing the GO 
period of individual stem cells. (Ikebuchi et al, 1987; Leary et 
al, 1988). Takanashi et al, (1993) studied the effects of LIF on 
blast cell progenitors from human acute myeloblastic 
leukaemia (AML) in serum free culture. In stark contrast to the 
work of Metcalf and Maekawa they conclude that when used in 
combination with GM-CSF, lL-3 or IL-6 LIF increases AML 
blast proliferation and does not induce differentiation. The 
responses of various leukaemic models to LIF are heterogenous 
not all respond and in those which do both stimulation and 
inhibition are seen.
Metcalf et al, (1988) note that LIF had no colony stimulating 
activity for normal granulocyte-macrophage progenitor cells 
and did not alter their responsiveness to other cytokines (IL-6 
and G-CSF) Metcalf, (1989). Several groups however suggest 
that LIF may have a role to play in the production of normal
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blood cells. Fletcher el al, (1990) undertook a study to test the 
effects of LIF on recovery and retroviral vector infection of 
CFU-S 13 in vitro. The frequency of CFU-S 13 infection was 
increased in groups of murine bone marrow cultured on 
irradiated virus-producing fibroblasts in the presence of LIF. 
As infection is thought to require the host to transit the cell 
cycle, it appeared that LIF either induced CFU-S proliferation or 
promoted their survival. The fact that there was no detectable 
alteration in the differentiation potential of the CFU-S suggests 
that the latter may be the case. Leary et al, (1990) report the 
ability of LIF, independently of IL-6, to act as a secondary 
cytokine augmenting IL-3 dependant proliferation of early 
haematopoeitic progenitors (CD34+ cells). Verfaillie and 
McGlave, (1991) take this work further concluding that LIF 
excerpts its activity by direct interaction with CD34 cells and 
does not require accessory cells. A study by Escary et al, 
(1992); Dumenil el al, (1993) using LIF deficient mice derived 
by gene targeting techniques shows these mice to have 
dramatically decreased numbers of stem cells in spleen and 
bone marrow. Two points of fundamental importance arise 
here. Firstly remaining stem cells retain pluripotency showing 
that if stem cell survival is a function of LIF it is not unique to 
LIF alone. Secondly the number of committed progenitors are 
reduced in spleen but not in marrow suggesting a differential 
role for LIF in haematopoiesis between these two. In brief LIF 
thus appears to be important for maintenance of a complete 
stem cell pool. It is worth considering that if LIF were really a 
redundant cytokine then surely its action in knockout mice
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would be taken up by another molecule and this pathology 
would not result. Schaafsma et al (1992) report that in LTBMC's 
LIF did not alter the proliferation and differentiation of 
committed haematopoietic progenitor cells.
The past five years has seen the emergence of LIF as an agent 
promoting megakaryopoiesis both in vitro (Metcalf et al, 1991) 
and in vivrr(Melcaif et al, 1990) (Review Waring et al, 1993). 
LIF injection to mice results in an increase of spleen 
megakaryocytes and circulating platelets (Metcalf et al, 1990) 
and in combination with IL-3 potentiates megakaryocyte 
production in cell culture (Metcalf et al, 1991). It is suggested 
that the CD34+ cell stimulation with IL-3 and enhanced by LIF 
may actually be elevated megakaryocytopoiesis. (Debilli et al ). 
Does this relate to the HPP-CFC meg population seen by Han 
(1994) ?
The pattern emerging from this work suggests that LIF in fact 
acts at two stages in haematopoiesis. Initially it may have a 
role in maintaining early stem cells. Later it may effect
megakaryocytopoiesis. (Diagram 8)
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DIAGRAM 8 THE INTERACTION OF LIF WITH HAEMATOPOIETIC CELLS . 
(It should be noted that some of these interactions are from 
human tissue whilst others are associated with murine 
haematopoiesis . The diagram represents a possible scheme of 
LIES action should these activities emerge as identical 
between murine and human tissue) .
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S u m m a r y
LIF is a highly piieolrophic molecule with a staggering array of
often contradictory functions. It is known most famously for its 
role in leukaemic cell differentiation but in fact this may prove 
a misnomer as this is a far from consistent finding. In 
haematopoiesis it may play at least a two stage role and in the 
murine form it contains the SDK sequence.
1.4 Aims
This study was primarily concerned with elaborating the role 
of factors associated with, or interacting with, leukaemic cell 
populations, in the control of the proliferation of normal
haematopoiesis.
Firstly Leukaemia inhibitory factor: LIF. The primary aim was 
to determine LlF's ability to regulate proliferation in 
populations of primitive stem cells and committed progenitor 
cells derived from femoral marrow and foetal liver, in vitro.
A second aim was to assay LIF's effects on the responses 
induced by other cytokines in these cell populations.
The ability of Lib to influence clonogenicity and DNA synthesis 
in a leukaemic cell population was also assessed.
Thereafter work focussed on activities associated with an X- 
irradiation induced murine myeloid leukaemia (SA2 JMBl).
The primary aim was to determine how this leukaemic cell 
population may interact with normal haematopoiesis. Thus
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conditioned medium derived from the leukaemic cells was 
assessed for its ability to regulate proliferation in populations 
of primitive stem cells and committed progenitor cells, in vitro 
As in studies with LIP, the effect of this conditioned medium on 
responses induced by other cytokines in these cell populations 
was also assessed. A further aim was to identify the 
activity(ies) which was/were associated with this conditioned 
medium.
CHAPTER 2: METHODS AND 
MATERIALS
2.1: MATERIALS
2.(1.1) Medium
Two types of medium were used in the course of this work:
a) Dulbecco's 10 x (Gibco) supplemented with: 50 lU/ml benzyl 
penicillin(Sigma); 50 pg/ml streptomycin sulphate(Sigma); 2mM 
L-glutamine (Flow); NaHCOg (BDH) according to manufacturer's 
recommendation; 20%(v/v) horse serum, unless otherwise 
quoted. (Globepharm Ltd)
This is referred to as 'Duibecco's 20%'.
b) Fischer's 10 x (Gibco) supplemented with: 50 IU/ml benzyl 
penicillin; 50 pg/mt streptomycin sulphate; 2mM L-glutamine; 
NaHCOg (BDH) according to manufacturer's recommendation; 
10%(v/v) foetal calf serum unless otherwise quoted
This is referred to as 'Fischer's 10%'
All media were prepared under conditions of absolute sterility 
in a Laminar horizontal flow hood (John Bass, Southampton).
As well as cell culture media a variety of conditioned media 
was used, details may be found below.
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2(1.2) Growth factors
The following growth factors were used throughout the course 
of this work:
RECOMBINANT
r mu Leukaemia inhibitory factor (LIF) (Gibco);
r hu Interleukin-la (IL-la) (Immunex);
r mu Interleukin-3 (lL-3) (Immunex);
r hu Macrophage colony stimulating factor (M-CSF) (Immunex); 
r mu Granulocyte-Macrophage colony stimulating factor (GM-
CSF) (Immunex).
CONDITIONED MEDIUM AS A SOURCE OF GROWTH FACTOR:
WEHl 3D myeiomonocytic Leukaemic cell line 
-source of lL-3 (Ihle et al (1982))
L929 fibroblast cell line - source of M-CSF (Stanley and Heard
(1977))
2(1.3) Tissue
All mice were housed in controlled animal house conditions and 
fed on a diet of chlorinated water, RMl chow (Special Dietary 
Services, Edinburgh) for general maintenance, or RM3 chow 
(SDS, Edinburgh) during breeding.
Tissue used was derived from four sources:
a) Femoral marrow from 9-12 week old CBA/H mice (Harwell); 
F)15 day foetal liver tissue from 9-12 week old CBA/H mice.
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c) Femoral marrow from 9-12 week old CDl mice (Charles 
River).
d) SA2 JMBl cells - a cloned cell line from, an X-irradiation 
induced myeloid leukaemia (Hepburn et al, 1987).
Mice were killed by ether inhalation overdose followed by 
cervical dislocation. The appropriate tissue was then removed 
from the animal.
2(1.3.1) Femoral marrow
In the case of femoral marrow the femur was removed to a 
petri dish (Sterilin). In the sterile laminar horizontal flow hood
excess muscle tissue was scraped away, and the end of the hip 
joint removed by single scalpel incision. With the cleaned 
femur held between a pair of sterile forceps a 1ml syringe 
(Becton Dickinson) with blue tip microlance needle (23G ( 
0.6mm x 25 mm )) ( Becton Dickinson) and containing 0.5ml 
Duibecco's medium was used to gently bore a hole through the 
epiphyseal cartilage plate (knee) just into the marrow cavity. 
This done the medium was gently forced into the femur 
through the syringe, washing the marrow out into a 5ml plastic 
vial scalpel. The femur was then inverted and, by gently 
inserting the needle at the level of the cut pelvic joint, washed 
through in the opposite direction with an equal volume of 
Duibecco's 20%. The femoral shaft was washed through in this 
manner several times. This process was repeated for each 
femur.
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Single cell suspension
To obtain a sinnle cell suupennion the collected marrow was 
gently sucked up and down the 1ml syringe,, firstly through the 
blue tipped mierneanee needle and secondly through an orange 
tipped microlance needle (25G (0.5mm x 16mm)) (Becton 
Dickinson). Cells were then transferred to alO ml red-top 
conical centrifuge tube (Sterilin), made up to a final volume of 
8mls with Duibecco's 20% and washed by spinning at 1000 
r.p.m. for ten minuues in a Centaur 2 cenrriuuge (F^on) -MSE) . 
The medium was then pouued oof, ceB) resuspended nn 1ml 
Duibecco's by gently sucking them up and down a PI000 
Pipettman (Gilson's) with blue c200v pipette tip (Greiner), 
made up to a final volume of 8ml with Duibecco's 20% and spun
as before. Again the medium was then poured off and the cells
resuspended in l-3ml Durbneeo'i 20%. The process is
summarised in diagram 9
2(1.3.2) Foetal liver
15 days after the appearance of a vaginal mucous plug,
pregnant mice were killed as described above 2(1,3). Tearing 
of the ventral skin followed by dissection of the abdominal
cavity revealed the uteri containing the foetuses. This was 
removed by cutting the horns of the uterus at the lateral
margins using sterile scissors, and lifting the foetuses clear
with sterile forceps. The tissue was then placed in a petri dish 
(Sterilin) lined with gauze (Smith and Nephew. Foetuses were
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removed firstly from the uterus, and then the amniotic sac, by
scalpel dissection, decapitated and laid out ventral side up. The 
large, red, haematopoietically active liver could clearly be seen
in the foetal abdominal cavity. The tips of Sterile watchmaker 
forceps were laid across the abdominal cavity with the liver in 
between. By applying gentle pressure to the forceps the liver
was forced from the abdominal cavity onto the forceps tips and 
could be removed. This method was useful in that it decreased 
the likelihood of non-experimental tissue being removed with
the liver.
Single cell suspension
To obtain a single cell suspension the liver was first sucked up
into a 1ml syringe (without needle) thus disrupting the 
structure. The resultant tissue was then treated exactly as
outlined for femoral marrow in 2 (1.3.1).
The process is summarised in diagram 9
Methods and materials.
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DIAGRAM 9 EXTRACTION OF BONE MARROW AND FOETAL LIVER TISSUE
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2(1.3.3) SA2 JMBl Cells
A clone of an X-irradiation induced murine myeloid leukaemia 
(SA2 JMBl) which grows in-vitro in the absence of exogenous
growth factors (Hepburn et al, 1987) was used to investigate 
the effects of myeloid leukaemia on normal haematopoiesis. 
The Leukaemic potential of the clones had been verified in CBA 
mice by intraperitoneal injection of 5 mice with 105 cells per 
mouse. After 23 days all mice were dead .Autopsy revealed 
enlarged infiltrated spleen.
SA2 JMBl cells were diluted in Fischer's 10% to 2 x 104 cells 
per ml. This medium was best for optimal proliferation of the 
cells over the desired incubation period. It sustained levels of 
proliferation which did not result in overcrowding of the 
culture flask, depletion of nutrients and/or accumulation of 
toxic products detrimental to the cells. 10 ml of this cell 
dilution was transferred to a 25ml vent topped cell culture 
flask (Nunclon) and incubated for 3 days in a Leec incubator at 
37°C with 5% CO2 and a fully humidified atmosphere. With a 
doubling time of approximately twenty-four hours under these 
conditions, cells proliferated to numbers approximating 
1million per ml.(Diagram 10)
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Single cell suspension
After three day incubation, cells were transferred to a 10ml 
conical bottom red topped centrifuge tube and centrifuge spun 
at 'lOOOrpm for 10 minutes. The medium was then poured off 
and discarded. The cells were resuspended in 8ml fresh 
medium by firstly, gently sucking them up and down a 10ml 
glass pipette, then a 5ml glass pipette, and finally a 2ml glass 
pipette (All John Poultern Ltd Essex). They were then spun as 
in 2(1.3.1). After spinning excess medium was again poured off 
and the cells resuspended in 3ml fresh medium.
Viablility of the cells was determined by transferring 1ml of 
cell suspension to a 5ml teklab, to which was added 50ul of fast
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green (Sigma) (2%(v/v) in 100ml 0.9%(v/v) NaCl filtered 
through a O.2pm millipore filter) (Bosanquet et al 1983). This 
was then incubated in a water bath at 37° C for 15 minutes. 
Fast green is a stain excluded by live cells. Using a 145mm 
glass pasteur pipette (John Poultern ltd, Essex) one-two drops 
of stained cell suspension was placed on a 76mmx26mm 
microscope slide(BDH), and a 22x22mm cover slip ( Chance 
Proper Ltd, England) gently laid on top. The suspension could 
then be screened under the light microscope (Ernst Leitz 
Weltzer, Germany) for the presence of dead cells, which were 
stained green. Viability of greater than 15% was considered 
suitable for further cell passage.
2(1.3.4) FDCP-A4 Cells
In the 1980's Spooncer et al described how haematopoietic cell 
lines could be isolated and cloned from murine long term bone 
marrow cultures (LTBMC's) These were dependent on IL-3 for 
their survival and proliferation and had a limited
differentiation potential in that under the correct conditions 
they could become neutrophils or macrophages. These lines 
were designated FDCP-factor dependent cell lines Patterson. 
Whereas these lines were derived from normal LTBMC's it was 
also found that following injection of bone marrow with a 
retrovirus carrying the SRC oncogene, growth factor dependent
cell lines could be generated which were multipotent. These 
were able to produce cells of the erythroid, megakaryocyte, 
neutrophil, macrophage, eosinophil, mast cell and osteoclast
Methods and materials 13
lineages. These were designated FDCP-mix cells because of this 
property. In the presence of IL-3 these cell lines undergo self­
renewal without differentiation. They are dependent absolutely 
on IL-3 for their survival and proliferation. At points in the 
latter part of this work it was neccessary to assay for the 
presence fof IL-3, FDCP-mix A4 cells (One FDCP-mix clone) 
were used routinely in this work.
General protocol
In a 30ml universal cells were diluted in F20% horse 
serum+10%WEHIcm, to a concentration of 6 x 104 cells/ml. 
10ml of this dilution was prepared. This was transferred to a 
25ml vent topped cell culture flask(Nunclon) and incubated for 
2-3 days in a Leec incubator as in 2(1.3.3) Cultures generally 
became static at 8-10 x 105 cells/ml.
2(1.3.5) Determining cellularity
Cellularity was determined by diluting a known volume of cell 
suspension in a known volume of Isoton (Coulter Euro 
Diagnostics), lysing the red cell population using three drops of 
Zaponin (an acetic acid based lysing agent ) (Coulter electronics 
Ltd) and counting on a Coulter counter model ZM (Coulter 
electronics Ltd). In the case of SA2 JMBl and FDCP/A4 cells 
zaponin addition was not necessary as no red cell population 
was present. Previous work had determined that the optimal 
Coulter settings for accurate cellularity readings were:
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TISSUE
PARAMETER
current
Lower threshold
Full Scale
Polarity
Attention
Preset gain
Table 1M: Cell Counting
2 (1.4) PREPARATION
Femur! Sa2 cells FDCPA4
Foetal liver
130 700 700
3 0 21 1 5
1 0 1 1
+ + +
1 1 1
2 1 6
OF CONDITIONED MEDIA
2 (1.4.1) SA2 JMBl Conditioned media
SA2 JMBl cells were diluted to a concentration of 105 cells/ml 
in Fischer's 10%. 10 ml of this dilution was transferred to a 
25ml vent topped cell culture flask (Nunclon). This was gassed 
with CO2 for 15-20 secs and incubated for three days in an 
incubator at 37°C, 5% CO2 in air, fully humidified atmosphere. 
Thereafter the cell suspension was transferred to a 10ml red 
topped conical bottomed centrifuge tube and centrifuge spun at 
lOOOrpm for ten minutes. This process resulted in a firm cell 
pellet being precipitated at the base of the centrifuge tube. By 
a quick single tip of the centrifuge tube the medium could be 
transferred to a second identical centrifuge tube leaving the 
cell pellet behind. The pellet was then either discarded or
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retained for the preparation of more conditioned medium. The 
medium was centrifuge spun at 3000 rpm for a further ten 
minutes. This led to a small opaque pellet, presumed to be cell 
debris, being precipitated at the base of the centrifuge tube. 
Again a single swift tip of the centrifuge tube allowed the 
medium to be poured off into a sterile 50ml glass beaker 
leaving the pellet behind to be discarded. The 'clean' medium 
was then aliquoted into 5ml plastic vials , labelled, frozen and 
stored at -20OC until use .
2 (1.4.1.1) Ultrafiltration in the Centricon 
microconcentrator
SA2JMB1 conditioned medium was screened by molecular 
weight in this work. In order to attain different molecular 
weight fractions it was necessary to filter the medium. This 
was accomplished on a Centricon micro-concentrator.
General Protocol
Concentration was achieved by ultrafiltering a sample of
conditioned medium through a Centricon 10 or Centricon 50 
microconcentrator (Amicon). The filter unit consists of three 
parts. Firstly the sample reservoir containing the important 
lOKd filter and into which a known volume of the solution to 
be filtered is placed. This is connected, at its base, to the second 
part: the filtrate cup. The third part, the retentate cup, is then 
placed on top of the sample reservoir. (Diagram 11).
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RETENTATE CUP
◄--------------- SAMPLE RESERVOIR
◄ --------------- SAMPLE
◄ --------------- FILTER UNIT
◄--------------- FILTRATE COLLECTION
CUP
DIAGRAM 11 STANDARD AMICON ULTRAFILTRATION UNIT
The entire device is then centrifuged. Centrifugal force drives 
the solution in the sample reservoir through the filter and into 
the filtrate cup. The size of the filter means that only molecules 
smaller than lOKd will pass through the filter thus 
concentrating the larger molecules on the other side. By ceasing 
centrifugation after a known volume has passed into the 
filtrate cup the level of concentration may be known. After 
initial centrifugation the filtrate cup may be separated from 
the sample reservoir. The sample reservoir is then inverted 
and centrifuge spun thus driving the remaining solution into 
the retentate cup. Both filtrate and retentate may then be 
stored and assayed for relevant activity.
Sterilising apparatus
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1n line with manufacturers recommendations all parts of the 
filter unit were placed into the sterile hood and treated with 
70% alcohol for lOminutes, then vigorously washed with sterile 
water. The apparatus was shaken dry. This meant that the 
solutions recovered from the filter could be used in bioassays 
without fear of contamination.
Ultrafiltration 1n the sterile hood
2ml of medium was aliquoted into the sample reservoir. The 
filtrate cup was then added and, in place of the Retentate cup, a 
piece of sterile foil tightly wrapped around the top of the 
sample reservoir. (The retentate cup did not fit in the 
centrifuge). The unit was now ready for the ultra-centrifuge. 
Units were placed in ruuber innerts, fod enn up. The inserts 
were then placed into the J-20 rotor (Beckman) and balanced. 
The rotor was then transferred to the J2-21 M/E ultra­
centrifuge (Beckman) at 4°C and spun at 6500rpm for 30mins- 
lhour. At the end of this time the filter units were carefully 
removed from the inserts, placed on ice and transferred to the 
sterile hood. The frittata cup now contained a sooutton ((.6­
1.8ml) with those molecules smaller than lOKD. The sample 
reservoir contained a solution (200-400ul) with those 
molecules larger than lOKD. The foil was removed from the 
sample reservoir and 1.8ml sterile distilled water added to the 
volume in the sample reservoir. The contents of the filtrate cup 
were transferred to a 2ml epindorph the foil cap replaced on 
the sample reservoir and the unit spun as before. This process 
was repeated twice .Thereafter the unit was topped up to 2ml
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with SA2cm and filtered as before. This was repeated three 
times. At the end of the third spin the foil was replaced with
the retentate cup. The capped sample reservoir was then 
removed from the filtrate cup inverted and reconnected via the 
retentate cup. The unit was then placed into the Centaur 
centrifuge and spun for 10 mins at 3000rpm. Thereafter the 
unit was returned to the sterile hood and the filtrate cup was 
separated from the retentate cup. 1ml sterile water was added 
to sample reservoir. The solutions from both cups were 
aliquoted into separate plastic vials, refrigerated at +4oC or 
frozen and stored at -20°c. Fractions were then assayed for 
activity as outlined in 2(3.1.5) (Diagram 12)
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◄------- - CUP REPLACED
WITH FOIL
----- ULTRA-CENTRIFUGE CONCENTRATED SAMPLE
FILTRATE
A
SAMPLE RESERVOIR ------
WITH CAP
SEPERATE THE TWO UNITS 
REPLACE FOIL WITH CAP 
INVERT AND CENTRIFUGE
FILTRATE CUP
ASSAY FRACTIONS AS NECESSARY
l
\
DIAGRAM 112 SUMMAR Y OF METHOD USED IN UL TRAFIL TRA TION
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2 (1.4.2) Source of a haematopoietic stimulator-
medium conditioned by regenerating bone marrow.
Following haematopoietic damage the normally quiescent stem
cell compartment is 'switched on', primitive cells come into 
cycle generate progeny and the system is regenerated. (Becker 
et al (1965)). A consequence of this regeneration is thought to 
be the production by mononuclear
phagaocytes of a stem cell specific cell stimulator. It has been 
determined that medium exposed to regenerating marrow will 
become rich in this stimulator and can then be used to 
stimulate quiescent 'stem cells'. (Lord et al (1977), Wright and 
Lord (1978), Wright et al (1982) ).
To obtain stimulator CDl mice were given 4.5Gy whole body y- 
irradiation (CIS Biointernational IBL 437C 137Cs y-radiation 
source with a dose rate of 4.66 Gy/min). Seven days later they 
were killed their femurs extracted and a single cell suspension 
of regenerating femoral marrow in Duibecco's 20% made as 
described in 2 (1.3.1) (Robinson et al (1994) ). Cellularity was 
then determined, adjusted to 15-25 x 10° cells/ml and the cell 
suspension transferred to a 30ml universal (Sterilin)
. The universal was incubated in a water bath at 37°C for 3 
hours. Thereafter the cell suspension was centrifuged, 
aliquoted and stored according to the protocol laid out for SA2 
JMBl cells in 2 (1.3.3). When thawed the medium was filtered 
through a 0.22|im pore filter (Millipore) into a 5ml plastic vial 
prior to use.
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2.2: ASSAYS
2(2.1) COLONY FORMING CELL ASSAYS
2 (2.1.1) Cell culture in semi-solid agar
Much of the present knowledge concerning haematopoiesis has 
come about as a result of techniques allowing in-vitro cell 
study. In this work use is made of clonogenic assays for 
progenitor and more primitive cells in semi-solid culture 
medium stimulated with a variety of growth factors or 
conditioned medium, (e.g. L929 fibroblast cell line - a crude 
source of M-CSF / CSF-1 or WEHI 3B myeiomonocytic 
Leukaemic cell line- a crude source of IL-3 ). The growth factor 
requirements and incubation times of individual assays may be 
manipulated to select for specific haematopoietic cell 
populations .
2 (2.1.2) Assay for the Granulocyte-Macrophage colony
forming cell (GM-CFC)
This assay allows the development of colonies containing 
mature cells from two distinct myeloid lineages from the 
granulocyte-macrophage progenitor cells. (See introduction) In 
brief the assay involves single layer semi-solid agar culture of 
haematopoietic cells with growth factors, for 7 days. (Heyworth 
and Spooncer (1993)).
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General protocol
A bottle of 3% (v/v) agar (Bactoagar, Difco) was suspended in a 
boiling water bath. In the stei^ilii horizontal flow hood 
Duibecco's 20% and growth factors in appropriate volr^rmes; 
were Pipetted into a 30ml universal. This was warmed for 
approximately five minutes in a 33°c water bath. Eighi 10ml 
triple vent non-tissue culture grade petri-dishes (Sterilin) were 
laid out in the hood and labelled. Femoral marrow or foetal 
liver cells extracted as outlined above were diluted to 5 x 10C 
/ml in Duibecco's 20%. The warmed universal was then 
removed from the water bath swabbed and placed in the 
sterile hood. 1ml of the cell suspension was pipetted into the 
universal using the Gilson P1OOO. This was thoroughly mixed 
by gentle inversion of the universal. 1ml of the now boiling 
3%(v/v) agar wws added to the univeilet using a 1ml 
disposable sterile syringe (Becton Dickinson). This was 
thoroughly mixed by repeatedly drawing it up and down a 1ml 
c200v blue tip pipette on a P1OOO Gilson Pipettman. 1ml of the 
mixture was then pipetted into each of the petri-dishes .Dishes 
were gently swirled around to spread the mixture out over the 
entire surface of the plate. The layer, which contained 
0.3%(v/v) agar, relevant growth factors and 5 x 10C cells/ml (5 
x 104 cells total), w as then aHwwed io set. Tsis took 
approximately ten minutes.
Incubation
Set cultures wwe stored in an alcohol sterilised plasdc
container and incubated in a 3?Cc, 5% CO2 in air, fully
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humidified incubator for 7 days. The short life span of the cells 
within colonies means that after this time they will die and the 
colonies disperse.
Counting
After seven days dishes were removed from the incubator. 
Using a stereoscopic zoom microscope (Kyowa, Tokyo ) at 
magnification setting 1.5, colonies were counted using a tally 
counter(ENM England). In this assay a colony is taken to be a 
group of 50 or more cells. Three types of colony may appear: 
the macrophage colony (appears as a large dispersed group of 
cells); the granulocyte colony (appears as a tighter 'ball' of 
cells) and the mixed granulocyte-macrophage colony (an inner 
dense centre with a periphery of more dispersed cells) 
(Heyworth and Spooncer (1993)). Although this is subjective 
where relevant it is possible to note the number of each colony 
type per dish. This can be checked by cytological studies on 
any individual colony. Differential counting of this sort was not 
routinely used throughout this work. The emphasis was 
directed towards alterations in overall colony numbers. A 
summary of the protocol is shown in diagram 13
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t
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DIAGRAM 13 SUMMARY OF THE GM-CFC ASSAY
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2 (2.1.3) Assay for the High Proliferative Potential
Colony-Forming Cell (HPP-CFC)
In the HPP-CFC assay cells more primitive than those seen in 
the GM-CFC assay may be stimulated to form colonies with a 
combination of growth factors. (Bradley and Hodgson (1979)) 
(See introduction). Briefly the assay involves semi-solid agar 
bi-layer culture of haematopoietic cells. The basal layer the 
'feeder layer' is loaded with defined growth factors and 0.5% 
(v/v) agar (Bactoagar, Difco). This makes it an excellent growth 
factor supply, but, due to its high agar content is itself unable 
to support colony formation. A second layer, the 'culture layer', 
containing the cells and 0.3%(v/v) agar overlays the 'feeder 
layer'. The lower agar content of this 'culture layer' means that 
cells within it responding to growth factors leached from the 
'feeder layer' will be able to proliferate to form colonies. As the 
HPP-CFC compartment is heterogeneous altering the growth 
factors in the feeder layer will alter the cell type responding in 
the culture layer. (See chapter 1) Thus different HPP-CFC 
populations may be assayed.
General protocol
Feeder layer
A bottle of agar 5%(v/v) (Bactoagar, Difco) was suspended in a 
boiling water bath. In the sterile horizontal flow-hood 
Dulbecoo'i 20% and relevant growth factors in appropriate
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volumes (see below) were pipetted into a 30ml universal.This 
was warmed for approximately 5 minutes in a 37°C water- 
bath. Four 50ml diameter triple vent non-tissue culture grade 
petri-dishes (Sterilin) were laid out in the sterile hood and 
labelled. The universal was removed from the water bath 
swabbed with 70%(v/v) alcohol and placed into the hood. 
Immediately 1ml of the now melted 5%(v/v) agar was added to 
the universal via a 1ml disposable, sterile syringe (Becton 
Dickinson). The mixture was thoroughly mixed by repeatedly 
drawing it up and down a 1ml pipette on a Pl000 Gilson 
Pipettman 2ml of this mixture was then immediately plated 
into each of the petri-dishes using the Pipettman. The dishes 
were then allowed to set (approximately five minutes).
Culture layer
A bottle of 3% (v/v) agar (Bactoagar, Difco) was suspended in a 
boiling water bath. In the sterile hood 8ml Duibecco’s medium 
was Pipetted into a 30ml universal. This was warmed for 
approximately five minutes in a 37°c water bath. The petri- 
dishes with feeder layers were either ready or, if they had 
been placed in an incubator to avoid a pH swing, were laid out 
in the sterile hood. Cells extracted as outlined were diluted to a 
concentration of 2 x 105 cells ml in Duibecco's ( This cell 
number was selected because previous work indicated that it 
contained sufficient HPP-CFC to count comfortably without 
overcrowding of the dish). The warmed universal was then 
removed from the water bath swabbed and placed in the 
sterile hood. 1ml of the cell suspension was pipetted into the
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universal using the Gilson PI000. This was thoroughly mixed 
by gentle inversion of the universal. 1ml of the now boiling 
3%(v/v) agar was added to the universal using a 1ml 
disposable sterile syringe. This was thoroughly mixed as 
outlined above. Using the Gilson P1OOO , 2ml of the mixture 
was delicately pipetted over the feeder layer, particular care 
being taken not to puncture the set feeder layer. It was found 
that the best way to avoid this was to pipette in a spiral motion 
very near to the plate. The layer, which contained 0.3%(v/v) 
agar and 2 x 104 cells/ml (4 x 104 cells total), was then allowed 
to set. This took approximately ten minutes.
Incubation
Set cultures were stored in an alcohol sterilised plastic 
container and incubated in a 37°c, 5% CO2 in air, fully 
humidified incubator for 14 days.
Staining
Approximately 12 hours before assay cultures were removed 
from the incubator and 1ml of an autoclaved solution of Img 2- 
^-iodophenyG-S-(4-nitrophenyl)-5-phenyltetrazoriumchloride 
(INT)/ml/)0.9%(w/v) NaCl (BDH ) was added to each culture. 
The plates were then returned to the incubator. Over the next 
twelve hours the INT was metabolised by viable cells to a red 
tetrazolium salt. This was visible as a dark staining within 
colonies.
Counting
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After twelve hours further incubation the cultures were 
removed from the incubator and colony numbers per plate 
assessed. This was accomplished by placing a 1mm acetate grid 
beneath a plate, scanning for colonies of a given size and 
counting them.
The protocol for counting were :
a) For cultures stimulated with conditioned media as a source 
of growth factor HPP-CFC derived colonies were those greater 
than 2mm in diameter.
b) For cultures stimulated with recombinant growth factors 
HPP-CFC derived colonies were those greater than 1mm in 
diameter.
The protocol is summarised in diagram 14. Photographs of 
stained HPP-CFC colonies are shown in figure PHI.
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petri-dish l
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DIAGRAM 14 A SUMMARY OF THE HPP-CFC ASSAY
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D
FIGURE PH1 : The effect of varying growth factor regimes 
on colony formation in 14 day semi-soiid agar assays of NBM .
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2(2.1.4) Assay for SA2JMB1 clonogenicity in the 
absence of growth factors
In brief this assay involved 7-day single layer semi-solid agar 
culture of a leukaemic cell line in the presence or absence of 
growth factors.
General protocol
A bottle of 3% (v/v) agar (Bactoagar, Difco) was suspended in a 
boiling water bath. In the sterile horizontal flow hood 8ml 
Dulbecco's 20% was pipetted into a 30ml universal. This was 
warmed for approximately five minutes in a 37°C water bath. 
Eight 10ml triple vent non-tissue culture grade petri-dishes 
(Sterilin)were laid out in the hood and labelled. A single cell 
suspension of SA2JMB1 cells prepared as outlined above was 
adjusted to 2 x 104/ml in Dulbecco's 20%. The warmed 
universal was then removed from the water bath swabbed and 
placed in the sterile hood. 1ml of the cell suspension was 
pipetted into the universal using the Gilson P1OOO. This was 
thoroughly mixed by gentle inversion of the universal. 1ml of 
the now boiling 3%(v/v) agar was added to the universal using 
a 1ml disposable sterile syringe (Becton Dickinson). This was 
thoroughly mixed by repeatedly drawing it up and down a 1ml 
c200v blue tip pipette on a P1OOO Gilson Pipettman. 1ml of the 
mixture was pipetted into each of the petri-dishes .Dishes were 
gently swirled around to spread the mixture out over the 
entire surface of the plate. The layer, which contained
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0.3%(v/v) agar, and 2 x 103 cells/ml (5 x 103 cells total), was 
then allowed to set. This took approximately ten minutes.
Incubation
Set cultures were stored in an alcohol sterilised plastic 
container and incubated in a 37°c, 5% C02 in air, fully 
humidified incubator for 7 days. The short life span of the cells 
within colonies meaning that after this time they will die and 
consequently the colonies would disperse.
Counting
After seven days dishes were removed from the incubator. 
Using a stereoscopic zoom microscope (Kyowa, Tokyo ) at 
magnification setting 1.5 colonies were counted using a tally 
counter(ENM England). In this assay a colony is taken to be a 
group of 50 or more cells. The colonies are very different to 
those seen in the GM-CFC assay being much tighter, denser 
centres of proliferation. This is convenient as it means that 
should leukaemic clones become differentiated any differences 
in colony type which may arise as a result would be obvious. 
Such observations could be confirmed by cytological studies.
2(2.1.5) Assay to measure the effect of preincubaSion 
with exogenous factors on the size of a colony forming 
cell pool
It was important not only to determine the effect of exogenous 
factors on colony formation by haematopoietic cell populations ,
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but also to determine the effect on these populations of 
preincubation with factors, prior to assay. Femora were 
removed from mice and a single cell suspension prepared in 
Dulbecco's 20% as outlined in 2 (1.3.1).Cellularity was 
determined and adjusted to 5 x 106 cells/ml. The required 
volume, dependent on the number of exogenous fcators under 
assay, of this dilution was prepared. One red-topped conical 
bottomed centrifuge tube for each test condition, was swabbed 
with 70% alcohol and placed into the sterile hood. Using the 
P1OOO Gilson Pipettman and C200v tips, 1ml aliquots of cell 
dilution were pipetted into each tube. Using C20v tips 
appropriate dilutions of relevant factors were aliquoted into 
each tube. The pipet tip was brought just into the 1ml cells to 
ensure that the entire aliquot was delivered. A control tube, 
received an aliquot of Dulbecco's 20% only. The tubes were 
then incubated in a 37° C water bath for 2 hours with occasional 
vortex mixing. At the end of this time 7ml Dulbecco's 20% was 
added to all tubes. Tubes were then washed twice by 
centrifuge spinning in the manner described in 2(1.3.1). 
Thereafter each washed cell pellet was resuspended in 1ml 
Dulbecco's 20% taking a fresh pipette tip for each tube. 
Cellularity was determined for each tube .2(1.3.4)
GM-CFC
The cells in each tube were diluted to a concentration of 5x 
lO5/ml. 2mls of this dilution was prepared. A GM-CFC assay 
stimulated with the relevant growth factor was carried out for
each tube. 2(2.1.2)
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HPP-CFC
The cells in each tube were diluted to a concentration of 2 x 
105 cells/ml. 4mls of this dilution was prepared for each tube.
Assays for HPP-CFC stimulated with relevant factor
combinations were performed for each tube .2(2.1.3)
2 (2.1.6) Assay to measure the uptake of tritiated
thymidine by femoral bone marrow in limited volume 
liquid suspension culture
In this experiment samples of whole bone marrow were 
cultured in limited volume liquid suspension culture with a 
known or unknown growth factor (s). Tritiated thymidine is 
taken up by cells in DNA synthesis. If a population of cells is 
treated with tritiated thymidine for a given time then washed 
any remaining radioactivity not washed away is a measure of 
thymidine uptake and is therefore an indication as to the 
proportion of a cell population in DNA synthesis over the 
period for which the thymidine label was available. By adding 
tritiated thymidine to limited volume cultures stimulated with 
growth factor(s) it was thus possible to determine the effect of 
this growth factor on the proportion of the cell population in S- 
phase.
General protocol
Femora were removed and a single cell suspension prepared as 
noted in 2( 1.3.1) above. Cellularity was determined and
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adjusted to 5 x 105 cells/ml. A 96 well microtitre plate (Nunc) 
and lid (Nunc) were placed into the sterile hood and removed 
from packaging. The plate was divided up as necessary 
depending on the required number of test conditions. Using the 
P200 Gilson Pipettman and C20V tips, lOOuL of cell suspension 
was pipetted into each of the well. Aliquots of test growth 
factors were pipetted into each well to a final well volume of 
two hundred ml.
Four replicate plates were prepared one for each of four time
points.
Plates were then placed in four vented plastic containers 
sterilised with 70% alcohol and placed in the incubator at 37°C 
with 5% CO2 in air and a fully humidified atmosphere.
At twenty four hours
Twenty four hours after incubation the first plate was removed 
from the incubator to the sterile hood. Tritiated thymidine 
(Amersham LTD) was diluted from a stock of 37 Mega 
Bequerels to 300KBq/ml. 25ul of this was added to all wells in 
both blocks. The plate was replaced in the plastic container and 
returned to the incubator for 18 hours.
Harvesting the cells
The cells were harvested using a Titerteck cell harvester 
(Skatron Norway). The equipment consists of three major parts: 
a cell suction head; a filter holder and a wash disposal system. 
The cells suction head has 12 pairs of small pipes mounted in a 
plastic casing which line up with the 12 wells in any one row of
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the microtitre plate. When activated one pipe carries the wash 
fluid (in this case saline-0.9%v/v NaCl) into each well, the other 
aspirates the wash and cells from each well .The filter holder 
consists of 12 0-rings mounted on a plastic casing which when 
locked onto a filter paper form 12 separate filter discs. Each 
disc corresponds to a well on the microtitre plate. The wash 
disposal system consists of a switch to control the wash cycle of 
cells and a collecting vessel in vacuum. When the switch is 
activated cells from the microtitre plate are washed to the 
filter paper where they are deposited, the remaining wash 
being sucked through into the collecting vacuum vessel. A 
separate switch to draw in air to 'dry' the filter paper after 
washing is also present.
Method
Having established a Vacuum in the collecting vessel a piece of 
glass fibre filter paper (Skatron) was inserted into the rear of 
the filter holder smooth side up. Notches on the filter paper 
allow it to be lined up with guides on the filter holder to 
optimize the number of wells sucked through one filter paper. 
The filter holder was then locked down onto the filter paper. 
The suction head was placed into an empty row of wells in a 
separate microtitre wash plate. The wash switch was pressed 
down (to operate) for 5 seconds. This pre-wet the filter paper 
in line with manufactures recommendations for optimal cell 
recovery. The wash plate was replaced with the experimental 
plate. The suction head was placed over the first row of wells 
to be harvested and the wash switch depressed for 10-15
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seconds. The air switch was then depressed for 10-15 seconds. 
The filter clamp was gently (to prevent filter discs sticking to 
the filter clamp) released and the filter paper moved forward 
to the next filter point by carefully lifting it on a paper towel. 
The clamp was then locked down on the new section of filter 
paper and the entire process repeated for the next set of wells . 
After all wells had been washed the filter paper was gently 
placed in an oven (Macfarlane Robson LTD) at 60°C for 1-2 
hours, to dry.
Measuring Thymidine uptake
Thymidine uptake was measured using a 1214Rackbeta 
scintillation counter (LKB Loughborough). Using plain tweezers 
dry filter discs were pushed out into labelled counting vials, an 
accurate note of this process was made. 2ml of a liquid 
scintillation fluid 'Optiphase safe' (LKB) was aliquoted into each 
tube. Tubes were then placed into racks and inserted into the 
scintillation counter which was set to measure activity from a 
tritiated source. Briefly the machine measures very low levels 
of light. These are generated by decaying radioactive material 
liberating radiation (in this case Beta) which reacts with 
scintillant to give photon emissions. The level of light emission 
is translated by the counter to a number. The greater the 
number the greater the light emissions.
This whole process was repeated for each time point.
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2 (2.1.7) Assay to measure the proportion of GM-CFC
and HPP-CFC in DNA synthesis- The S-phase suicide 
assay.
Measuring the proliferative activity of GM-CFC or HPP-CFC
requires a manipulation of the colony assay techniques 
outlined above. Cells which possess a colony forming potential 
will express that potential when plated in semi-solid agar 
supplemented with appropriate colony forming signals. This 
gives a measure of the clonogenicity of that population but 
does not tell us about the proportion of that clonogenic 
population in DNA synthesis at any one time. However, if, prior 
to plating, the cells are treated with an agent which will 
selectively destroy those cells in DNA synthesis, this killing 
effect would translate as a loss of colony-forming capacity in a 
colony assay. Thus there would be a decrease in the overall 
number of colonies which when compared to a control (which 
had not been treated with a killing agent ) would give an 
indication as to the percentage of that population in S-phase. 
Such an S-phase specific killing agent is cytosine arabinoside 
(1 -b-D-arabinofuranosylcy tosine (ARA-C) ). This agent is 
treated by the cell as cytosine being incorporated into the 
newly synthesized DNA. Unlike cytosine however, ARA-C 
sterically hinders the binding of subsequent bases to the DNA 
chain preventing successful replication and ultimately leading 
to cell death. Within normal femoral marrow in-vitro the HPP- 
CFC population is generally not cycling with a relatively low 
background value of 10-15% S-phase. The level of cycling in
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the GM-CFC population however is higher with 20-30% in S- 
phase (Robinson et al 1993). Thus it is possible to test an 
exogenously added factor as a possible stimulatory signal for
normal HPP-CFC and as an inhibitor for normal GM-CFC .
General protocol
A known dilution of cells is aliquoted into paired red topped 
conical bottomed centrifuge tubes, one pair for each exogenous 
factor under study plus one control pair .The exogenous factor 
under study is then added to both tubes in each pair. Tubes are 
then incubated in a water bath for a given number of hours 
dependent on whether a factor is being tested as an inhibitor 
(4hr) or stimulator (2hr). At the end of this incubation Ara-C 
(the S-phase specific killing agent) is added to one tube in each 
pair and all tubes returned to the water bath for a further one 
hour incubation. At the end of this time cells are washed 
resuspended, counted, diluted and assayed using either the 
HPP-CFC or GM-CFC assays described above.
2 (2.1.7.1 ) Manipulation of the percentage HPP-CFC in 
S-phase
The assay outlined above is limited in that it can examine only 
the effect of potential stimulators on HPP-CFC. It is often 
desirable to test the potential of an exogenous factor as an 
inhibitor for HPP-CFC cycling. In order to do this it is first 
necessary to bring the quiescent HPP-CFC into cycle. This can 
be accomplished in two ways:
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Direct
1 By introducing an 'insult' to the femoral marrow.
In this case mild irradiation was used to push the HPP-CFC 
population into cycle (Robinson et al 1993).
Regenerating femoral bone marrow.
CBA mice were given 2Gy whole body g-irradiation (CIS 
Biointernational IBL 437C 137Cs y-radiation source with a dose 
rate of 4.66 Gy/min). Three days later they were killed their 
femurs extracted and a single cell suspension of regenerating 
femoral marrow in Dulbecco's medium made as described 
above. (Note that the cells were NOT washed by centrifuge 
spinning ). Cellularity was determined, adjusted to 5 x 106 
cells/ml. Exogenous factors could then be tested as an inhibitor 
of HPP-CFC cycling in this population following the protocol in 
2(2.1.4.2.)
Indirect
Normal femoral marrow can be 'switched on' by the addition of 
a factor which brings the quiescent HPP-CFC population into 
DNA synthesis. One such stimulator of DNA synthesis in the 
primitive stem cell pool is the conditioned medium derived 
from 7 day post 4.5 grey gamma irradiation mice as outlined in 
2(1.4.2). Normal femoral marrow cells are pre-treated with 
this stimluator in the presence or absence of exogenous factors. 
An S-phase suicide assay for HPP-CFC is then performed as
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outlined in(2(2.1.4.2)). The level of S-phase kill can then be 
taken to show whether exogenously added factors have acted
to inhibit the stimulation of HPP-CFC.
2(2.1.8) Assay tt meanLire the abnliy of exoggnoois 
factors to interfere with the action of a stem cell
stimulator- the 'stimulator-block assay'
This assay is designed to study the effects of exogenous factors 
on the action of a stem cell stimulator defined above 
(2(2.1.5.2)). It is essentially a refinement of the stimualtor
assay.
General protocol
A known dilution of cells is aliquoted into paired red topped 
conical bottomed centrifuge tubes, one pair for each exogenous 
factor under study plus one control pair. 1ml of ’stimulator’ 
was then aliquoted into all but the control tubes to which 1ml 
of Delbecco’s 20% medium is added. The exogenous factor 
under study is then added to both tubes in one pair, to a 
second pair and the control pair an equal volume of medium is 
added. The tubes are then incubated in a water bath for 2hr. 
Thereafter the assay continues as a standard S-phase suicide 
assay 2(2.1.7).
Assays for HPP-CFC stimulated with relevant factors are
performed for each tube.
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2(2.1.9) Assay to measure the ability of exogenous 
factors to interfere with the production of a stem cell 
stimulator- the 'stimulator production block assay'
Exogenous factors could prevent cell cycling by interfering with
the action of cell stimulator or the manufacture of cell 
stimulator. This technique assays the ability of factors to block 
the synthesis of stem cell stimulator.
General protocol
To obtain stimulator the protocol in 2 (1.4.2) was used. Post 
femur extraction cells were centrifuge washed twice 2(1.3.1). 
Cellularity was determined and adjusted to 25 x 106 cells/ml.
As much as possible of this dilution was made- ideally twelve 
ml or more. For every four ml of cell dilution 1 red-topped 
conical bottomed centrifuge tubes was swabbed with 70% 
alcohol and placed into the sterile hood. Using the Gilson 
Pipettman 4ml aliquots of cell dilution were pipetted into each 
tube. The exogenous factor under study was then added to each 
relevant tube and an equal volume of medium to the control 
tubes. The tubes were then incubated in a water bath at 37®C 
for 3 hours. Thereafter the cell suspensions were centrifuged 
aliquoted and stored according to the protocol laid out for 
conditioned media, above 2(1.4.2). When thawed the medium 
was filtered through a 0.22pm pore filter (Millipore) into a 5ml 
plastic vial prior to use.
The medium was then used as a source of stimulator in a the 
stimulator assay laid out in 2(2.1.7.1).
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2.3: DATA
2(3.1) STATISTICS
2(3.1.1) Comparing data
Data was always normalised as a percentage of the control. 
That is in any experiment where results were not quoted as a 
percentage (e.g colony assays) the control was set as 100%. All 
other data within the experiment was expressed as a 
percentage value relative to this control .
For example consider specimen experiment 1:
CONTROL CONDITION A CONDITION B
MEAN COLONY
NUMBER
24 24 20
AS A 100% 24/24 X 100 20/24 X 100
PERCENTAGE 100% 83%
This meant that data between experiments could be compared 
as it was expressed in absolute terms.
Data was evaluated with respect to controls by comparing the 
mean of the treatment condition data with the mean of the
control data via the Student’s T-test.
This is a parametric test for assessing whether the means of 
two populations can be regarded as equal. The initial 
assumption is that the two means are the same (the null
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hypothesis). If it turns out that there is a very low probability 
of obtaining the results when the null hypothesis is true we
reject it in favour of the alternative hypothesis. This is
significance testing and the critical level of probability used to 
reject the hypothesis is known as the significance level (P
value). This is set at 5% (p=0.05) to avoid errors known as type
1 and type 2. The assumption is that given a normal 
distribution with a critical value of 5%, 2.5 % of the distribution 
lies in the upper tail of the curve and 2.5% in the lower tail. 
Hence we use a two-tailed t-test with a critical value of 5% 
(p=0.05). If the P value is smaller than 0.05 then the data 
under comparison are said to be significantly different. If P is 
greater than 0.05 then the opposite is true.
2(3.1.2)Determining the percentage in S-phase
Post assay colony numbers for each condition were known. For 
any one condition comparing the colony numbers in the 
cultures derived from cells which were treated with the S- 
phase specific killing agent, ARA-C, with colony numbers 
derived from those treated only with Duibecco's 20% or 
relevant media gave an indication as to the percentage of the 
population in S-phase. Comparing the percentage in S-phase in 
the control group with the percentage S-phase in the treatment 
groups indicated whether or not treatment had altered the 
fraction of the population in DNA synthesis.
2(3.2) STAINING AND PHOTOGRAPHY
Methods and materials UL5
2(3.2.1) Blood films
A drop of blood was placed in the centre of a labelled 76 x 
26mm glass slide (BDH) about l-2cm from the end. An identical 
slide was then placed just in front of the drop on the first slide 
at an angle of forty five degrees. The second slide was then 
moved back to touch the drop and spread quickly along the 
length of the first slide drawing out the blood. The sample was 
then air dried.
2(3.2.2 ) Agar colony plates
Post counting the colony plates were stored at 4°C for at least 1 
hour. A shallow plastic container was filled with cold Isoton 
solution. The fact that this is Isotonic prevents the cells in 
colonies from lysing and stops colony degradation. Colony 
plates were removed from the fridge and gently submerged in 
the Isoton. Using a dissecting needle the agar disc containing 
the colonies was gently teased from the dish to be free floating 
in the Isoton. A 76 x 51mm microscope slide was submerged in 
the Isoton and used to catch the agar disc. The slide with the 
disc on top was delicately withdrawn from the Isoton. A 4.5cm 
piece of filter paper (Whatman) was placed on top of the agar 
disc and everything then placed on a drying plate (Hearson) at 
50°C for 2-4 hours. Thereafter the filter paper was removed 
from the agar disc which had now dried onto the slide. The 
slide was ready for staining .
2(3.2.3 ) Jenner-Giemsa staining
Methods and materials
The selective staining of components within the cell relies on 
differences in chemical structure. With Romanowsky dyes such 
as Jenner and Giemsa acidic and alkaline differences in 
chemical composition are explotted to allow selective 
differential staining. Tenner's stain is the most complex of the 
Romanowsky stains Giemsa the most primitive. When used in 
conjunction they give results superior to those achieved when 
using either singly, or indeed, any of a variety of other stains. 
After preparation, slides were immersed in methanol (BDH) for 
10 mins to fix the ceUs. They were then to a
staining jar containing 168ml Tenner's stain/ 132ml water for 5 
mins. The slides were then removed and rinsed in water before 
being submerged in a second staining jar containing 45ml 
Giemsa / 225 ml water. The slides were left there for lOmins 
before being rinsed. They were then sat on end and left to air 
dry. The slides could then be examined under the microscope.
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CHAPTER 3: LEUKAEMIA 
INHIBITORY FACTOR
3.1: FEMORAL MARROW
In this section Leukaemia Inhibitory Factor was assessed i n 
vitro as an agent influencing certain aspects of haematopoiesis. 
This fell into two broad categories: direct action, where LIF's 
actions on cells derived from femoral marrow were assessed; 
indirect action, where LIF's aattons on agents which act on 
cells derived from marrow were assessed . In all
experiments (unless otheewise notee) three concentrations of 
LIF were tested: lOOOunits/ml; 500 units/ml and 100/units ml. 
These were prepared by diluting LIF in Dulbecco's 20% to 
concentrations of 25,000 units/ml; 12,500 units/ml and 2500 
units/ml .Identical vooumes (44pl) of each dilution added 
per 1ml of culture fluid gave lOOOumts/ml; 500 units/ml and 
100 units/ml respectively. The concentrations chosen were 
based on previously published data (Metcalf, 1991; Fletcher, 
1990; Metcalf, 1989 ).
All results for individual experiments were normalised as a 
percentage of the control. This validated the comparison of data 
between individual experiments and also meant that data could
be pooled as a mean.
An unpaired two-tailed t-test was used to analyse data. (See 
2(3.1.1)) P values are shown below means. The means of data 
for individual experiments are given below the P value.
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DIRECT ACTION
3(1.1) The effect of Leukaemia Inhibitory Factor (LIF) 
on the colony forming potential of GM-CFC in semi­
solid agar culture.
To determine the role LIF may play in the development of 
lineage restricted progenitor cell populations LIF was assayed 
in vitro for colony stimulating activity on populations of GM-
CFC (7 day semi-solid agar cultures).
3(1.1.1) PROCEDURE
In a standard GM-CFC assay varying concentrations of LIF were 
assessed both as an agent acting alone, and as a synergistic 
agent with the following growth factors:
GROWTH FACTOR FINAL CONCENTRATION
GM-CSF 40U/ml
M-CSF 50U/ml
IL-3 80U/ml
TABLE 3.1: Summary of factors used to stimulate 7-day 
cultures.
In all cases three replicate experiments were performed.
3(1.1.2)RESULTS
Table 3R.1 and figure G3.1 show the effect of LIF on colony 
formation by populations of GM-CFC. In all cases (except for IL- 
3 stimulated colony formation supplemented with 100 U/ml 
LIF) the addition of LIF at any of the test concentrations had no
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significant effect on colony formation when compared to 
controls, (p always > 0.05)
In the case of IL-3 stimulated colony formation + lOOU/ml LIF, 
there is a statistically significant reduction in colony 
formation, compared to the control. (p<0.005) The reduction is 
not great: 94% ±1.2 with LIF, compared to 100% without. 
However it is present and is consistent throughout the three 
expreiment from which the mean value was derived (96%, 92% 
and 95%) .
TABLE 3R.1: The effect of Leukaemia Inhibitory Factor on the 
colony forming potential of GM-CFC from NBM in semi-solid
agar culture.
LIF CONC. 
(U/ml)
0 100 500 1000
COLONY FORMATION
(%)
FACTOR
/ 0 0 0 0
GM-CSF 100.0 114.0+8.0 99.6+6.0 109.0+8.0
(40U/ml) 0.05<p<0.1 p>0.4 0.1<p<0.375
N=3 N=3 N=3
19.0+4.2 19.0+1.3 17.2+5.3 22.5+5.5
22.5+1.5 25.5+5.5 22.5+5.5 21.0+2.0
14.5+2.5 18.0+0.2 16.0+7.0 17.0+3.0
M-CSF 100.0 106.0+17.5 122.0±31.9 118.0+17.0
(50U/ml) 0.1<p<0.375 0.1<p<0.375 0.1<p<0.375
N=3 N=3 N=3
21.5+2.5 15.5+7.5 21.5+0.5 27.0+3.0
13.5+5.5 17.5+1.5 25.0+6.0 19.5+0.5
11.0+1.0 13.0+6.0 9.0+3.0 9.5+2.5
IL-3 100.0 94.0+1.2 120.0+12.8 88.0+12.9
(80U/ml) p<0.005 0.05<p<0.1 0.1<p<0.375
N=3 N=3 N=3
15.5+0.5 15.3+1.4 17.0+1.0 15.0+0.4
16.3+2.5 15.1±3.5 16.0+5.2 17.3+3.5
11.2+1.4 11.5+0.5 17.3+0.5 7.0+5.3
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FIGURE G3.1: Colony formation (expressed as percentage of 
control OU/ml LIF) in 7-day semi-solid agar cultures of NBM 
stimulated with varying growth factor regimes in the presence 
or abscence of varying concentrations of LIF.
3(1.2) The effect of LIF in vitro on the colony forming
potential of HPP-CFC in semi-solid agar culture.
To determine the role LIF may play in the development of 
early stem cell populations, LIF was assayed in vitro for colony 
stimulating activity on populations of HPP-CFC (14 semi-solid 
agar cultures ).
3( 1.2.1) PROCEDURE
In a standard HPP-CFC assay LIF was assessed both as an agent 
acting alone and as an agent acting synergistically to promote 
HPP-CFC colony formation. HPP-CFC populations were 
stimulated with the following growth factor combinations;
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In all cases three replicate experiments were performed.
GROWTH FACTORS FINAL CONCENTRATION
L929 CM/ 10%V/V
WEHI CM 10%V/V
GM-CSF 40U/ml
M-CSF 50U/ml
IL-3 80U/ml
M-CSF 50U/mi
IL-la 1 OU/ml
IL-3 80U/ml
M-CSF 50U/ml
IL-la 1 OU/ml
IL-3 80U/ml
IL-la 1 OU/ml
M-CSF 50U/ml
TABLE 3.2: Summary of factors used to stimulate 14 day HPP-CFC 
cultures.
3(1.2.2)RESULTS
Table 3R.2 and figure G3.2 show the effect of LIF on colony 
formation by populations of HPP-CFC. In all cases the addition 
of varying concentrations of LIF has had no statistically 
significant effect on colony formation in 14 day culture. (P
always > 0.05) .
Thus LIF does not act directly to support the proliferation of an 
HPP-CFC population, nor is it synergistic with other growth 
factors for the proliferation of HPP-CFC sub-populations.
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TABLE 3R.2: The effect of Leukaemia Inhibitory Factor on the 
colony forming potential of HPP-CFC from NBM in semi-solid
agar culture.
LIF CONC. 
(U/ml)
0 100 500 1000
COLONY FORMATION (%/control)
FACTOR
....... /...... .. 0 0 0 0
L929/WEHI 100.0 103.0+10.0 101.3+7.0 92.3+5.7
0.375<p<0.4 p>0.4 0.1<p<0.375
N=3 N=3 N=3
26.5±2.8 25.8+1.2 26.4+2.1 25.8+2.0
19.8±1.1 23.5+0.6 23.0+1.1 19.7+2.0
23.6±1.2 21.3+1.4 23.5+0.7 19.3+1.8
GM-CSF/ 100.0 125.0+28.0 124.0+26.0 111.0+12.2
M-CSF 0.1<p<0.375 0.1 <p<0.375 0.1<p<0.375
N=3 N=3 N=3
4.5±1.4 8.3+0.75 7.0+1.6 5.8+0.5
11.8+1.1 11.0+1.2 11.8+1.5 14.2+1.2
15.5±2.3 15.0+3.0 14.5+1.5 13.0+4.0
IL-3/ 100.0 98.0+2.0 92.0+5.0 93.0+5.1
M-CSF 0.1<p<0.375 0.1<p<0.375 0.1<p<0.375
N=3 N=3 N=3
38.5+0.5 36.0+0.0 32.0+3.2 31.5+2.5
23.0+2.0 23.3+1.0 23.5+1.5 22.0+1.0
25.3+0.5 25.8+1.5 23.3+1.5 25.5+0.7
IL-1/IL-3/ 100.0 112.0+22.0 107.0+19.0 98.0+11.0
M-CSF 0.1<p<0.375 0.1<p<0.375 p>0.4
N=3 N=3 N=3
9.5±0.5 13.5+2.5 13.5+2.5 11.0+4.0
12.0+1.0 15.0+1.0 12.5+0.5 12.5+1.5
14.5+2.5 10.0+2.0 11.0+1.0 11.0+2.0
IL-1/IL-3 100.0 119.6+18.0 100.6+9.2 86.6+12.1
0.1<p<0.375 p>0.4 0.1<p<0.375
N=3 N=3 N=3
5.3±4.3 6.5+2.5 6+3.0 4.3+2.4
5.8+2.0 5.0+0.0 4.8+2.4 4.0+1.8
5.0±7.1 7.5+0.5 5.3+1.0 5.5+2.0
IL-1/ 100.0 102.0+23.0 81.7+12.0 96.0+11.5
M-CSF P>0.4 0.1<P<0.375 0.375<P<0.4
N=3 N=3 N=3
15.3+3.5 9.5+1.0 8.8+1.0 14.5+1.8
15.0+1.0 15.5+4.5 14.5+1.5 11.5+0.5
11.5+0.5 16.5+3.5 10.5+2.5 13.5+2.5
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PERCENTAGE COLONY FORMATION (HP.P-CFC)
WITH VARYING GROWTH FACTOR REGIMES
LIF CONC.(U/ml)
FIGURE G3.2: Colony formation (expressed as a percentage of 
the control OU/ml LIF) in 14 day semi-solid agar cultures of 
NBM stimulated with varying growth factor combinations in 
the presence or absence of varying concentrations of LIF
3(1.3) The effect of LIF as a short term incubation
agent in liquid suspension culture on the colony
forming potential of GM-CFC and HPP-CFC.
The colony assay techniques above study the effect of non­
toxic concentrations of LIF on a seeded colony forming cell 
population of given size. That is, in a cell population a given 
fraction will be a specific HPP-CFC subpopulation. The colony 
assays above pick out these HPP-CFC sub-populations without 
altering the size of the population .In contrast this experiment 
looked at the effect of pre-incubating femoral marrow for a
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short time with non toxic concentrations of LIF to determine if 
this altered the size of the colony forming cell pool prior to 
plating. Washing the marrow after short term incubation 
ensured that LIF was only available to the cell population for a
brief period and thus any alteration in colony forming cell pool
size was a direct result of LIF.
In other words can LIF pre-incubation alter the size of HPP-CFC 
and/or GM-CFC populations ?
3(1.3.1) PROCEDURE
In a standard pre-incubation assay, cells were incubated with 
LIF for two hours. Thereafter assays for GM-CFC stimulated 
with 10% WEHIcm, and HPP-CFC, stimulated with WEHI/L929 
conditioned media, GM-CSF/M-CSF (HPP 3) and lL-1a/IL-3 / M-CSF 
(HPP 1), were performed for each tube. The effect of LIF pre­
incubation on colony formation in these assays could thus be 
assessed.
Three replicate experiments were performed.
3(1.3.2)RESULTS
In the case of GM-CFC (Table 3R.3.1/figure G3.3) pre-incubation 
with varying concentrations of LIF has had no statistically 
significant effect on colony formation in all cases (p>0.05), 
except cultures stimulated with IL-3 + lOOU/ml LIF. (p<0.05). 
In the case of these cultures the difference is not great: 109%±3 
with LIF, compared to 100% without. As LIF was not present in 
cultures but available only before assay this increase in 
colony formation suggests that LIF increased the size of the 
colony forming pool available to IL-3.
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In all other cases LIF does not alter the size of the colony 
forming cell pool available to the growth factor stimuli.
In the case of HPP-CFC (Table 3R .3.2/figure G3.4) the addition 
of LIF has had no statistically significant effect on the level of 
colony formation from a variety of HPP-CFC populations. 
(p>0.05) Thus LIF does not alter the size of the HPP-CFC cell 
pool available to growth factor stimuli .
TABLE 3R.3.1: The effect of Leukaemia Inhibitory Factor as a
short term pre-incubation agent on the colony forming 
potential of GM-CFC.
LIF CONC.
(U/ml)
PRE-INC
0 100 500 1000
COLONY FORMATION (%/control)
FACTOR
/ 0 0 0 0
M-CSF 100.0 120.0+19.0 104.0+5.0 101.0+3.0
(50U/ml) 0.1 <p<0.375 0.1<p<0.375 0.1<p<0.375
N=3 N=3 N=3
19.8+11 18.3+1.3 22.5+3.0 18.5+3.0
17.0+2.0 27.8+3.5 18.0+2.8 18.8+1.4
18.0+1.1 20.0+3.0 17.0+1.8 19.0+2.0
IL-3 100.0 109.0+3.0 97.0+6.0 103.0+13.9
(80U/mI) 0.025<p<.05 0.1<p<0.375 0.375<p<0.4
N=3 N=3 N=3
28.5+2.0 32.8+4.8 31.3+5.4 29.5+2.4
16.5+21 18.5+2.6 15.5+0.5 21.0+3.7
29.3+1.4 30.0+11 26.0+1.0 23.8+7.0
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PERCENTAGE COLONY FORMATION
FIGURE G3.3: Colony formation (expressed as percentage of 
the control OU/ml LIF) in 7-day semi-solid agar cultures of 
NBM stimulated with varying growth factor regimes after 
preincubation with varying concentrations of LIF.
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TABLE 3R.3.2: The effect of Leukaemia Inhibitory Factor as a
short term pre-incubation agent on the colony forming 
potential of HPP-CFC in semi-solid agar culture.
LIF CONC.
(U/ml)
PRE-INC.
0 100 500 1000
COLONY FORMATION (%/control)
FACTOR
....... /........ 0 0 0 0
L929/WEHI 100.0 102.0+3.0 108.3+14.8 107.0+7.3
0.1<p<0.375 0.1<p<0.375 0.1<p<0.375
N=3 N=3 N=3
27.0+1.7 26.5+2.4 27.0+4.1 25.8+11
25.8+2.4 25.8+2.3 22.5+1.0 27.8+5.5
22.8+1.0 25.0+1.9 31.3+6.0 27.8+1.2
GM-CSF/ 100.0 106.0+13.4 101.8+13.9 98.0+13.0
M-CSF 0.1<p<0.375 p>0.4 p>0.4
N=3 N=3 N=3
7.0+1.5 5.8+1.3 5.5+1.5 6.5+1.0
5.8+11 7.5+1.9 7.3+11 5.0+1.3
3.3+0.6 3.5+0.9 3.3+0.9 3.8+1.0
IL-3/IL-1 100.0 115.3+17.7 86.0+18.7 103.0+11.0
M-CSF 0.1<p<0.375 0.1<p<0.375 0.375<p<0.4
N=3 N=3 N=3
12.0+1.3 10.0+2.9 12.5+1.6 10.8+11
11.0+1.4 14.3+1.4 11.8+1.5 10.5+1.6
10.0+0.9 12.3+1.9 5.0+1.9 12.8+1.8
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LIF PRE-INCUBATION CONC.(U/ml)
FIGURE G3.4: Colony formation (expressed as apercentage of 
the control) in 14 day semi-solid agar cultures of NBM 
stimulated with varying growth factor combinations after 
preincubation with varying concentrations of LIF
3(1.4) The effect of LIF in vitro on the proportion of 
GM-CFC and HPP-CFC in DNA synthesis-S-phase suicide 
assay
These experiments were designed to determine whether LIF 
could stimulate or inhibit DNA synthesis in populations of 
haematopoietic cells.
3(1.4.1) PROCEDURE
lOOOunits LIF, 500 units LIF and 100 units LIF were assayed 
as potential stimulators and inhbitors of DNA synthesis in a 
modification of 2(2.1.5.2).
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3 (1.4.1.1)As a potential stimulator of DNA synthesis
HPP-CFC
In NBM the HPP-CFC population is essentially quiescent with
only a small fraction ,10-15%, in S-phase. Thus it was possible 
to assess LIF as a stimulator of DNA synthesis in HPP-CFC 
populations .All tubes were incubated in a 37°C water bath for
2 hours and Cytosine arabinoside (ARA-C) used in a standard 
suicide assay 2(2.1.5).
The cells in each centrifuge tube were diluted to a 
concentration of 2 x 105 cells/ml. 4mls of this dilution was 
prepared for each tube. Assays for HPP-CFC stimulated with 
WEHI/L929 conditioned media, were performed for each tube. 
Three replicate experiments were performed.
3 (1.4.1.2) As a potential inhibitor of DNA synthesis
GM-CFC
In NBM a significant proportion of the GM-CFC population is in 
S-pase (30-40%). Thus it was possible to assess LIF as an 
inhibitor of DNA synthesis in this population.
The procedure was exactly as that outlined to test LIF as a 
stimulator in 3 (1.4.1.1) with the exception that cells are 
incubated for three hours prior to the one hour ARA-C 
treatment. A standard GM-CFC assay with WEHIcm as a source 
of growth factor was carried out for the cells in each tube.
Four replicate experiments were performed.
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HPP-CFC
To determine whether HPP-CFC can be switched out of cycle by
LIF it is necessary to firstly bring the HPP-CFC into cycle. This 
is accomplished by introducing an 'insult' to the femoral 
marrow 2(1.3.1).
CBA mice were given 2Gy whole body y-irradiation. Three days 
later femoral marrow was removed from mice and LIF was 
assessed as an agent able to inhibit DNA synthesis in HPP-CFC 
stimulated to colony formation with WEHI/L929.
Four replicate experiments were performed.
(Summary of protocol is shown in diagram 15)
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LABELLED CENTRIFUGE TUBES CONTAINING 1 ML CELL DILUTION
CONTROL 1000UNITS/ml LIF 500 UNITS/ml LIF 1OOUNITS/ml LIF
TESTING AS INHIBITOR TESTING AS STIMULATOR
4 HOURS INCUBATION 2 HOURS INCUBATION
AT 370C AT 370C
ADDITION OF ARA-C TO ONE TUBE PER PAIR 
EQUAL VOLUME DELBECCOS TO OTHER
I
1 HOUR INCUBATION 370CI
WASH BY CENTRIFUGE SPINNING
I
COUNT/DILUTE TO APPROPRIATE CELL NUMBER
(V AND REFER TO THE PRESENCE OR ABSCENCE OF ARA-C)
CONTROL 1000 UNITS LIF 500 UNITS LIFI 100 UNITS LIF
ASSAY FOR HPP-CFC OR GM-CFC
DIAGRAM 15 SUMMARY OF ASSAY USED TO TESTTHE EFFECT OF LIF 
ON DNA SYNTHESIS
Leukaemia Inhibitory Factor 12.2
3(1.4.3) RESULTS
AS A POTENTIAL STIMULATOR
Table 3R.4.1and figure G3.5 show the effect of LIF on the 
proportion of the HPP-CFC population in S-phase. At all 
concentrations tested LIF has had no statistically significant 
effect on the proportion of HPP-CFC (WEHI/L929) in S-phase.
(P>0.05).
AS A POTENTIAL INHIBITOR
Table 3R.4.2 and figure G3.6 show the results for GM-CFC 
treated with LIF. At all concentrations tested LIF has had no 
statistically significant effect on the proportion on GM-CFC 
(WEHI) in S-phase. (p>0.05).
Table 3R.4.3 and figure G3.7 show the results for HPP-CFC 
treated with LIF. At both concentrations tested LIF has had no 
statistically significant effect on the proportion of HPP-CFC in S- 
phase.
These results indicate that LIF does not stimulate or inhibit 
DNA synthesis in any of the cell populations tested.
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The effect of Leukaemia Inhibitory Factor of GM-CFC(WEHI) 
and HPP-CFC(WEHI/L929) in DNA synthesis.
AS A STIMULATOR OF DNA SYNTHESIS
TABLE 3R.4.1: HPP CFC
LIF CONC. 
(U/ml)
0 100 500 1000
S-PHASE w
FACTORS
(HPP-CFC)
......../.......... 0 0 0 0
L929/WEHI 9.4±1 9.0±2.8 11.4±1.2 9.6±1.5
N=3 N=3 N=3
p>0.4 0.375<p<0.4 p>0.4
11.00 13.85 9.00 10.00
7.63 9.27 13.00 7.00
9.71 4.08 12.28 12.00
THE PROPORTION QF HPP-CFC IN S-PHASE
WITH VARYING LIE CONCENTRATIONS
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FIGURE G3.5: The proportion of HPP-CFC (WEHI/L929) from 
NBm in S-phase (%) following incubation with varying 
concentrations of LIF
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AS A POTENTIAL INHIBITOR OF DNA SYNTHESIS
TABLE 3R.4.2: GM-CFC
LIF CONC. 
(U/ml)
0' 100 500 1000
S-PHASE W/o
FACTOR
(GM-CFC)
....... /........ 0 0 0 0
WEHI 22.014.0 24.013.0 26.014.2 22.014.0
p>0.4 0.1<p<0.375 p>0.4
N=4 N=4 N=4
25.04 29.00 21.09 28.01
18.05 30.00 17.08 31.07
35.89 17.07 32.65 18.00
13.70 20.13 35.30 11.00
THE PROPORTION OF GM-CFC IN S-PHASE
WITH VARYING LIF CONCENTRATIONS 
30 1 ——
0 100 500 1000
LIF CONC. (U/ml)
FIGURE G3.6: The proportion of GM-CFC (WEHI) from NBM in
S-phase (%) following incubation with varying concentrations of
LIF
Leukaemia Inhibitory Factor
TABLE 3R.4.3: HPP-CFC
LIF CONC. 
(U/ml)
0 100 1000
S-PHASE w
FACTOR
(HPP-CFC)
....... /........ 0 0 0
L929/WEHI 30.6+2.2 27.9±6.0 27.4±4.0
0.1 <p<0.375 0.1<p<0.375
N=4 N=4
36.50 33.55 15.32
25.60 9.76 32.73
29.70 32.90 27.36
30.83 35.80 34.48
THE PROPORTION OF HPP-CFC IN S-PHASE
CONC. LIF (U/ml)
FIGURE G3.7: The proportion of HPP-CFC (WEHI/L929) from 
regenerating bone marrow in S-phase (%) following incubation 
with varying concentrations of LIF
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3(1.5) Does LIF alter the uptake of tritiated thymidine 
by femoral bone marrow in limited volume liquid 
suspension culture ?
It is possible to examine DNA synthesis by a population of cells 
in more than one way. In this experiment samples of whole 
bone marrow were cultured in limited volume liquid 
suspension culture with a known growth factor (GM-CSF), in 
the presence or absence of LIF. Trititated thymidine is taken 
up by cells in DNA synthesis. If a population of cells is treated 
with tritiated thymidine for a given time, then washed, any 
remaining radioactivity not washed away is a measure of 
thymidine uptake. This is an indication as to the proportion of a 
cell population in DNA synthesis over the period for which the 
thymidine label was available. By adding tritiated thymidine to 
limited volume cultures stimulated with LIF alone, or with GM- 
CSF in the presence or absence of LIF, it was thus possible to 
determine the effect of this growth factor on the proportion of 
the cell population in S-phase.
3(1.5.1) PROCEDURE
This protocol was a mooificction of toe shendarn thymidine 
assay 2(2.1.4) Plates were set up aa foUows:
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3 (1.5.1.1) LIF only
The plate was divided into four blocks of six wells. The first six 
wells, the control wells had no factor present. lOOpl of 
Dulbecco's 20% was pipetted into each of the six wells. In the 
subsequent groups 40pl of the appropriate LIF diilnioDn was 
added to each of the six wells. 60pl Dulbecco's 20% was then 
added. This was repeated for each of the three LIF dilutions.
3 (1.5.1.2) GM-Stimulated cells
The plate was divided up into four groups of six wells. GM-CSF 
had been diluted to a concentration of 800units/ml. 50pl of this 
was pipetted into each of the twenty four wells. The first six 
wells, the control wells had only GM-CSF present. 50pl of 
Dulbecco's 20% was pipetted into each of the ssx wells. In the 
subsequent groups 40 pi of the LIF diluiton was
added to each of the six wells. lOpl Dulbecco's 20% was then 
added. This was repeated for each of the three LIF dilutions.
Four replicate plates were prepared one for each of four time
points.
Two replicate experiments were performed .A summary of the 
microtitre plate is shown in diagram 16.
Leukaemia Inhibitory Factor 1 1^
I
INCUBATION
I
ADDITION OF TRITIATED THYMIDINE
I
FURTHER 18 HOUR INCUBATION
I
HARVEST CELLS
I
COUNT IN SCINTILATION COUNTER
DIAGRAM 16 MICROTITRE ASSAY PLATE : LIF ON NBM CELLS
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3(1.5.2)RESULTS
In this instance results are compared to the control result for 
the same day. (i.e. day 2 lif 100 U/ml is compared to day2
control etc).
Table 3R.5 and figure G3.8 show the results for populations of 
bone marrow cells treated with LIF alone. At day 1 there is a 
statistically significant difference between the level of 
thymidine uptake observed with 500 U LIF as compared to the 
control (0.025<p<0.05). However by day 2 this has disapeared 
and does not re-appear in day 3 (0.1<p<0.375 in both cases). 
This would suggest that this initial difference, although 
stastistically significant, was not important and that this 
concentration of LIF did not contribute to sustained altered 
proliferation within the population.
For all other conditions there is no statistically significant 
alteration in thymidine uptake at any time point. (P>0.05 in all 
cases). LIF has not altered the level of proliferation within 
populations of bone marrow cells at any of the test
concentrations.
Table 3R.5.2 and figure G3.9 show the results for populations of 
bone marrow cells stimulated with GM-CSF ± LIF. As above, in 
one instance, (Day 0 lOOU/ml LIF) there appears to be a 
statistically significant difference between this result and that 
seen in the control (0.0005<p<0.05). Again this difference 
dissapears by day two of the experiment and does not re­
appear.
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In all other cases there is no statistically significant difference 
in thymidine uptake compared to controls at any iime point 
with any concentration of LIF. (0.1<p<0.375 in all cases)
LIF does not alter the level of proliferation seen in cuttures of 
bone marrow cells stimulated with GM-CSF.
TABLE 3R.5: The effect of varying concentrations of LIF on 
the uptake of thymidine by a limited volume liquid suspension
culture of Normal bone marrow cells.
CONDITION
(NBM)
DAY 1 CONTROL
MEAN THYMIDINE UPTAKE
(%/control)
± STANDARD ERROR
100.0
306.53+54.35
375.89±94.83
DAY 2 CONTROL 76.0+1.0
231.72±4.900
292.13+26.5
DAY 3 CONTROL 88.5+47.5
127.90+17.53
514.12+74.27
DAY 1 100 ULIF 95.5+6.5 0.1<p<0.375
271.49+14.12
383.62+93.02
DAY2 100 U LIF 118.0+55.0 0.1<p<0.375
194.36+23.16
653.09+117.69
DAY3 100 ULIF 74.0+36.0 P>0.4
118.94±4.94
414.28+24.97
DAY 1500 ULIF 117.5±5.5 0.025<P<0.05
345.07+61.83
465.91+122.78
DAY2500 ULIF 93.5+17.5 0.1<p<0.375
234.15+35.72
417.69+21.68
DAY3500 ULIF 67.5127.5 0.1<p<0.375
125.4919.59
360.07134.50
DAY 1 1000 U LIF 156134 0.1<p<0.375
375.40121.82 ;
714.051184.10 ’
DAY2 1000 ULIF 70.5116.5 0.375<P<0.4
165.11111.88
325.8129.31
DAY3 1000 ULIF 89.5113.5 P>0.4
233.16123.43
388.37139.00
In all cases N=2
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Figure G3.8: Mean thymidine uptake (expressed as a 
percentage of the appropriate control) by NBM over three days
in the presence or absence of varying concentrations of LIF.
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culture of Normal bone marrow cells .stimulated with GM-CSF.
TABLE 3R.5.2: The effect of varying concentrations of LIF on 
the uptake of thymidine by a limited volume liquid suspension
CONDITION
(NBM±40U/ml GM-CSF)
DAY 1 CONTROL
MEAN THYMIDINE
UPTAKE(%control)
+STANDARD ERROR
1 00
2577.121259.37
2458.611233.67
DAY2 CONTROL 267.5176.5
4941.911288.34
8448.211472.89
DAY 3 CONTROL 469115
11705.901818.11
11896.181358.76
DAY4 CONTROL 321.51130.5
11650.841579.26
4695.611356.78
DAY1 100 U LIF 108.510.5 0.0005<P<0.005
2826.521144.37
2669.64188.89
DAY2 100 ULIF 328144 0.1<p<0.375
7339.491730.57
9161.841623.82
DAY3 100 ULIF 498113.5 0.1<p<0.375
13197.9811460.01
11933.461951.6
DAY4 100 ULIF 249.51110.5 0.1<p<0.375
9298.871535.76
3425.191514.86
DAY 1500 ULIF 10617 0.1<p<0.375
2923.761400.35
2436.90161.88
DAY2 500 ULIF 321125 0.1<p<0.375
7653.391303.80
8496.551258.41
DAY3500 ULIF 482.5128.5 0.1<p<0.375
11699.321981.57
12567.901659.59
DAY4500 ULIF 209.5164.5 0.1<p<0.375
7066.071671.57
3564.881149.60
DAY 1 1000 U LIF 100.510.5 0.1<p<0.375
2567.241147.90
2506.36189.71
DAY2 1000 ULIF 338.5118.5 0.1<p<0.375
8225.581400.90
8775.641279.87
DAY3 1000 ULIF 513.5155.5 0.1<p<0.375
14651.491932.32
11254.591393.44
DAY4 1000 ULIF 196167 0.1<p<0.375
6788.131231.84
3173.851139.45
In all cases N=2
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Figure G3.9: Mean thymidine uptake ( expressed as a 
percentage of the relevant control) by NBM over three days in 
the presence or absence of varying concentrations of LIF in 
cultures stimulated with GM-CSF.
INDIRECT ACTION
3 (1.6) Does LIF alter the action of a haematopoietic
stimulator on a defined HPP-CFC subpopulation
in vitro ?
Normal femoral marrow is in a resting state of haematopoiesis.
It can be 'switched on' however by the addition of a factor 
which brings the quiescent HPP-CFC population into DNA 
synthesis. One such stimulator of DNA synthesis in the 
primitive stem cell pool is the conditioned medium derived 
from 7day post 4.5 gy gamma irradiated mice 2(1.4.2). This
Leukaemia Inhibitory Factor_______________  ______________________________13_4
experiment is designed to test whether lOOOU/ml. LIF
interferes with the ability of this stimulator to act on HPP-CFC 
stimulated to colony formation with WEHIcm + L929cm.
3(1.6.1) PROCEDURE
This was a modifictaion of the stimulator-S-phase suicide assay 
2(2.1.5.2) 2000units LIF (80ul of the appropriate dilution) was 
aliqouted into two centrifuge tubes, 80ql Dulbecco's 20% into all 
others.others.
The assay then progressed as a standard stimulator/S-phase 
suicide assay with cytosine arabinoside .
Assays for HPP-CFC stimulated with WEHI/L929 conditioned 
media were performed for each tube.
Three replicate experiments were performed.
Leukaemia Inhibitory Factor
Summary of the protocol used is shown in diagram 17. 
LABELLED CENTRIFUGE TUBES
CONTROL
mb
CELLS + 'STIMULATOR' CELLS + ’STIMULATOR’ 
+ 1000U.N>TS/ml. LIF
1ML CELLS
IMLDULBBECCO'S 20%
80ul DULBECCO’S 20%
1ML CELLS 
1ML’STIMULATOR’
80ul DULBECCO’S 20%
1 ML CELLS 
1ML’STIMULATOR’
80ul APPROPRIATE
DILUTION LIP
I
. PROTOCOL AS FOR STIMULATOR TEST
I
DILUTE TO APPROPRIATE CELL NUMBER
(’+’ AND ’-’ REFER TO THE PRESENCE OR ABSCENCE OP ARA-C)
CELLS + STIMULATOR
I
ASSAY FOR HPP-CFC
CELLS + STIMULATOR 
+1000 UNITS LIP
DIAGRAM 17 THE EFFECT OF LIF ON THE ACTION OF A STEM CELL STIMULATOR
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3(L6.9) RESULTS
Table 3R.6 and figure G3.10 show the results for the effect of 
lOOOU/ml LII7 on th e cctinn o f a stem cell stimulator. A 
significant increase in thr proportion of HPP-CFC(WEHIIL929) 
in S-phase is seen in the presence of a stem cell stimulator 
(0.01<p<0.095). lOOOU/ml LIF fails to inhibit the action of this 
stimulator with the level of HPP-CFC cycling remaining 
significantly higher than in the control (0.05<p<0.1)
Thus LIF doee not indirectly block stem cell p^rc^li^fen^ci^:^c^n by 
interfering with the action o1 r semm cell stimulator.
TABLE 3R.6: The effect of LIF on the action of a stem cell 
stimulator.
LIF CONC. 
(U/ml)
0
NBM
0
NBM/STIM
1000
NBM/STIM
S-PHASE ________
FACTOR
(HPP-CFC)
L929/WEHI 10.61+2.30 34.52+9.22 29.90+10.1
0.01<P<.025 0.05<P<0.1
N=4 N=4
11.18 28.16 21.76
4.12 23.73 17.80
15.52 61.90 59.20
11.63 23.65 17.19
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Figure G3.10: The proportion HPP-CFC (WEHI/L929) from 
NBM in S-phase (%) after treatment with a stem cell stimulator 
in the presence or absence of LIF.
3 (1.7) Does LIF influence the production of a
haematopoietic stimulator in vitro?
As outlined previously it is possible to generate a stimulator 
for primitive stem cells. Negative regulators of cell proliferation 
could act indirectly by blocking the action or manufacture of 
this stimulator. This experiment is designed to determine if 
lOOOU/ml or lOOU/ml LIF interferes with the production of 
this stimulator.
3(1.7.1) PROCEDURE
This was a modificiation of the protocol used to generate stem 
cell stimulator 2(1.4.2). 4000units LIF (160pl of the appropriate
Leukaemia Inhibitory Factor US
dilution) was aliqouted into one centrifuge tube. In the same
way 400 units LIF was aliqouted into the second tube. The 
third tube, the control tube, received an aliquot of 160pi 
Dulbecco's 20% .The assay then progressed as a standard assay 
to determine the effect of exogenous factors on stimulator
production.
Assays for HPP-CFC stimulated with WEHI/L929 conditioned 
media were performed for each tube
Three replicate experiments were performed. A summary of 
the protocol is shown in diagram 18.
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LABELLED CENTRIFUGE TUBES
CONTROL
4ml CELLS
160uL DELBECCO’S 20%
1000UNITS/ml LIF
4ml CELLS 
160uL LIF AT 
APPROPRIATE
DILUTION
4
100 UNITS/ml LIF’
4ml CELLS 
160uL LIF AT 
APPROPRIATE
DILUTION
INCUBATE FOR THREE HOURS AT 370C
4
CENTRIFUGE SPIN TO REMOVE CELLS AND DEBRIS 
FILTER THROUGH 0.22uM PORE FILTER
4
PREPARE CENTRIFUGE TUBES FOR STIMULATOR SUICIDE ASSAY
CONTROL ’STIMULATOR’
DULBECCO’S
’STIMULATOR’ 
1000 UNITS/ml
UJF
’STIMULATOR’
100 UNITS/ml
LIE
FOLLLOW PROTOCOL FOR STIMULATOR SUICIDE ASSAY
DIAGRAM 18 THE EFFECT OF LIF ON THE PRODUCTION OFA STEM CELL STIMULATOR
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3(1.7.2) RESULTS
Table 3R.7 and Figure G3.11 show the results for the level of 
DNA synthesis in an HPP-CFC population treated with 
stimulator manufactured in the presence or absence of LIF. In 
all cases there is a statistically significant increase in the 
proportion of HPP-CFC in S-phase in the presence of stimulator 
(p<0.05).
Thus the presence of LIF has not prevented the production of 
stimulator.
TABLE 3R.7: The effect of varying concentrations of LIF on
the production of a stem cell stimulator.
CONDITION NBM NBM/STIM NBM/STIM NBM/STIM
LIF CONC.
DURING
STIM
FROD.
(L/ml)
/ 0 100 1000
S-PHASE 1%)
HPP-CFC
(WEHI/ 11.75+1.09 31.99+4.04 23.59+3.82 31.69+0.85
L929) .005<P<.0005 0.01<P<.025 P<0.0005
N=3 N=3 N=3 N=3
13.24 37.16 21.74 30.49
12.39 24.04 18.10 33.33
9.62 34.78 30.94 31.25
Leukaemia Inhibitory Factor J^l
THE EFFECT OF VARYING CONCENTRATIONS
OF LIF ON THE PRODUCTION OF A STEM CELL STIMULATOR
Figure G3.8 :The proportion HPP-CFC from NBM in S-phase (%) 
after incubation with a stem cell stimulator produced in the 
presence or absence of LIF.
3.2: SA2 CELLS
LIF's interaction with a variety of human and a murine 
Leukaemic cell line are documented. No general pattern of 
responsiveness to treatment with LIF is observed in' these 
populations. In this section LIF's actions in vitro on a cloned 
cell line (SA2JMB1) from an X-irradiation induced murine 
myeloid leukaemia were investigated.
3 (2.1) The effect of Leukaemia Inhibitory Factor (LIF)
on the clonogenicity of SA2JMB1 cells in semi-solid
agar culture.
Leukaemia Inhibitory Factor 14J.
When plated in Semi-solid agar in the absence of exogenous 
growth factors and cultured at 37°C for 7-days SA2JMB1 cells 
will form distinctive colonies In this experiment it was decided 
to examine the effect of LIF alone, and as a synergistic agent 
with GM-CSF, on the colony forming potential (the 
clonogenicity) of SA2JMB1 cells in 7-day culture.
3 (2.1.1 ) PROCEDURE
SA2JMB1 colony formation in the presence of LIF alone 
8 petri-dishes were 1 aid oot in the sterile hood and labelled. 
40pi of the appropriate LIF dilution was added directly into 
each of the petri-dishes. This protocol was eepaate d for each 
LIF dilution. A control was prepared by pepetting 40pl of 
Dulbecco's 20% into each of eight petri-dishes. A standard assay 
for SA2 clonogenicity was then carried out as in 2(2.1.8).
SA2JMB1 colony formation in the presence of GM-CSF ± LIF 
8 petri-dishes wwe lald out in the sleriie hood labeUed and 
40pi of the appropriate LIF dilution added directly into each of 
the petri-dishes. A control was prepared by pipetting 40pl of 
Dulbecco's 20% into each of eight petri-dishes. A 30ml 
universal was prepared containing 7ml Dulbecco's20%, 1ml 
diluted cells, 1ml GM-CSF at a of 400u/ml and
just prior to plating 1ml melted 3%(v/v) agar. (One for each 
condition).
Suspension was plated as in 2(2.1.8).
In both instances three replicate experiments were performed.
Leukaemia Inhibitory Factor
3(2.1.2) RESULTS
Table 3R.8 and figure G3.12 show the results for SA2 
clonogenicity in the presence or absence of LIF.
In all cases the addition of LIF to cultures does not alter the 
level of colony formation compared to that seen in the control. 
(P>0.05).
TABLE 3R.8: The effect of Leukaemia Inhibitory Factor on the 
colony forming potential of SA2 JMBl cells in semi-solid agar
culture.
LIF CONC. 
(U/ml)
0 100 500 1000
COLONY FORMATION (%/control)
FACTOR
ADDED
/ 100.0 114.5+16.9 116.4+24.6 100.8+21.3
0.1 <p<0.375 0.1<p<0.375 P>0.4
N=3 N=3 N=3
78.0 90.6 93.6 66.1
82.1 69.5 59.2 61.2
42.2 60.1 65.94 60.1
GM-CSF 100.0 103.1+3.0 108.2+5.0 99.1+4.1
(40U/ml) 0.1<p<0.375 0.05<P<0.1 P>0.4
N=3 N=3 N=3
72.8±6.3 78.3+6.3 76.5+7.1 72.5+6.5
69.3±8.3 72.3+6.5 81.8+4.1 75.5+5.0
58.0+1.9 56.5+5.9 57.3+6.3 54.7+8.0
Leukaemia Inhibitory Factor AA
SA2JMB1 COLONY FORMATION IN THE
PRESENCE OF VARYING GROWTH FACTOR COMBINATIONS
CONCENTRATION LIF (U/ml)
Figure G3.12: The effect (expressed as a percentage of the 
control OU/ml LIF) of varying concentrations of LIF on the 
colony forming potential of SA2 JMBl cells in semi-solid agar 
culture.
3 (2.2) The effect of LIF as a short term pre­
incubation agent on the clonogenicity of SA2JMB1 cells
In this experiment LIF was assessed as an agent able to alter 
clonogenicity prior to plating. In the above experiment LIF is 
present throughout the 7 day incubation period. Here it is 
available only for a short time prior to plating .LIF was 
assessed both as an agent acting alone and as a synergistic 
agent, in association with GM-CSF.
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3(2.2.1) PROCEDURE
This was a modification of the standard preincubation assay
2(2.1.5).
Centrifuge tubes were supplemented with lOOOU/ml LIF, 
500U/ml LIF and lOOU/ml LIF in the presence or absence of 
40U/ml GM-CSF. Controls were also prepared.
For cultures containing LIF alone three replicate experiments 
were performed. For those containing GM-CSF two replicate 
experiments were performed.
3(2.2.2)RESULTS
Table 3R.9 and figure G3.12 show results for the clonogenicity 
of SA2JMB1 cells following preincubatinn with LIF ± GM-CSF.
In all cases except one (GM-CSF + lOOU/ml LIF ) the 
preincubation of SA2JMB1 cells with LIF has had no effect on 
the clonogenicity of the cells (P>0.05 in all cases). In the case of 
GM-CSF +100U/ml LIF there is a statistically significant 
increase in the level of colony formation seen as compared to 
controls ( Control 100% against GM-CSF + lOOU/ml LIF 
112.0%±3.1). .
Thus LIF at one concentration appears to alter the size of the 
colony forming cell pool available to GM-CSF.
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TABLE 3R.9: The effect of preincubation with varying 
concentrations of Leukaemia Inhibitory Factor on the colony
forming potential of SA2 JMBl cells in semi-solid agar culture .
LIF CONC.
(U/ml)
(PRE-INC)
0 100 500 1000
COLONY FORMATION (%/COntrol)
FACTOR
ADDED
(PRE-INC)
/ 100.0 94.8+1.8 96.9 + 1.1 99.3+2.4
0.01<P<.025 0.01<P<.025 P<0.4
N=3 N=3 N=3
101.0+2.0 97.2+6.3 97.0+5.2 104.2+4.2
85.5+5.5 83.0+7.5 84.2+4.9 85.7+4.0
82.7+1.8 75.5+1.8 79.2+5.1 78.2+9.5
GM-CSF 100.0 112.0+3.1 96.3+2.4 108.5+14.5
(40U/ml) 0.025<P<.05 0.1 <p<0.375 0.1<p<0.375
N=2 N=2 N=2
72.8+3.2 83.7+3.9 71.8+3.8 68.5+5.39
66.5+5.0 72.7+5.8 70.7+10.0 81.7+3.59
SA2JMB1 COLONY FORMATION FOLLOWING
PREINCUBATION WITH VARYING GROWTH FACTOR COMBINATIONS
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Figure G3.13: Colony formation(expressed as a percentage of the 
appropriate control OU/ml LIF ± GM-CSF) by SA2JMB Icells following 
pre-incubation with varying concentrations of Leukaemia Inhibitory 
Factor on the colony forming potential of SA2 JMBl cells in semi-solid 
agar culture .
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3 (2.3) The effect of LIF on the proportion of SA2JMB1 
in DNA synthesis.
A high proportion of the Leukaemic cell population is in DNA
synthesis (approximately 60%). It is thus possible to assay 
exogenous factors as potential inhibitors of DNA synthesis in 
this cell population. For LIF this is a particularly relevant 
experiment as one manner in which a leukaemia could be 
stripped of its potency is if it were to be prevented from 
proliferating further. This experiment was designed to assay 
the ability of LIF to inhibit DNA synthesis in SA2JMB1 cells.
3(2.3.1) PROCEDURE
This technique was a variation of the standard Inhibitor/S- 
phase suicide assay 2(2.1.5). A single cell suspension was 
prepared as in 2(1.3.3) and adjusted to 5xl05/ml in Dulbecco's 
20%. Cells were treated with l OOOunits LIF, 500 units LIF and 
100 units in the presence of controls.
A standard S-phase suicide assay using cytosine arabinoside 
was performed.
Assays for SA2JMB1 colony formation in the absence of growth
factors were performed for the cpIIs derived from each tube.
Four replicate experiments were performed.
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3(2.3.2)RESULTS
Table 3R.10 and figure G3.14 show the level of clonogenicity in 
SA2JMB1 cells following incubation with LIF. In the control it 
can be seen that a high proportion of the cell population is in S- 
phase (74.7 3 5.43) treatment of cells with varying
concentrations of LIF has had no statistically significant effect 
on the proportion of the cell population in S-phase when 
compared to the control. (lOOU/ml LIF 69.50%±6.37 / 
lOOOU/ml LIF 72.67%±5.35; p>0.05 in both cases)
Thus LIF does not inhibit the DNA synthesis of SA2JMB1 cells.
TABLE 3R.10: The effect of Leukaemia Inhibitory Factor on
the proportion of SA2JMB] in DNA synthesis.
LIF CONC. 
(U/ml)
0 100 1000
S-PHASE 74.73+5.43 69.50+6.37 72.67+5.35
(%) 0.1<p<0.375 0.375<P<0.4
N=4 N=4
84.03 81.60 77.42 j
83.59 79.13 85.50
62.22 61.22 62.90
69.01 56.10 64.87
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THE PROPORTION SA2JMB1 CELLS IN
S-PHASE FOLLOWING INCUBATION WITH LIF
Figure G3.14: The proportion of SA2JMB1 in DNA synthesis 
(%) in the presence or absence of LIF.
3(2.4) Does LIF alter the uptake of tritiated thymidine 
by SA2 JMBIcpIIs in limited volume liquid suspension 
culture ?
In this experiment SA2JMB1 cells were cultured in limited 
volume liquid suspension culture in the presence or absence of 
LIF. The principle of thymidine labelling is exactly the same as 
outlined for femoral marrow in 3(1.5). The experiment 
represented a trcnnd manner in which to investigate the 
effects of LIF on DNA synthesis in SA2JMB1 cells.
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3(2.4.1) PROCEDURE
This was a modification of the standard tritiated thymidine 
uptake assay. 2(2.1.4). Cellularity was determined and adjusted 
to 2x103 cells/ml. A microtitre plate was divided into four 
groups of six wells. lOOul cells was added to all wells. 
lOOOU/ml LIF, 500U/ml LIF, lOOU/ml LIF were assayed for 
the ability to alter the level of thymidine uptake as compared 
to a control.
The protocol was exactly as outlined for femoral marrow above
3(1.5.3).
Four replicate plates were prepared one for each of four time 
points.
Three replicate experiments were performed.
3(2.4.2) RESULTS
Table 3R.I1 and figure G3.15 show the effect of LIF on the 
uptake of tritiated thymidine by SA2JMB1 cells. The pattern of 
results here is interesting. Specifically at day three, in all cases, 
(i.e. lOOU/ml LIF, 500U/ml LIF and lOOOU/ml LIF) there is a 
statistically significant difference in the level of tritiated 
thymidine uptake when compared to the relevant controls. 
(P<0.05 in all cases). Examining the data it is obvious that these 
differences are not large. These findings are discussed more 
fully in 3D.4.
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TABLE 3R.11: The effect of varying concentrations of LIF on 
the mean thymidine uptake (%) by SA2JMB1 cells over three
days
CONDITION 
(SA2 CELLS)
DAY 1 CONTROL
MEAN THYMIDINE UPTAKE
(%/control)
± STANDARD E 
100.00
602.32±69.85
868.50±26.07
931.64+92.71
:rror
DAY 2 CONTROL 275.33+8.97
1355.01+69.38 
2501.99±72.68 
2615.19+116.22
DAY3 CONTROL 530.00+163.44
1466.02+87.40
7024.71+526.51
5191.94+348.85
DAY1 100 U LIF 94.87+3.96
600.87+69.38
856.97+14.07
806.18+46.75
0.1<p<0.375
DAY2 100 U LIF 302.67+35.35
1508.77+37.18
3236.04+516.04
2379.87+116.22
0.1<p<0.375
DAY3 100 U LIF 680.67+80.31
3774.57+169.16
7276.54+368.83
5349.8+348.85
0.1<p<0.375
DAY 1 500 U LIF 89.67+8.35
564.2+106.85
861.22+48.67
686.12+35.77
0.1 <p<0.375
DAY2 500 U LIF 280+15.53
1554.33+65.34
2761.67+193.44
2530.65+46.85
0.1<p<0.375
DAY3 500 ULIF 626+22.03
3989.70+149.97
5475.90+440.72
5456.65+253.15
0.1<p<0.375
DAY 1 1000 U LIF 87.33+6.01
502.95+51.25
858.56+11.53
732.56+41.07
0.05<P<0.1
DAY2 1000 U LIF 293+33.65
1466.02+115.99
3102.46+51.96
2605.38+88.08
0.1<p<0.375
DAY3 1000 U LIF 580.33+41.13
3528.61+112.57
5624.21+593.78
4713.86+333.60
0..375<p<0.4
In all cases N=3
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Figure G3.15: Mean thymidine uptake (expressed as
percentage of relevant control) by SA2JMB1 cells over three 
days in the presence or absence of varying concentrations of 
LIF
3.3: 15 DAY FOETAL LIVER
15 day foetal liver represents an active haematopoietic 
environment. As LIF is noted to exhibit different functions 
between different haematopoietic environments (Escary 1993) 
it was decided to assay the effects of LIF on cell populations 
derived from this haematopoietic tissue.
3 (3.1) The effect of LIF on the colony forming
potential of HPP-CFC in semi-solid agar culture
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This experiment was designed to assay the effect of LIF on the 
number of colonies formed by an HPP-CFC subpopulation.
3(3.1.1) PROCEDURE
LIF was assessed in vitro as an agent able to influence colony 
formation by HPP-CFC. It was assayed both as an agent able to 
stimulate colony formation, and as a synergistic agent on 
populations of HPP-CFC stimulated with:
- 10% WEHI cm + 10% L929 cm;
- GM-CSF + M-CSF (HPP 3);
- IL-3 + M-CSF (HPP 2);
- IL-la + IL-3 + M-CSF (HPP 1);
The protocol used was exactly as outlined for femoral marrow
(3(1.2)) but with foetal liver tissue.
Three replicate experiments were performed in the case of the 
first two subpopulations. Two replicate experiments were
performed for the latter.
3(3.1.2)RESULTS
Table 3R.12 and Figure G3.16 show the effect of LIF on the 
number of colonies formed by populations of HPP-CFC.
The pattern of results found here is interesting for a number of 
reasons. Firstly the effect of LIF on colony formation appears to 
be more notable here than in any other instance, but no 
discernable consistent pattern emerges.
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In the case of HPP-CFC stimulated with WEHI/L929 + 100 U/ml 
LIF there is a statistically significant decrease in the level of 
colony formation compared to controls. (0.025<p<0.05). 
However neither of the two other LIF concentrations have a 
similar effect on this HPP-CCC population in both
cases).
In the case of HPP-CFC stimulated with GM-CSF/M-CSF + 500 
U/LIF there is a statistically significant increase in colony 
numbers as compared to controls. (0.05<p<0.1). However 
neither of the two other LIF concenirations show a similar 
effect on this HPP-CFC population. (0.1<p<0.375 in both cases) . 
In the case of HPP-CFC stimulated with IL-3/M-CSF LIF does 
not alter the level of colony formation in any instance (P>0.05 
in all cases)
In the case of HPP-CFC stimulated with IL-la/IL-3/M-CSF 
+500U/ml or lOOOU/ml LIF there is a statistically significant 
decrease in colony formation(p<0.05 in both cases). However at 
the lower concentration of 100 U/ml LIF there is no effect on 
colony formation (0.1<P<0.375).
These results are discussed fully in 3D.5
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TABLE 3R .12: Colony formation by HPP-CFC from foetal liver 
(expressed as percentage of control) in the presence or absence
of varying concentrations of LIF.
LIF CONC. 
(U/ml)
0 100 500 1000
COLONY FORMATION (%/control)
FACTOR
....... /.......... 0 0 0 0
L929/WEHI 100.0 83.8+7.3 108.0+14.8 96.0+5.8
0.025<P<.05 0.1<p<0.375 0.1<p<0.375
N=3 N=3 N=3
20.5+1.3 19.5+7.5 27.2+1.5 22.0+1.3
29.2+0.8 25.2+2.0 23.9+1.8 25.5+2.9
31.7+3.5 22.5+2.1 35.0+4.14 29.7+2.3
GM-CSF/ 100.0 88.5+12.6 114.6+8.4 112.5+15.7
M-CSF 0.1<p<0.375 0.05<P<0.1 0.1<p<0.375
N=3 N=3 N=3
14.8+1.6 15.5+31 15.2+1.9 14.5+2.4
11.3+2.1 7.7+0.7 14.9+1.4 16.3+0.7
11.7+1.0 11.2+1.6 13.0+2.3 11.2+1.6
IL-3/ 100.0 84.5+15.5 96.5+11.5 88.5+7.5
M-CSF 0.1<p<0.375 0.375<P<0.4 0.1<p<0.375
N=2 N=2 N=2
26.5+1.7 26.8+0.3 22.5+2.6 25.8+3.4
26.0+1.4 18.8+1.9 28.0+1.6 21.8+1.9
IL-1/IL-3/ 100.0 93.0+18.0 76.5+5.5 73.5+6.5
M-CSF 0.1<p<0.375 0.01<P<.025 0.025<P<.05
N=2 N=2 N=2
32.0+3.4 24.3+6.3 22.7+1.9 25.7+3.8
35.0+3.1 31.5+4.9 28.8+1.8 23.5+3.5
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COLONY FORMATION BY HPP-CFCffl)
STIMULATED WITH VARYING GROWTH FACTOR
REGIMES ± LIF
Wehi/L929
GM-CSF/M-CSF
IL-3/M-CSF
IL-1/IL-3/M-CSF
Figure G3.16: Colony formation by HPP-CFC from foetal liver 
(expressed as a percentage of the control) in the presence or 
absence of varying concentrations of LIF .
3 (3.3) The effect of LIF in vitro on the proportion of 
HPP-CFC in DNA synthesis.
Whereas normal femoral marrow was relatively quiescent, 
foetal liver is haematopoietically very active. In HPP-CFC 
derived from foetal liver approximately 20-30% of the 
population are in cycle. Thus it is possible to test LIF as an 
inhibitor of an innately cycling HPP-CFC population in this 
tissue.
3(3.3.1) PROCEDURE
With the exception that the tissue was foetal liver and did not 
require prior irradiation, the protocol was identical to that used
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to test LIF as an inhibitor of HPP-CFC in femoral marrow
2(2.1.4).
Assays were performed for HPP-CFC stimulated to colony 
formation with WEHIcm and L929cm.
Three replicate experiments were performed,
3(3.3.2) RESULTS
Table 3R.13 and figure G3.17 show the effect of LIF on the 
proportion of HPP-CFC stimulated to colony formation with 
WEHIcm and L929cm, in S-phase. There is a relatively large 
proportion of the HPP-CFC population in S-phase (21.34%±2.81). 
Neither concentration of LIF has had a significant effect on the 
level of DNA synthesis within the HPP-CFC population 
(lOOU/ml LIF 23.66%±4.09/ lOOOU/ml LIF 24.15%±3.31 where 
0.1<p<0.375 in both cases ).
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TABLE 3R.13: The proportion HPP-CFC (WEHI/L929) from 
foetal liver in S-phase in the presence or absence of varying
concentrations of LIF.
LIF CONC. 
(U/ml)
0 100 1000
S-PHASE W
FACTORS
(HPP-CFC)
....... /........ 0 0 0
L929/WEHI 21.34+2.81 23.66+4.09 24.15+3.311
0.1 <p<0.375 0.1 <p<0.375
N=3 N=3
25.29+16.99 31.78+7.98 25.42+5.11
22.89+6.47 20.51+9.79 29.13+10.19
15.91+8.52 18.69+7.95 17.89+8.24
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Figure G3.17: The proportion HPP-CFC (WEHI/L929) from 
foetal liver in S-phase in the presence or absence of varying 
concentrations of LIF.
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3D:DISCUSSION
3D.1: The effect of LIF on Colony formation in 
semi-solid agar culture
In all cases LIF has failed to support the proliferation of 
haematopoietic cell populations in semi-solid agar culture. In 
almost all cases, whether as a direct acting agent in the dish, or 
as a pre-incubation agent prior to culture, LIF has had no effect 
on the number of HPP-CFC or GM-CFC stimulated to colony 
formation by a variety of growth factor combinations.
The two cases in which LIF was shown to alter the level of 
colony formation as compared to controls were perplexing. In 
the first of these (IL-3 stimulated colony formation ) the 
addition of 100 U/ml LIF to cultures results in a decrease in 
the level of colony formation. In the sccndd aase, the additinn 
of lOOU/ml LIF to a popula^on o f wool e ooe e marrow cells 
prior to assay for GM-CFC stimulated with IL-3 results in 
increased colony formation. Thus a picture of colony 
stimulation and inhibition emerges. In addressing this anomaly 
several points must be considered. Firstly in both cases the 
shift in the level of colony formation is not great (94%± 1.2 
against 100%; 109%±3 against 100%, respectively). This begs 
the question-What would be the physiological significance of a 
change of this maonltude ? Tins is best answered by 
considering daaa room compalabSe experimonis. In work by 
Metcalf et al (1990 ) where LIF is shown to alter the level of
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murine megakaryocyte colony formation stimulated by IL-3, 
the change in colony numbers is not great. (Control :16 
megakaryocyte colonies per 50,000 cells plated, against 21 
colonies per 50,000 cells in the presence of 1000 U/ml LIF ). In 
other work such as that by Verfaillie and McGlave (1991), LIF 
mediates substantial increases in colony number for given 
human cell populations, as compared to controls. For example 
the LIF mediated increase in colony numbers of MIX-CFC is 5 
times that seen in the control (560% against 100%). There is 
evidence therefore that LIF can induce both a substantial and a 
subtle alteration in the level of colony formation with 
precedents for accepting the validity of both.
There is considerable evidence from other groups (Metcalf e t 
aU 1988; 1989; Verfaillie and McGlave, 1991) that LIF is unable 
to alter the level of human GM-CFC colony formation either 
alone, or in combination with other factors (IL-3 and GM-CSF). 
The majority of the data from tables 3R.1 and 3R.3 concur with 
this finding. Furthermore the fact that the change in levels of 
colony formation is so small and not observed with other 
concentrations of LIF strongly suggests the apparent 
stimulation and inhibiton noted in this work may in fact be 
unimportant. It is perhaps worth noting, however ,that in the 
work of Verfaillie and McGlave, foetal calf serum is used in 
assays where here horse serum is used. Could there be a factor 
in horse serum which interacts with LIF thus allowing it to 
alter the level of colony formation seen in GM-CFC stimulated 
with IL-3? Again this seems unlikely as the majority of the
data in this work do not support this notion.
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The ability of LIF to enhance the level of murine 
megakaryocyte colony formation stimulated by IL-3 is noted 
(Metcalf et al, 1990; Debilli et al, 1993) The same is true for 
human megakaryocyte colony formation. (Burnstein et al, 
1990). The possibility that LIF is enhancing an IL-3 stimulated 
megakaryocyte colony formation should be considered. This 
seems unlikely for a number of reasons. Firstly the MEG-CFC 
assay is subtly different to the GM-CFC assay and thus this 
possibility should be discountable. Secondly LIF enhances 
colony formation in those assays where here, in one instance, it 
inhibits. Thirdly if LIF as a pre-incubation agent were 
increasing the size of the Meg-CFC pool then concentrations of 
LIF able to enhance the IL-3 megakaryocyte colony formation 
should exceed lOOU/ml. Therefore the increase in colony 
formation seen in this assay should have been larger at the 
higher concentrations.
Perhaps most intriguing is the fact that LIF has acted both to 
stimulate and inhibit at identical concentrations on an identical 
progenitor cell population. The difference lies in the assay 
technique. In the first instance LIF (at non-toxic 
concentrations) is acting in synergy with IL-3 to reduce GM- 
CFC colony formation. In the second instance LIF is increasing 
the size of the GM-CFC pool either by an active increase or by 
increasing the level of cell survival over the incubation period 
prior to assay with IL-3. Is LIF increasing survival of this cell 
pool ? In considering this it is interesting to note that Escary et 
al (1993 ) implicate LIF in the maintenance of GM-CFC numbers 
in the spleen and to a much lesser extent in the marrow. This
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implies that LIF is capable of performing a role in maintaining 
cell populations. However, it suggests that such a role is not 
seen in femoral marrow cell populations. This would seem to 
confirm that this result is unimportant.
From the data it seems reasonable to assume that LIF does not 
alter levels of colony formation in populations of GM-CFC, 
either as an agent in the dish, or as a short term pre-incubation
agent.
HPP-CFC colony formation.
LIF failed to support colony formation by HPP-CFC. This is 
unsurprising as HPP-CFC populations are at least partly defined 
by the dependence of their proliferation on multiple growth 
factor combinations. The failure of LIF to alter the level of 
colony formation seen in any of the HPP sub-populations tested 
is curious. Verfaillie and McGlave (1991) showed that LIF is 
capable of inducing growth and increased proliferation of 
immature multi-lineage colonies in cultures supplemented with 
foetal calf serum. Leary et al (1990) looked at the effects of LIF 
on IL-3 dependent colony formation by human haematopoietic 
progenitors (very primitive blast colony forming cells) 
methycellulose culture supplemented with foetal calf serum. 
They concluded that LIF was effective in enhancing colony 
formation. This correlates well with the work of Metcalf et al 
(1989). They demonstrated that, when present at high 
concentrations, LIF causes an increase in the number of 
immature blasts present in murine haematopoietic organs. The
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blast-CFC cell population is thought to be closely related in the 
haematopoietic developmental hierarchy to HPP-CFC. This 
would suggest that whilst LIF can be active on primitive blast 
cells, as the HPP 1 and HPP 2 populations tested are insensitive 
to it they are thus somehow distinct from the BL-CFC. It should 
be noted here however that although a murine BL-CFC has 
been assayed Leary et al worked on human BL-CFC. The HPP 
populations tested were murine in origin although they do 
have an in vitro human counterpart. It is perhaps also worth 
noting that the LIF used in Leary's work came from a different 
source to that used in the work contained in this thesis.
At this point it seems prudent to consider the HPP-mCFU-MK 
population of Han (1994). This HPP population is argued to be 
HPPl expressing a latent potential for megakaryocytic 
development in the presence of relevant concentrations of IL-6 
and IL-3, or unknown factors from a conditioned medium. In 
the development of megakaryocytes, IL-6 and LIF have similar 
roles to play with a probable degree of functional overlap at 
certain points. (Review Burnstein, 1994; Long, 1993). Given 
LIF's noted ability to enhance megakaryocytopoiesis, it seems 
reasonable to suggest that LIF, at appropriate levels, may have 
an action like IL-6 in stimulating HPP-mCFU-MK. In Han's work 
there is a very slight increase in overall colony numbers in 
assays for HPP-mCFU-MK as compared to assays for HPPl. 
They identify the HPP-mCFU-MK on a morphological basis. It 
may be that in these experiments LIF has stimulated the 
formation of HPP-mCFU-MK without a significant rise in the 
overall colony numbers. As a consequence the nature of its
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action in stimulating differential HPP populations has not been 
evident as a morphological assay for this population was not 
undertaken. Equally it may be that LIF was not used at a 
concentration likely to promote formation of this population 
although its use at these concentrations is justified by other 
work, as discussed in the methods . The dvvelopmen t of 
HPPmCFU-MK may be completely independent of LIF. If HPP 
(and at least three populations of different maturity have been 
tested here) are insensitive to LIF it would suggest that BL-CFC 
are in this respect a distinct population. A sensitivity to LIF 
poses the question "is this important in megakaryocytopoiesis 
?". The differentiation of a primitive stem cell imo 
megakaryocyte progenitors is poorly understood. Is there a 
role for BL-CFC and is it related to Han's HPP population ? 
Interestingly IL-6, an important ingredient in the development 
of HPPmCFU-MK, was shown to act in a similar but more rapid 
manner to LIF in promoting the IL-3 dependent blast cell 
colony formation.
Finally there is a question of experimental protocol. In both the 
work by Leery et al ((990) and tlto work of Verfaillie and 
McGlave (9999) foetal calf serum is used in assays. In all of the 
work in this thesis horse serum was used. Does horse serum 
represent a possible evvlropment in winch certem ol LIF's 
actions are lost ? It is worth noting that colony stimulation seen 
with LIF alone in the presence of foetal calf serum is not seen 
when serum is withdrawn. (Ver^illie and McGlave, 9999) This 
strongly suggests that LIF interacts with some component of 
foetal calf serum. Schaafsma et al (9992) report work in which
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LIF does not affect the proliferation or differentiation of human 
haematopoietic progenitor cells in LTBMC. In noting that these 
experiments produce contrasting results to Verfaillie and 
Mcglave (1991), Schaafsma et al point out that the source of 
LIF was different. The LIF used by Verfaillie and Mcglave was 
derived from a different cell line to that used by Schaafsma et 
al. The implication is that other factors produced by cell lines 
may interact with LIF. This could explain apparent 
contradictions in reports of LIF's actions. Given that Verfaillie 
seems to have controlled for this possibility it is perhaps worth 
considering that in the LTBMC studied by Schaafsma et al they 
do not seem to have controlled for endogenously produced LIF 
(membrane bound). Thus this particular assay system may 
already be saturated with LIF. Notably, however, Schaffsma 
does not use foetal calf serum in his assays. Could the inability 
of LIF to stimulate proliferation be related to the absence of 
this serum ?
In the assay system used in the work contained in this thesis 
LIF is unable to support HPP-CFC proliferation and has no 
effect on the level of colony formation by populations of HPP- 
CFC.
3D2: LIF and DNA synthesis.
In all cases LIF has had no statistically significant effect on the 
proportion of HPP-CFC or GM-CFC in S-phase. Robinson et al 
(1993) demonstrated the importance of the -SDK- sequence in 
the biology of the pentapeptide AcSDKP. It was shown to be
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that part of the molecule which blocked the action of stimulator 
on a population of HPP-CFC. Murine LIF contains the -SDK- 
sequence. If the sequence were responsible for a similar 
activity in LIF then this result would be unsurprising as LIF 
would be expected to have a mode of action similar to the 
tetrapeptide AcSDKP. However set against work by Fletcher et 
al (1990) these results (specifically for the HPP sub population 
) initially seem puzzling. Their work was designed to test for 
the effects of LIF on the recovery and retroviral infection of 
murine CFUS13 in vitro. They conclude that LIF enhances the 
recovery and retroviral-vector infection efficiency of normal 
haematopoietic progenitors. This would suggest that LIF may 
well stimulate HPP-CFC proliferation. This would be in direct 
contrast to the work of Robinson et al (1993). Interpretation of 
these results requires care. Firstly the enhanced recovery of 
CFUS13 brought about by LIF is open to a variety of 
explanations. It may be that LIF, in cultures of whole bone 
marrow, acts to stimulate proliferation of CFUS13. The main 
evidence for this would be the increased numbers of CFUS13 as 
compared to controls, and the high infection rate in these 
colonies. Several points weigh against this possibility. Most 
importantly the populations of CFUS13 from LIF treated 
cultures show no loss in differentiative capacity as assayed by 
morphological study of spleen colonies. This would imply that 
LIF had induced proliferation without differentiation. This is of 
course a documented function of LIF in ES cell cultures (Smith 
et al, 1990). So initially this would seem an inviting prospect. 
Fletcher et al however point out that many of the CFUS13
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derived colonies have identical pro-viral insertion patterns.
This could only occur if a CFUS 13 precursor had been infected, 
subsequently divided, and given rise to two identical daughter 
cells from which these colonies arose. This suggests that LIF 
acts on an earlier precursor. This earlier precursor may not be 
equivalent to the HPP populations assayed by Robinson et al 
(1993). This explanation relies on proliferative status alteration 
of CPUS 13 or a precursor cell population by LIF.
A second explanation may be that LIF does not increase the 
size of the CPUS population but increases the survival of that 
population or indeed a precursor population which gives rise to 
CPUS 13. Cultures lasted 72 hours, certainly a long enough 
period to allow cell death. The assumption with retro-viral 
labelling is that proliferation and labelling are directly 
proportional. Although Fletcher et al highlight significant 
evidence for this possibility they point out that infection may 
be unrelated to replication status. There is evidence that LIF 
may play a role in the maintenance of haematopoietic stem cell 
numbers (Escary et al, 1993). It has also been documented 
(Pesce et al, 1993) that LIF (in common with the cytokine SCF) 
reduced the occurrence of apoptosis, thus increasing cell 
survival, in Primordial germ cells during the first hours in 
culture. This ability certainly did not extend to a 72 hour time 
period, however, as Pesce points out the PGC's were cultured 
with the soluble form of LIF. In Fletcher's work bone marrow 
aspirates were in contact with stroma over the incubation 
period and thus the fibroblasts could have been induced to 
express membrane bound LIF or other cytokines. Work by
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Verfaillie (9993) seems to corroborate this. In a delicate 
manipulation of LTBMC she cultures primitive human cells 
either in the absence of a stromal layer (stroma free) or 
separated from a stroma layer by a microporous membrane 
(Stroma non-contact). She concludes that although both 
systems were supplemented with growth factors (including 
LIF) clonogenic cell expansion in stroma non-contact cultures 
was greater. Equally conservation of LTBMC-IC was greater in 
stroma cultures. This suggests that factors such as LIF are 
important for early stem cell survival but may function by 
inducing stroma to produce soluble factors. This is a subtle 
dynamic and may relate to the findings of Schaffsma et al 9992 
(although they have not examined the LTBMC-IC survival.) 
Relating this work to the findings contained in this thesis for 
GM-CFC and HPP-CFC populations, raises several points. The 
suicide assay technique results for GM-CFC cell populations are 
in agreement with the findings of Schaffsma et al (9992); 
Verfaillie and McGlave (9999); Metcalf et al (9989) The 
tritiated thymidine work confirms these findings. LIF alone is 
not able to enhance proliferation as compared to controls 
within the normal bone marrow cell population. Equally where 
assays have been stimulated with GM-CSF which should induce 
proliferative activity within GM-CFC, LIF does not enhance the 
level of proliferation as compared to controls. The apparent 
insensitivity of HPP-CFC to LIF could be a consequence of the 
HPP sub-population studied. HPP studied were stimulated with 
WEHI/L929 essentially IL-3/M-CSF (review methods). As 
noted in earlier discussions on HPP this would relate to a
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relatively mature HPP population. The CFUS-13 or indeed the 
precursor which appears sensitive in Fletcher's work may well 
be less mature than this population. The HPPmCFU-MK and 
BL-CFC populations may indeed overlap with Fletcher's 
population and thus it could be that LIF has a window of 
sensitivity which is being missed in work contained in this 
thesis. LIF is certainly not stimulatory or directly inhibitory for 
DNA synthesis in this particular HPP sub-population. The 
question of LIF acting as a survival agent should be considered. 
This could be manifested as proliferation without 
differentiation ie expansion of the cell pool. This seems unlikely 
however as there is no increased killing effect in LIF 
stimulated cultures. Secondly it could be maintenance in GO 
without cell death. Again this seems unlikely as there was no 
drop in colony numbers in HPP from non LIF treated controls. 
Incubation periods used here (3 hours stimulation/5 hours 
inhibition) were not sufficient to allow induction of secondary 
cytokines which may act as outlined by Verfaillie (1993.) If LIF 
could induce secondary factors which could alter the level of 
DNA synthesis in populations of haematopoietic cells this would 
only reinforce the finding that LIF does not directly alter the 
proliferative status or survival of HPP stimulated to colony 
formation with WEHI/L929.
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3D3: The interaction of LIF with a stem cell 
stimulator
Robinson et al (1993) demonstrated that -SDK- was the
functionally important part of the AcSDKP molecule with 
respect to inhibition of stimulatory activity. Thus this work 
examined whether LIF, which contained the -SDK- sequence, 
would have a similar role to play in blocking the action of a 
stem cell stimulator. LIF is not unique in containing this 
sequence, perhaps most notably murine and human TNF-a also 
contain the sequence of the peptide. (L'enfant et al, 1989). This 
is a known inhibitor of progenitors and primitive stem cells. 
However as reported by Bonnet et al (1995) the likelihood is 
that TNF-a does not exert its inhibitory activity via the -SDK- 
sequence; although there appears to be no work which directly 
assays the effects of TNF-a on a stem cell stimulator. In the 
work presented here LIF (murine) has failed to block the action 
of a stem cell stimulator. The proportion of the in vitro HPP-CFC 
in S-phase in normal femoral marrow was 10.6%±2.3. In the 
presence of medium conditioned by regenerating femoral 
marrow it was 34.5%±9.2(a significant increase p<0.025). This 
increase was not significantly altered by the addition of 
lOOOU/ml LIF, 29.9%±10.12, p>0.1. Immediately this poses the 
question: "what is the significance of this sequence ?" In order 
to fully address this question it would be necessary to fully 
understand two points of the stimulator/stem cell interaction. 
Firstly the nature of the stimulator itself; as yet its identity is 
unknown. Secondly the precise manner in which the -SDK-
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sequence and stimulator interact. Do the two interact directly ? 
Does -SDK- block the stimulator receptor ? Does it bind to cells 
directly (Bonnet et al, 1993) and interfere with an intracellular 
pathway or down-regulate stimulator receptors as has been 
seen with TGF-3 and MIP-l-a ? (Maltman et al, 1993) Only 
with an accurate understanding of this interaction can an 
explanation for murine LIF's inability to mimic this response be 
offered. Considering the work on TNF-a it is obvious that 
simply possessing the sequence is not sufficient to guarantee 
functional equivalence to the tetrapeptide. The assumption 
must be that its potential inhibitory function is modified by the 
sequences which surround it.
Although the -SDK- sequence is known to block the action of an 
already manufactured stem cell stimulator it was noted that 
monocytes and macrophages have hihh nnmbers of LIF 
receptors where earlier cells have few (Metcalf et al, 1989; 
Fletcher et al, 1990). Cells of the monocyte/macrophage lineage 
were the cells shown to produce stimulator and indeed 
inhibitor (review intro). It had been demonstrated the LIF did 
not affect in viiro diffe^j^fseth^t^i^i^^ oo GM-CFC (Metcatf f t a I, 
1989) although it may play some role in the survival of spleen 
derived GM-CFC and to a lesser extent of NBM GM-CFC (Escary 
et al, 1993). It seemed possible that if LIF did not play a 
significant role in the regulation of these ceBs yet receptors 
were present in monocytes and macrophages then it may be 
that LIF modulated some end function not directly concerned 
with cell differentiation. Could this possibly be the production 
of stimulator ? In all cases LIF has failed to inhibit the
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production of a stem cell stimulator by populations of aspirated 
bone marrow. Presuming LIF bound to receptors on 
money te/macrophage cells this would suggest that LIF's 
function here is not concerned with the manufacture of 
stimulator, at least as an inhibitory activity.
3D4: LIF and a murine myeloid Leukaemic cell 
line
LIF was initially characterised on the basis of its ability to 
induce macrophage differentiation in a murine myeloid
Leukaemic cell line Ml. SA2JMB1 was an X-irradiation induced 
murine myeloid leukaemia.
In all cases LIF has had no effect on the clonogenicity of 
SA2JMB1 cells in semi-solid agar culture either alone or in 
combination with GM-CSF. At all concentrations the level of 
colony formation is not statistically different to that seen in the 
control (p>0.05 in all cases). SA2JMB1 colonies were distinct 
and easy to distinguish from normal GM-CFC colonies. LIF had 
no effect on the appearance of SA2JMB1 colonies. Where 
SA2JMB1 cells were pre-incubated with LIF the picture is more 
complicated. In preincubation cultures supplemented with 100 
or 500 U/ml LIF there has been a significant decrease in the 
level of colony formation as compared to controls. This 
difference is not apparent at higher concentrations and has not 
been accompanied by a change in size or appearance of the 
remaining colonies. In pre-incubation cultures stimulated with 
GM-CSF there is a statistically significant increase in colony
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formation with lOOU/ml LIF. In the presence of 500 and 1000 
U/ml LIF this increase is not present. This pattern suggests two 
distinct effects of LIF on SA2JMB1 colony formation. In the 
former case it is able to reduce it whereas in the latter (when 
incubated with GM-CSF) it is able to increase it. As in earlier 
discussions on the effect of LIF on colony formation the first 
striking point about these results is the magnitude of the 
difference. Where LIF has decreased clonogenicity the 
difference is slight (Control 100%; lOOU/ml LIF 94.83%±1.83; 
500U/ml LIF 96.9%± 1.05U/ml). This change is so small, 
seemingly decreasing as the LIF concentration increases, that 
its relevance must be questioned. It is possible that LIF has 
such a small effect when used alone in pre-incubation cultures 
that it is barely apparent. Weighing against this is the fact that 
in cultures where GM-CSF was also present the reduction in 
clonogenicity is not seen at the appropriate concentrations and 
in fact at lOOU/ml LIF is replaced with an increase. This would 
mean that this particular factor combination was able to 
increase the fraction of the population forming colonies 
presumably by increasing the numbers in cell cycle. Thus as a 
transient agent alone LIF did not alter clonogenicity whereas in 
association with GM-CSF it increased it. The effects of LIF on 
Leukaemic cells are often very different. In the case of Ml cells 
LIF is able to induce significant differentiation within cell 
populations in agar culture. (80-100% at 400U/ml after 7 days 
in culture) (Metcalf, 1989). Interestingly molecules which had 
no or a very slight effect on Ml cell differentiation when used 
in conjunction with LIF or IL-6 significantly enhanced the level
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of differentiation. If LIF were having only a slight effect on
SA2 cells it may be that this could be accentuated in 
conjunction with appropriate growth factors. The work of 
Maekawa et al 1990 on the growth of human myeloid 
Leukaemic cell lines HL60 and U937 concludes that LIF in 
combination with GM-CSF can reduce HL60 colony numbers 
where LIF alone cannot. Similarly in U937 cells LIF in a 
synergistic interaction with IL-6 and G1M-CSF can i^igT^'ifiaandy 
decrease colony numbers, alone it h as no su ch action. 
Takanashi et al (1993) presented work on the growth of human 
acute myeloid leukaemias in an assay system which eliminates 
the need for foetal calf serum. They studied the effects of LIF, 
IL-6, IL-3 and GM-CSF on various parameters of Leukaemic 
cell growth. In AML cells from 11 patients LIF was shown to 
have a variety of actions. In 2 cases it reduced colony 
formation, in 7 it had no effect and in a further 2 it increased 
colony formation. In the cases where there was no stimulation 
of colony formation combination of other cytokines IL-6 
showed a colony stimulating activity. In combination with GM- 
CSF LIF was able to significantly increase the number of 
colonies seen when compared to those produced by GM-CSF 
alone. It may be that LIF is acting here to increase the number 
of blasts able to be stimulated by GM-CSF. If this is the case 
and a comparable stimulation is being observed in this work 
then why is it only seen in the case where LIF is present as a 
transient agent ? In the work of Takanashi et al cytokines are 
available throughout the n^c^i^l^^i^^n period (7 days). 
Differences exist in the protocol used by Takanashi and that
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used in these experiments. Specifically these relate to factor 
concentrations, culture media, inclusion of serum, use of a 
cloned cell line. Nevertheless Takanashi's work reflects a 
general pattern for the interaction of LIF with Leukaemic cell 
populations. It may stimulate, inhibit or have no effect on 
colony formation. Further confirmation of this comes from 
Wang et al (1990). They note that LIF could stimulate or inhibit 
human Leukaemic blast cell colony formation. In using a cloned 
cell line it had been hoped to overcome most of these problems 
however results suggest that LIF has opposing effects on a 
Leukaemic cell line dependent on the incubation conditions. 
These results are certainly significant but how relevant are 
they ? Would a larger pool of data accentuate or diminish them 
? It should be noted that it is only where LIF is present as a 
pre-incubation agent that any effect is detected. This suggests 
that this four hour incubation period is where LIF at certain 
concentrations may be interacting with the Leukaemic cell 
population.
In the light of previous reports on the effects of LIF on murine 
or human Leukaemic cells, it is reasonable to conclude that a
variation in response is observed.
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The effect of LIF on the proliferation of SA2JMB1 cells
LIF at concentrations of 100 or lOOOU/ml has had no 
statistically significant effect on the level of DNA synthesis as
compared to the control. (P>0.05 in both cases) tritiated 
thymidine studies confirm this work and extend it. Over three 
days in culture LIF fails to significantly alter the level of 
thymidine uptake as compared to controls. These results 
indicate that LIF does not interact with the Leukaemic cell 
cycle. If this is the case then it suggests that in the previous 
experiments LIF's ability to alter colony numbers is not 
brought about by LIF altering the level of the population in S- 
phase. It has been suggested that LIF is capable of inducing the 
GO-Gl transition in normal blast cells (Leary et al (1990); 
Fletcher et al, 1990; Ikebuchi et al, 1987). Equally Wang et al 
(1990) report that LIF can prolong the doubling time of newly 
established human acute myeloblastic cell lines in liquid 
culture. A combination of effects such as this might appear to 
have excellent value in the therapeutic treatment of leukaemia. 
However as Wang et al point out although the generation of 
Leukaemic blasts is slowed down consequently the effect of an 
S-phase specific killing agent is reduced. This coupled with 
LIF's extreme plieotrophic actions appears to discount its 
possible use as a chemotherapeutic agent. Again this work 
highlights the disparate nature of LIF's actions on Leukaemic 
populations.
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3D5: The effects of LIF on HPP-CFC derived from 
foetal liver
The basis for testing LIF on primitive haematopoietic cells 
derived from foetal liver was the observation that LIF
differentially regulated the maintenance of pluripotent stem 
cells (CFU-S) and progenitor cells (BFU-E and GM-CFC) between 
spleen and bone marrow. (Escary et al, 1993; Dumenil et al, 
1993). With respect to colony formation the effects of LIF are 
varied depending on the concentration used and the factor 
combinations used to stimulate colony forming cells. In the case 
of HPP-CFC stimulated by GM-CSF - M-CSF or IL-3+M-CSF LIF 
has had no effect on colony formation as compared to controls. 
Where colonies have been stimulated by L929 +WEHI cm the 
inclusion of lOOU/ml LIF in cultures has significantly reduced 
the level of colony formation as compared to the control 
(83.77%±7.33 against 100% in the control). This reduction is not 
observed at 500U/ml or lOOOU/ml LIF. This finding is curious 
in that it is not observed in cultures stimulated with IL-3+M- 
CSF the recombinant factor combination thought to be 
responsible for stimulation in WEHI/L929 cm. With lOOU/ml 
added to cultures stimulated by IL-3+M-CSF there is a 
comparable decrease in the level of colony formation however 
in this instance it is not significant. (84.5%±15.5 against 100% 
P>0.05). The basis for this inhibition of colony formation is 
difficult to define. It is apparent from other studies that LIF is 
capable of enhancing the activity of IL-3 with respect to colony 
formation. (Leary et al, 1990; Debilli et al, 1993) and
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Leukaemic cell growth (Takanashi et al, 1993). Since the 
inhibition of colony formation is not seen in the recombinant 
IL-3+M-CSF cultures it seems likely that LIF is interacting with 
some component of conditioned medium. This observation 
would gain valldity from the ooservvttons of Verfaillie and 
McGlave (1991) that LIF can interact with components of 
serum to induce proliferative changes which otherwise it would 
not. Similarly the proposal of Schaffsma et al that LIF could be 
interacting with components of conditioned medium to give 
alterations in the proliferative status of haematopoietic cells is 
worth noting here. In the case of HPP stimulated with IL-l+IL- 
3+M-CSF it seems that LIF at 500U/ml and lOOOU/ml is able to 
significantly reduce the level of colony formation as compared 
to the control. Thus the effect of LIF has been to reduce the size 
of the cell population on which IL-1+IL-3+M-CSF can have its 
colony stimulating activity. If, aa in bone mwowv , this 
combination oo' growth is stimulalins a primitive stem
cell compartment this would mean that LIF was 
protecting/removing part of the compartment, from the effects 
of differentiation cues thus preventing terminal differentiation. 
The purpose of this is not clear. Is exogenously added LIF 
acting as a survival agent ?
Foetal liver represents a tissue in which HPP-CFC are already in 
cycle. This is an excellent opportunity to study an innately 
cycling population i.e. one that has not been induced to cycle by 
exceptional non-physiooogical parameters. LIF S s uabMe oo 
block the cycling associated with this cell population. This
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indicates that LIF does not appear to play a role in the
proliferation regulation of foetal liver HPP-CFC.
CONCLUSIONS: LIF and Haematopoiesis
LIF appears to have a role in murine and non human primate 
megakaryocytopoiesis/development and function of platelets. 
(Metcalf et al, 1990; Metcalf et al, 1991; Debilli et al, 1993; 
Waring, 1993). It may have a role in the proliferation of early 
human haematopoietic stem cells or their precursors (Leary et 
al, 1990) and multipotential human haematopoietic
progenitors(Verfaillie and McGlave, 1991). It is necessary for 
maintenance of normal haematopoietis in mice and thus may 
have a role as a possible survival factor (Escary et al, 1993; 
Dumenil et al, 1993) such as that seen for LIF (In common with 
stem cell factor) in PGC's (Williams et al, 1989; Pesce et al, 
1993). LIF is thought to manage this by preventing apoptosis. 
It is perhaps worth considering that terminal differentiation 
can itself be seen as cell death.
It is thus possible to envisage a situation in which LIF may 
have actions at several points in haematopoiesis (Review 
diagram 8 ).
It is clear from the work contained in this thesis that LIF is not 
active in altering colony formation by the majority of HPP-CFC 
or GM-CFC populations in semi-solid agar culture. Where it is 
its actions are not straight-forward and there is the possibility 
that it may be acting as a survival agent. Furthermore the 
possibility that LIF induces morpholgical changes within
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colonies derived from HPP cells is not discounted. With respect 
to proliferation regulation of an HPP-CFC sub-population LIF 
was unable to alter the level of proliferation either directly or 
indirectly. This finding suggests that although LIF contains the 
-SDK- amino acid motif, thought to be the important part of the 
AcSDKP molecule wiih respect to inhibiiton of stimulator 
activity, it is unable to mimic the inhibitory action of AcSDKP. 
This may be unsurprising due to the fact that the sequence is 
not conserved between species and there is little overlap 
between the functions of LIF and AcSDKP (Review Bonnet et al, 
1995; Hilton et al, 1992). On a murine myeloid Leukaemic cell 
population LIF appears to exert +ve and -ve effects on in vitro 
colony formation but is unable to aller the level of 
proliferation. In some populations of HPP-CFC derived from 
foetal liver certain cc^nc^^ntrt^tti^r^js of LIF are able to inhibit 
colony formation. This may represent suppression of terminal 
differentiation and tbus maintenance oo ant eerly stem cell 
population.
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CHAPTER 4: SA2JMB1 
CONDITIONED MEDIUM
The term leukaemia is used to categorise a group of 
haematopoeitic proliferative disorders which are malignant in 
nature. Leukaemic patients present with symptoms associated 
with the suppression of normal haematopoiesis: anaemia; 
thrombocytopenia and infection. This reflects the nature of the 
disease it is a perturbation of the dynamic balancing the level 
of primitive cell proliferation with the level of end cell output. 
This can be construed as a spectrum of leukaemias differing in 
the particular cell lineage in which neoplastic proliferation is 
noted and the level of differentiation associated with the 
leukaemia. A leukaemia can be acute with poorly differentiated 
cells or chronic in which cells are more differentiated. In both 
the result is abnormal white blood cell production. (Diagram 19 
) These abnormal cells infiltrate the haematopoietic system, 
liver and spleen amongst other tissues Perhaps the most 
significant aspect of leukaemia is the suppression of normal 
haematopoiesis. It seems likely that this phenomenon is due to 
the production by Leukaemic cells of leukaemia associated 
factors. These factors are able to alter the proliferative status 
of normal cells whilst Leukaemic cells remain insensitive to 
them. (Bognacki et al, 1981; Riches and Robinson, 1993). 
Identification of such factors is thus of fundamental importance 
in the treatmentt of leukaemias.
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In this chapter SA2JMB1 conditioned medium (SA2cm) was 
assessed in vitro as an agent affecting certain aspects of 
haematopoeisis. Attempts were made to identify activities
interacting with aspects of haematopoiesis .
HAEMATOPOIESIS IN LEUKAEMIA
STEM CELLS 
-A leukemic 
lesion may 
develop in 
one stem cell .
PROGENITOR CELLS
- As cells mature 
leukemic lesions may 
accumulate resulting 
in the development of 
large numbers of
leukemic progenitor cells.
FUNCTIONAL END CELLS 
- Do NOT get increased
numbers of end cells in 
line with increased
numbers of progenitors 
actually see a decrease
in numbers.
DIAGRAM 19 SCHEMATIC APPRECIATION OF 
BLOOD CELL FORMATION IN LEUKEMIC INDIVIDUALS
4.1: FEMORAL MARROW
Again as in work investigating LIF, this work falls into two 
broad categories: direct action and indirect action. SA2JMB1 
were grown (according to the protocol laid out in 2(1.3.3)) in 
Fischer's 10%. In all experiments SA2cm was routinely used at 
a range of concentrations not exceeding 20%(v/v). (Diagram 20)
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All results for individual experiments were normalised as a 
percentage of the control. This validated the comparison of data 
between individual experiments and also meant that data could 
be pooled as a mean.
An unpaired two-tailed t-test was used to analyse data. (See 
2(3.1.1)) p values are shown beneath the mean for each 
condition.
Means of data for individual experiments are shown beneath p 
values.
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METHOD
FLASK CONTAINING 
SA2JMB1 CELLS GROWN 
FOR THREE DAYS IN
MEDIUM .
USE THE MEDIUM: TO 
PRETREAT NORMAL 
BONE MARROW CELLS
/
ADD THE MEDIUM
DIRECTLY TO THE
CULTURE DISH
CULTURE IN AGAR
i
WITH GROWTH FACTORS
BONE MARROW
CELLS
DIAGRAM 20 SUMMARY OF METHODS TO STUDY SA2CM ACTION
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DIRECT ACTION
4 (l.l)The effect of SA2JMB1 conditioned medium (SA2
cm) on the colony forming potential of GM-CFC in 
semi-solid agar culture
It was decided to test a range of concentrations of SA2cm in 
vitro for colony stimulating activity on 7 day semi-solid agar 
cultutres. SA2cm was tested as an agent acting alone and as a 
synergistic agent with GM-CSF, IL-3, WEHIcm and L929cm.
4(1.1.1) PROCEDURE
a) GM-CFC stimulated with SA2cm alone.
SA2cm was assayed at 20%(v/v), 10%(v/v), 5%(v/v), 2%(v/v) 
and l%(v/v)
The protocol was a modification of the standard GM-CFC assay 
(2 (1.3.1)). 30ml universals were supplemented with 
appropriate volumes of SA2cm. (E.G 2mlSA2cm in 10ml prep 
for 20%v/v; 1ml in 10ml prep for 10%v/v etc). A control 
universal was prepared which was not supplemented with 
SA2cm. A standard GM-CFC assay was then performed for each 
condition.
b) GM-CFC stimulated with SA2cm and other factors.
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The above protocol was repeated but with universals 
supplemented with various other growth factors, final volumes 
were altered appropriately.
The table below summarises the factors tested:
FACTOR
ALL CONC GM-CSF IL-3 WEHI CM L929 CM
SA2CM (40U/ml) (80U/ml) 10% (v/v) 10%(v/v)
TABLE 4.1 summary of factors used to stimulate 7-day cultures 
Four replicate experiments were performed.
(4.1.1.2) RESULTS
Table 4R.la, 4R.lb and Figures G4.1a, G4.1b show the results 
for 7 day colony formation in the presence or absence of 
varying concentrations of SA2cm.
In the case of cultures supplemented with SA2cm only, table 
4R.la shows that a complicated pattern emerged with no 
consistent finding throughout the four individual experiments. 
In cultures supplemented with 1% V/V SA2cm there is no 
significant increase in the level of colony formation as 
compared to the control in any of the individual experiments. 
At 2%SA2cmV/V a significant increase is observed in 2 of the 
experiments (P<0.05). At 3% SA2cm V/V there is a statistically 
significant increase in the level of colony formation in three of 
the experiments. At 10 and 20% SA2cm V/V a similar pattern 
emerges with three of the four experiments showing a 
significant increase in the level of colony formation. In all 
instances the level of colony formation is not high. This is 
illustrated in figure G4.1a.
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In 7 day culture of femoral marrow SA2cm appears able to
support limited colony formation.
Table 4R.lb show the effect of SA2cm on the level of colony 
formation induced by other growth factors. In the case of IL-3 
stimulated cultures supplemented with varying concentrations 
of SA2cm there is no statistically significant difference in 
colony formation with 1 ,2, 5, and 10 %v/v SA2cm. (P.>0.05) in 
all cases. In the case of IL-3 stimulated cultures supplemented 
with 20% SA2cm there is a significant increase in the level of 
colony formation as compared to the control. (P<0.05)
In cultures supplemented with GM-CSF there is a statistically 
significant increase in the level of colony formation at all 
concentrations of SA2cm (P<0.05) except l%v/v (P>0.05). The 
same picture emerges for L929 stimulated cultures.
In the case of cultures stimulated with WEHIcm there is no 
statistically significant increase in the level of colony formation 
at any concentration of SA2cm (p>0.05).
Thus with respect to influencing colony formation in 7-day 
semi-solid agar culture SA2cm shows a differential pattern of
activity.
SA2JMB1 conditioned medium
TABLE 4R.la: The effect of varying concentrations of SA2cm 
on the colony forming potential of GM-CFC from NBM in 7-day 
semi-solid agar cultures .Data for four individual experiments 
is shown.
CONC
SA2CM
(%V/V)
0 1 2 5 10 20
COLONY FORMAT ION (PER 5x10* cells)
7 DAY 0.0±0.0 0.0+0.0 0.0 ± 0.0 1.510.5 2.010.0 12.011.0
ASSAY .025<P<.05 P<.0005 P<.0005
WITH 0.0 + 0.0 0.0+0.0 2.010.0 2.011.0 10.515.5 18.511.5
SA2CM P<.0005 .005<P<0± .05<P<± P<.005
ALONE 0.0+0.0 0.5+0.S 3.010.0 3.510.5 9.512.5 7.514.5
.1<P<.375 P<.0005 P<0.01 P<0.05 .1<P<.375
0.0+0.0 0.0+0.0 0.010.0 3.011.0 4.010.0 10.512.5
P<0.05 P<.0005 P<.05
SA2JMB1 conditioned medium JJL2
THE LEVEL OF COLONY FORMATION IN CELLS
DERIVED FROM FEMORAL MARROW AFTER
FIGURE G4.1a: Colony formation(expressed as colony number 
per 5x 104 cells plated) in 7-day semi-solid agar cultures of 
NBM in the presence or absence of varying levels of SA2cm. 
Data for four individual experiments is illustrated.
SA2JMB1 conditioned medium ILfi.
TABLE 4R.lb: The effect of varying concentrations of SA2cm 
on the colony forming potential of a variety of GM-CFC in 7-day
CONC.
SA2CM
(%V/V)
0 1 2 5 10 20
GM-CFC COLONY FORMATI ON (%/C ONTROL)
ASSAY
IL-3 100.0 101.71 6 99.7114 1 21.3111 120110.5 13819.6
.375<P<.4 P>0.4 0.05<P<.1 0.05<P<1 P<0.005
15.011.0 15.510.5 19.011.5 20.512.5 21.011.0 24.512.5
14.012.0 14.510.5 16.511.5 20.013.0 19.011.0 20.510.5
24.512.5 28.013.0 22.511.7 28.513.5 25.514.2 31.514.5
23.019.0 20.012.3 14.511.5 21.513.5 23.012.3 27.510.5
GM-CSF 100.0 10717.8 13418.8 185136.8 213135 220.7141
.1<P<.375 P<0.005 P<.005 P<0.01 .01<P<.03
15.014.0 16.013.0 23.013.0 33.012.0 40.512.5 39.011.0
11.011.0 11.011.0 16.018.0 30.010.0 31.011.0 34.513.5
22.014.0 20.212.5 26.011.0 26.514.5 31.015.0 31.013.0
21.012.0 27.011.0 25.013.0 27.5+10 35.011.0 35.011.5
L929 100.0 84.5139 141.2120 168.7122 21519 251127.6
.1<P<.375 .03<P<.05 .01<P<.03 P<0.0005 P<0.005
14.514.5 18.010.0 20.011.0 30.517.5 35.011.0 37.513.5
20.013.0 9.011.0 28.013.0 28.015.0 40.012.0 46.515.5
17.011.0 17.014.0 26.012.0 30.012.0 36.512.5 39.010.0
15.011.0 19.011.0 18.011.0 21.510.5 31.011.0 40.513.5
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WEHI 100.0 90.5127.5 101.318.5 89.3112.2 116.5125 106.3112
.1<P<.375 1<P<.375 .1<P<.375 .1<P<.375 .1<P<.375
11.013.0 13.010.0 14.013.7 13.513.5 20.515 15.012.0
18.515.0 11.510.5 14.510.5 11.011.5 13.015.0 15.012.0
20.511.5 22.011.0 22.011.0 17.510.5 22.511.5 20.013.0
21.512.5 21.511.5 21.5111 20.512.5 21.512.5 23.011.0
In all cases N = 4
THE EFFECT OF SA2CM ON GM-CFC
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FIGURE G4.1b: Colony Oormrtiob(expressed as a percentage of 
the control 0%V/V SA2cm) in 7-day semi-solid agar cultures of 
NBM stimulated with varyious growth factors in the presence 
or absence of varying levels of SA2cm
SA2JMB1 conditioned medium. 1±2
4 (1.2)The effect of SA2cm on the colony forming 
potential of HPP-CFC in semi-solid agar culture
In an attempt to define a role for SA2cm in interacting with 
primitive haematopoietic cell populations SA2cm was assayed
in vitro for colony stimulating activity on HPP-CFC. It was 
assayed both as an agent able to stimulate colony formation on 
its own and as a synergistic agent in cultures stimulated with :
- 10% WEHI cm + 10% L929 cm;
- GM-CSF + M-CSF (HPP 3);
- IL-3 + M-CSF (HPP 2);
- IL-1 a + IL-3 + M-CSF (HPP 1);
- IL-1 a + IL-3;
- lL-1 a + M-CSF;
4(1.2.1) PROCEDURE
The protocol used was a modification of the standard HPP-CFC 
assay 2(2.1.3).
a) HPP-CFC stimulated with SA2cm alone
FEEDER LAYERS
SA2cm was assayed at 20%(v/v), 10%(v/v) and 5%(v/v) feeder 
layers were prepared containing SA2cm at these final 
concentrations. A control was prepared in which feeder layers 
contained no SA2cm (i.e. 9ml Dulbecco’s 20% and just prior to 
plating 1ml 5% agar ).
SA2JMB1 conditioned medium W
b) HPP-CFC stimulated with SA2CM and other growth factors.
The above protocol was repeated but with universals 
supplemented with various other growth factors, final volumes
altered apporopriately.
The table below summarises the conditions tested:
FACTOR
WEHI GM-CSF IL-3 IL-1a IL-1a IL-1a
CM (40U/ml) (80U/ml) (lOU/ml) (lOU/ml) (lOU/ml)
ALL (10% v/v) + + + + +
CONC. + M-CSF M-CSF IL-3 IL-3 M-CSF
SA2CM L929 CM
(10% v/v)
(50U/ml) (50U/ml) (80U/ml)
+
M-CSF
(50U/ml)
(80U/ml) (50U/ml)
TABLE 4.2: Summary of factors used to stimulate HPP-CFC in 14-day 
semi-solid agar cultures.
Standard HPP-CFC assays were performed for each condition 
Three replicate experiments were performed.
4(1.2.2) RESULTS
Table 4R.2a, 4R.2b and Figures G4.2a, G4.2b show the results
for the effect of SA2cm on the level of colony formation in 14
day semi-solid agar cultures .
Table 4R.2b shows that in three individual experiments where 
cultures were supplemented with SA2cm an inconsistent
SA2JMB1 conditioned medium UL4
pattern of colony formation emerges. With 5 or 20%V/V SA2cm 
a significant increase in the level of colony formation emerges
in two of the three experiments. At 10%SA2cmV/V a 
significant increase in colony formation is seen in only one 
experiment. Thus SA2cm does appear able to support limited 
colony formation in 14 day culture. Notably the level of colony 
formation is far less than that seen in 7day cultures. There is 
also no sustantial increase in the level of clonony for mation 
seen with 20%SA2cm V/V as compared to that seen with 
5%SA2cm V/V. This is illustrated in figure 4G.2a. This would 
suggest that SA2cm contains very low levels of factors able to 
stimulate the production of HPP-CFC.
Table 4R.2b shows that in cultures stimulated with WEHI/L929 
there is no significant difference in the level of colony 
formation seen in the presence of any concentration of SA2cm 
as compared to that seen in the control. (P>0.05 in all cases)
In cultures stimulated with GM-CSF/M-CSF there is a 
statistically significant increase in the level of colony 
formation at 5 and 10% v/v SA2cm as compared to the 
control(P<0.05). This is not observed at 20%v/v SA2cm where 
P>0.05.
In the case of cultures stimulated with IL-3/M-CSF there is no 
significant difference in the level of colony formation at 
concentrations of 5 or 10 %v/v SA2cm (P>0.05). With 20%v/v 
SA2cm there is a significant increase in the level of colony 
formation (P<0.05).
For cultures stimulated with IL-1/I1-3/M-CSF or IL-l/M-CSF a 
similar picture emerges. At concentrations of 5 or 20 %v/v
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SA2cm there is a significant increase in colony formation 
(P<0.05). At 10%v/v SA2cm no such increase is observed
(P>0.05).
The actual increase in the level of colony formation is much 
greater in cultures supplemted with IL-1+ M-CSF than those 
supplemented with IL-1+IL-3+M-CSF.
Thus SA2cm has a variety of effects on the level of colony 
formation seen in 14 day agar culture. These effects appear to 
be related to the growth factor combinatioins with which 
cultures were supplemented.
TABLE 4R.2a: The effect of SA2CM on the colony forming 
potential of HPP-CFC from NBM in semi-solid agar culture. Data 
from three individual experiments is shown.
CONC
SA2CM
(%V/V)
0 5 10 20
COLONY FORMATION (%/control)
14 DAY 0.0+0.0 1.0±0.4 0.5+0.3 1.0+0.7
ASSAY .01<P<.025 .05<P<.01 .1<Pc.375 j
WITH 0.0+0.0 0.5+0.5 2.0+2.0 1.0+0.0
SA2CM .1<P<.375 .1<P<.375 P<.0005
ALONE 0.0+0.0 1.0+0.0 3.0+0.0 1.510.5
P<.0005 P<.0005 .025<P<.05
SA2JMB1 conditioned medium JLM
THE LEVEL OF COLONY FORMATION IN CELLS
DERIVED FROM FEMORAL MARROW AFTER 14
DAY SEMI-SOLID AGAR CULTURE WITH SA2cm
FIGURE 4G.2a: Colony formation (expressed as colony number 
per 4x104 cells plated) in 14 day semi-solid agar cultures of 
NBM in the presence or absence of varying concentrations of 
SA2cm Data from three individual experiments is illustrated.
SA2JMB1 conditioned medium J 97
TABLE 4R.2b: The effect of SA2CM on the colony forming 
potential of HPP-CFC from NBM in semi-solid agar culture.
CONC
SA2CM
(%V/V)
0 5 10 20
HPP-CFC COLONY FORMATION (%/CONTROL)
ASSAY i
WEHI/L929 100.0 103.7+3.7 98.717 112.319.1
0.1<P<.375 P>0.4 0.1<P<.375
29.0+3.0 29.511.5 25.513.5 29.512.5
18.0+0.0 29.512.4 28.511.5 31.012.0
29.5+7.0 20.511.5 22.012.0 23.510.5
GM-CSF + 100.0 154.3124 181.9126 178163
M-CSF .025<P<0.05 0.01<P<.025 0.1<P<.375
11.0+1.0 11.013.0 20.013.0 10.011.0
5.513.5 16.011.0 12.510.5 19.511.5
13.5+3.5 16.014.0 18.512.5 15.010.5
IL-3 + M-CSF 100.0 92.315.0 102.716.2 104.311.3
0.05<P<0.1 0.1<P<0.375 0.01<P<.025
31.512.5 26.512.5 30.513.5 32.511.5
38.514.5 2711.5 26.512.5 29.510.5
27.511.5 2513 3113 2812
IL-1 + IL-3 + 100.0 106.012.5 116.019.2 119.017.9
M-CSF 0.025<P<.05 0.05<P<0.1 0.025<P<.05
40.015.0 41.513.5 46.014.0 46.512.5
31.017.0 34.512.5 41.510.5 41.013.0
38.510.5 40.011.0 38.016.0 41.511.5
SA2JMB1 conditioned medium ILS
IL-1+ M-CSF 100.0 150.7112.0 157.3137.0 213.3133.0
0.05<P<0.1 0.1<P<.375 0.01<P<.025
20.514.5 26.011.0 10.013.0 33.513.5
8.510.5 8.510.5 10.510.5 16.512.5
4.510.5 4.510.5 25.010.0 12.510.5
In all cases N=3
THE EFFECT OF SA2CM ON HPP-CFC
COLONY FORMATION .
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FIGURE 4G.2 b: Colony formation (expressed as a percentage 
of the control) in 14 day semi-solid agar cultures of NBM 
stimulated with varying growth factor combinations in the 
presence or absence of varying concentrations of SA2cm.
4 (1.3) The effect of SA2cm in vitro on the proportion
of GM-CFC and HPP-CFC in DNA synthesis.
The principle here was identical to that employed when testing 
the effect of LIF on the proportion of a cell population in S-
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phase. It is possible that Leukaemic cells may gain a 
proliferative advantage by actively altering the proliferative 
status of normal haematopoietic cells. Thus normal cells cannot 
respond to the decreased end cell production associated with
leukaemia.
In this experiment SA2cm was assessed as an agent able to 
alter the proportion of haematopoietic cell populations in S-
phase.
4(1.3.1) PROCEDURE
As a potential stimulator of DNA synthesis 
In normal femoral marrow the HPP-CFC population is largely 
quiescent with 10-15% in S-phase. Thus it is possible to assay 
SA2cm as a stimulator of DNA synthesis in populations of HPP- 
CFC derived from femoral marrow.
The protocol was a modification of the standard stimulator-S- 
phase suicide assay. Four red-topped conical bottomed 
centrifuge tubes recieved 1ml aliquots of cell dilution. The 
tubes were then set out in two pairs. 200ul of SA2cm was 
aliquoted into both tubes of the first pair. This gave two 
identical tubes containing 1ml 5x106 cells, 20%(v/v) SA2cm. 
The second pair, the control tubes, received aliquots of 200ul 
Fischer's 10% .A standard stimulator S-phase suicide assay with 
ARA-C was then performed.
Assays for HPP-CFC stimulated with WEHI/L929 conditioned 
media were performed for each tube
As a potential inhibitor of DNA synthesis
SA2JMB1 conditioned medium 2U0
A high proportion of the GM-CFC population in normal femoral
marrow is in S-phase. It is thus possible to assay SA2cm as an
agent able to reduce levels of DNA synthesis within this cell 
population.
GM-CFC
The method used is exactly as that outlined to test SA2cm as a 
stimulator with the exception that cells are incubated for three 
hours prior to the one hour ARA-C incubation. Assays for GM- 
CFC stimulated with WEHI were performed.
HPP-CFC
As in the earlier studies involving LIF, regenerating bone 
marrow was used as a source of cycling HPP-CFC. The protocol 
was identical to that used to test SA2cm as a stimulator with 
the exception that the cells were incubated for four hours prior 
to the one hour ARA-C incubation.
In all cases four replicate experiments were performed.
4(1.3.2) RESULTS
Table 4R.3.1 and Figure G4.3 show the effect of SA2cm on DNA 
synthesis in a population of HPP-CFC. There is no statistically 
significant difference between the level of cycling seen in the 
control and that seen in the population treated with 20%v/v 
SA2cm (controll3.9%±1.8 / 20%V/V SA2cm 13.6+1.4 where 
0.1<p<0.375).
Table 4R.3.2 and Figure G4.4 show the effect of SA2cm on DNA 
synthesis in a population of GM-CFC. The addition of SA2cm to
SA2JMB1 conditioned medium 2 0 1
cultures failed to alter the proportion of the cell population in
DNA synthesis as compared to the control (control 26.7%±2.43 / 
20% SA2cm 25.0±2.7 where P > 0.4).
The addition of Table 4R.3.3 and fugure G4.5 show the effect of 
SA2cm on DNA synthesis in HPP-CFC derived from regenerating 
femoral tissue. In this tissue a relatively high proportion of the 
population is in DNA synthesis (Control 28.0% ±4.4) The 
addition of SA2cm fails to alter the level of DNA synthesis seen 
in this population (20% SA2cm 21.4%±2.6 where P>0.05 )
Thus SA2cm at this test concentration does not alter the level 
of DNA synthesis in any of the colony forming cell populations 
tested.
SA2JMB1 conditioned medium 2JLI
TABLE 4R.3.1: HPP-CFC
CONDITION NBM NBM
SA2CM(20%V/V)
+
PROPORTION S-PHASE (%)
FACTORS
(HPP-CFC)
L929/WEHI 13.9±1.8 13.5+1.4
0.1<P<0.375
13.24 13.50
10.81 10.71
12.39 12.64
18.97 17.27
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FIGURE G4.3: The proportion of HPP-CFC(WEHI/L929) from 
NBM in D.N.A synthesis^) following incubation with varying 
concentrations of LIF.
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AS A POTENTIAL INHIBITOR OF D.N.A SYNTHESIS 
TABLE 4R.3.2: GM-CFC
CONDITION NBM NBM
SA2CM(20%V/V)
±
PROPORTION S-PHASE (%)
FACTORS
(GM-CFC)
WEHI 26.8±2.4 25.0±2.7
P>0.4
28.03 20.21
22.00 31.05
24.56 24.00
33.82 27.00
THE EFFECT OF SA2CM ON THE 
PROPORTION OF GM-CFC IN S-PHASE
0 20
CONCENTRATION SA2CM (%V/V)
FIGURE4.4: The proportion of GM-CFC (WEHI) from NBM in S-phase (%) 
following incubation with varying concentrations of LIF
SA2JMB1 conditioned medium 2 Q 4
TABLE 4R.3.3: HPP-CFC
CONDITION RBM RBM
SA2GM(20%V/V)
+
PROPORTION S-PHASE (%)
FACTORS
(HPP-CFC)
L929/WEHI 28.0+4.4 21.412.6
0.1<P<0.375
38.46 25.00
31.94 26.50
22.09 15.29
19.47 18.86
THE EFFECT OF SA2CM ON THE
PROPORTION OF HPP-CFC (FROM
CONDITION
FIGURE G4.5: HPP-CFC (WEHI-L929) from regenerating bone marrow 
in S-phase(%) following incubation with varying concentrations of 
SA2cm
INDIRECT ACTION
SA2JMB1 conditioned medium 2 O 5
A Leukaemic cell population could gain a proliferative 
advantage over normal haematopoietic cell populations in a 
number of ways. Of these interference with the level of DNA 
synthesis in cell populations has been excluded in the above 
work. It is possible that Leukaemic associated factors could act 
to interfere with those activities responsible for the initiation 
of DNA synthesis in normal haematopoietic cell populations. 
This work attempted to define a role for SA2cm in interacting 
with a stem cell stimulator.
4 (1.4) Does SA2cm alter the action of a
haematopoietic stimulator on a defined HPP-CFC 
subpopulation?
A stem cell stimulator has been shown to be produced 
reproducibly by femoral marrow recovering from irradiation.
It is reasonable to assume that such a stimulator may be 
produced in vivo in response to haematopoietic stress such as 
that associated with the development of a leukaemia. This 
experiment was designed to assay the ability of SA2cm to 
interfere with the production of this stimulator.
4(1.4.1) PROCEDURE
The poolocol waa a moditicatton of the standard stimulator
block assay.
A single cell suspension was prepared and cellularity adjusted 
to 5 x IO6 ccHs/ml. 8 ml of this dilution was prepared. 1ml
SA2JMB1 conditioned medium 2JL6
aliquots of this cell dilution were pipetted into each of six red- 
topped conical bottomed centrifuge tubes. The tubes were then 
set out in three pairs. 1ml of 'stimulator' was added to four of 
the tubes. 400ul SA2cm was aliquoted into two of these tubes. 
400ul Dulbecco's 20% into the other two. 1400ul of Dulbecco's 
20% was added to each of the two remaining tubes, the control 
tubes. A standard stim-block assay was performed.
Assays for HPP-CFC stimulated with WEHI/L929 conditioned 
media were performed for each tube.
Five replicate experiments were performed.
4(1.4.2) RESULTS
Table 4R.4 and figure G4.6 show the effect of SA2cm on the 
action of a stem cell stimulator.
In Normal bone marrow a small proportion of this HPP-CFC 
sub-population are involved in DNA synthesis ( 17.08%±1.16). 
In the presence of a stem cell stimulator there is a statistically 
significant increase in the proportion of the population in DNA 
synthesis. (30.31 %±3.42 where 0.0005<P<0.005 ). In the 
presence of 20%v/v SA2cm this increase in the level of DNA 
synthesis is lost. (18.09% ±2.70 where 0.1<p<0.375).
Thus SA2cm has blocked the action of a stem cell stimulator on 
a population of HPP-CFC.
SA2JMB1 conditioned medium 2JLZ
TABLE 4R.4: The effect of LIF on the action of a stem cell 
stimulator.
CONDITION NBM NBM+STIM NBM + SUM +
SA2CM(20%VA/)
FACTORS PROPORTION S-PHASE (%)
(HPP-CFC)
WEHI/L929 17.0811.16 30.3113.42 18.0912.70
0.0005<P<0.005 0.1<P<0.375
17.20 36.84 16.07
12.87 34.78 21.65
20.00 35.71 26.63
17.86 24.04 13.27
17.48 20.18 12.87
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FIGURE G4.6: The proportion of HPP-CFC(WEHI-L929) from 
NBM in S-phase(%) after treatmentt with a stem cell stimulator 
in the presence or absence of SA2cm.
SA2JMB1 conditioned medium IO
4.2; IDENTIFICATION OF THE
ACTIVITIES WITHIN SA2cm
SECTION COLONY PROMOTING ACTIVITY
The pattern of colony promoting activity emerging for SA2cm 
suggested that it may contain IL-3. (See results and discussion). 
This is not to suggest that SA2cm was thought to be a source of 
lL-3 alone, but that its actions in promoting colony formation 
in both HPP-CFC and GM-CFC cultures suggested that it may 
contain lL-3 as one of its exponents,
A svries of experiments were undertaken to confirm this.
4(2.1.1) The effect of SA2cm on the proliferation of 
IL-3 factor dependent cell lines
Cell lines were available (A4 and C2GM) whose proliferation 
was dependent on the presence of lL-3. It had been shown that 
SA2cm supported the proliferation of these factor dependent 
cell ltev/. This work set out to determine the molecular weight 
band in which the signal was contained .
4(2.1.1.1) PROCEDURE
Concentration and filtration of SA2cm conditioned media
It was nvcvssary initially to filter and concentrate the 
SA2cfndtttonvd medium. Centricon microconcentrators with a 
lOKD molecular weight cut off were used 2(1.4.1.1).
SA2JMB1 conditioned medium 2J 2
FDCP-A4 cells (See 2) were cultured in limited volume liquid 
suspension culture in the presence or absence of fractions of 
SA2cm, F10% or WEHI cm at a range of concentrations. A4 
cellularity was determined as in 2.(1.3.4) and adjusted to 5 x 
106cells/ml in F10%. A 96 well mkrrotttre plate was prepared 
and in a standard thymidine uptake aasay foo A4 cells 2() both 
fractions of SA2cm were tested at concentrations of 50%v/v, 
25%v/v, 12.5%v/v, 6.25%v/v and 3.125%v/v. F10% was tested 
at identical concentrations. WEHIcm was tested at 10%v/v, 
5%v/v, 2.5%v/v, 1.25%v/v and 0,75%v/v • Plates were then 
placed in the incubator at 37°C with 5% CO2 in air and a fully 
humidified atmosphere for forty eight hours.
Protocol as outlined in 2 (2.1.5.3)-2(2.1.5.5.)
Two replicate experiments were performed.
4(2.1.1.2) RESULTS
Table 4R.5.1, Table 4R.5.2, Table 4R.5.3 and figures G4.7, G4.8 
show the results for the effect of SA2cm, F10% and WEHlcm on 
the uptake of tritiated thymidine by FDCP-A4 cells.
Table 4R.5.1 shows that there is a significant increase in the 
mean thymidine uptake in wells supplemented with 3.125 or 
6.25 %v/v SA2cm<10KD; P<0.05 in both cases .At 
concentrations of 12.5, 25 or 50%v/v no comparable increase in 
thymidine uptake is observed; P>0.05.
For the fraction of SA2cm>10KD, there is a significant increase 
in the mean thymidine uptake in wells supplemented with all 
concentrations of SA2cm (P<0.05) except those wells 
supplemented with 50%v/v SA2cm> lOKD ( P>0.05). The
SA2JMB1 conditioned medium 2 10
magnitude of the increase in thymidine uptake is notable. At a 
concentration of 25%V/V SA2cm>10KD the uptake was over 
three hundred times that which was seen in the control.
Table 4R.5.2 shows that there is a significant increase in the 
mean thymidine uptake in wells supplemented with 3.125, 
6.25 and 50%v/v F10%V/V (P<0.05 in all cases) .At
concentrations of 12.5 or 25%v/v no comparable increase is 
observed P>0.05. Importantly the change in the level of 
thymidine uptake is not large and, alone, could not explain the 
substantially larger increase seen in Table 4R.5.1 for 
SA2cm>10KD.
Thus SA2cm >10KD significantly increased the level of 
thymidine uptake by A4 cells in a way that F10% or 
SA2cm<10KD did not. This is illustrated in Figure G4.7.
Table 4R.5.3 and figure G4.8 show that WEHIcm increases the 
level of thymidine uptake in a titratable manner. There is a 
statistically significant increase in thymidine uptake with all 
concentrations of WEHIcm as compared to the control. (P<0.05 
in all cases). The level of thymidine uptake is far greater in the 
oresvncv of WEHIcm than in the presence of SA2cm>10KD. 
(25%V/V SA2cm>10KD mean thymidine uptake 4855.0±293.8 
cpm / 10% WEHIcm mean thymidine uptake
10479.3±21 lVcpm). Thus WEHIcm was a richer source of a 
factor able to induce A4 cell prfltfvrattoe than SA2cm >10KD.
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TABLE 4R.5.1: The effect of Fractions of SA2cm on the 
proliferation of FDCP-A4 cells.
CONCENTRATION LARGE FRACTION 
(>10KD)
SMALL FRACTION 
(<10KD)SA2CM (%V/V)
MEAN UPTAKE (CPM)
THYMIDINE
50 968.1+642.5 40.2 + 10.5
0.1<P<0.375 0.05P<0.1
1610.63 29.71
325.54 50.77
25 4855.0+293.8 43.5 + 15.2
0.0025<P<0.005 0.1<P<0.375
5148.87 28.23
4561.18 58.70
12.5 4929.5+86.4 43.2 + 15.5
P<0.0005 0.1<P<0.375
5015.81 27.78
4843.06 58.72
6.25 59.7+8.4 57.6 + 9.7
0.01<P<0.025 0.025<P<0.05
68.03 47.90
51.32 67.37
3.125 58.3+5.5 45.7+2.1
0.01 <P<0.025 P<0.005
63.89 47.84
52.80 43.59
0 16.2 + 3.7 16.8 + 0.7
12.48 17.51
19.92 16.15
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TABLE 4R.5.2: The effect of F10% on the proliferation of 
FDCP-A4 cells.
CONCENTRATION F10%
(% V/V)
MEAN THYMIDINE UPTAKE (CPM)
50 53.3±6.3
0.005<P<0.01 j
59.59 i
46.93
25 43.5 ± 15.5
0.05<P<0.1
28.23
58.70
12.5 43.2 ± 15.5
0.05<P<0.1
27.78
58.72 !
6.25 57.6 ± 9.7
0.01<P<0.025
47.90
67.37
3.125 45.7 ± 2.1
0.0005<P<0.005
47.80
43.59
0 1 00
0.0
0.0
THE EFFECT OF VARYING INCUBATION
REGIMES ON THE PROLIFERATION OF
FIGURE G4.7: Mean thymidine uptake (CPM) by FDCP-A4 cells in the 
presence of varying concentrations of SA2cm fractions.
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TABLE 4R.5.3: The effect of WEHIcm on the proliferation of 
FDCP-A4 cells.
CONCENTRATION WEHICM 
(% V/V)
MEAN THYMIDINE UPTAKE (CPM)
1 0 10479.3±211 .7
P<0.0005
10691.04
10267.61
5 8745.5±521.4
P<0.005
9266.84
8224.06
2.5 6883.6±137.5
P<0.0005
6546.14
6821.04
1.25 5997.8+1421.3
0.01<P<0.025
7419.10
4576.50
0.75 3671 .3±1 52.1
P<0.0005
3823.47
3519.18
0 1 6.8 + 0.5
17.33
16.33
THE_EFFECT. OF VARYING CONCENTRAT1ONS-OF
WEHI CM ON THE PROLIFERATION OF
FIGURE G4.8: Mean thymidine uptake (CPM) in the presence of 
varying concentrations of WEHIcm.
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4(2.3.)The effect of anti-murine IL-3 neutralising 
antibody on the colony promoting activity of SA2cm
Work was undertaken to determine whether the IL-3 like 
activity responsible for proliferation within the IL-3 dependent 
cell line was also the activity responsible for the altered 
pattern of colony formation seen in colony assays. This was 
accomplished by pre-incubating SA2cm with anti-murine IL-3 
antibodies. It could then be assayed for its colony enhancing 
ability in GM-CFC and HPP-CFC cultures.
4(2.1.3.1)PROCEDURE
Initially SA2cm was pre-treated with Goat anti-Murine IL-3 as 
outlined in .
Assays for HPP-CFC stimulated with GM-CSF+L929cm(a source 
of M-CSF) and HPP-CFC stimulated with IL-la + L929cm ,were 
carried out. For each condition three replicate sets of plates 
were prepared one set of which was supplemented with pre­
treated SA2cm, another with normal SA2cm and a control 
withF10% only.
Four replicate experiments were performed .
4(2.3.2) RESULTS
Table 4R.6 and figures 4G.9a and 4G.9b show the effect of 
pretreating SA2cm with antiIL3 on the colony enhancing
activity of SA2cm in HPP-CFC cultures.
In the case of HPP-CFC populations stimulated with
L929cm+GM-CSF or IL-la +L929cm there was a significant
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increase in the level of colony formation when cultures were 
supplemented with 10%v/v SA2cm. (P<0.05 in both cases).
No comparable increase in colony formation is observed in 
L929+GM-CSF cultures supplemted with 10%v/v SA2cm which 
had been pre-treated with anti-IL-3 (Control 100 % / 10% V/V 
SA2cm pre-treated with anti-IL-3 110.0%±14.1 where P>0.05 ) 
In the case of IL-I-a + L929cm cultures supplemented with 
SA2cm pre-treated with anti-IL-3 there is an increase in the 
level of colony fomation ( Control 100% / 10% SA2cm pre­
treated with anti-body 112.0% ±5.80 where 0.025<p<0.05). This 
increase is however much less than that seen in culture 
supplemented with SA2cm not pre-treated with antibody. 
(10% V/V SA2cm not pre-treated 217.5 ±4.9 / 10% V/V SA2cm 
pre-treated 112.0+5.8).
Thus in one instance the pre-treatmentt of SA2cm with anti­
body blocks the colony enhancing activity of SA2cm. In the 
second instance it significantly reduces it. Photographs of 
colonies formed in the presence of normal SA2cm or SA2cm 
pre-treated with anti-IL-3 are shown in figure PH2.
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TABLE 4R.6: The effect of IL-3 antibodies on the synergistic 
activity of SA2cm on 14 day HPP-CFC NBM semi-solid agar 
cultures.
CONDITION CONTROL SN2CM
(10%V/V)
SN2pretreated
with antibody
(10%v/v)
FACTORS COLONY FORMATION (%o/controI)
(HPP-CFC)
L929 + GM-CFC 100.0 219.3+27.6 110.0+14.1
0.005<p<0.005 0.1<p<0.375
11.75+1.00 23.50+1.80 13.50+1.55
10.25+1.00 16.75+2.50 13.25+1.25
9.75+1.25 21.25+1.00 12.50+1.26
9.00+1.58 26.25+3.25 6.25+1.38
IL-1 a + L929 100.0 217.5+4.9 112.0+5.8
p<0.0005 0.025<p<0.05
9.00+1.96 19.75+1.25 11.25+2.17
8.25+0.5 18.25+2.25 9.50+3.00
8.75+131 19.50+2.10 8.50+1.00
9.00+1 18.75+1.00 10.00+1.00
N=4 in all cases
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FIGURE G4.9a: Colony formation (expressed as a percentage 
of the control 0% V/V SA2cm) in 14 day semi-solid agar
cultures of NBM stimulated with GM-CSF+L929 in the presence 
or absence of SA2cm ± anti-IL-3 antibodies.
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FIGURE G4.9b: Colony formation (expressed as apercebtrge of 
the control 0% V/V SA2cm ) in 14 day semi-solid agar cultures 
of NBm stimulated with IL-Ia+L929 in the presence or absence 
of SA2cm ± anti-IL-3 antibodies.
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FIGURE PH2 : The effect of SA2cm on the colony formation 
seen in assays stimulated with varying growth factor regimes
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4.2.4 ACTIVITY INTERFERING WITH THE ACTION OF 
STIMULATOR
It had been dvmfe/trated that SA2cm blocked the action of a
stem cell stimulator. However the identity of this activity was
unknown.
A series of experiments was carried out in which fractions of 
SA2cm or other factors which could be the active component of 
SA2cm, were assayed in attempts to match the action of whole 
SA2cm in blocking stimulator.
4(2.4.1) PROCEDURE
In all cases these experiments were modifications of the 
protocol laid out in 4(1.4). The HPP-CFC population examined 
was always that stimulated to colony formation by WEHI/L929. 
The test conditions used are outlined in the table below:
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EXPERIMENT CONDITION
N (Normal)
1 NS (Normal +Stlmulator)
NSSa(Normal + stimulator
+20%v/v SA2cm)
NSIL-3 (Normal + stimulator +
80U/ml IL-3)
NSW(Normal + stimulator
+10%V/VWEHI cm)
NSSas(Normal + Stimulator
+SA2cm fraction < 10KD 20%v/v)
NSSal(Normal +Stimulator
+SA2cm fraction >10KD 20%»v/v)
N (As above)
NS(As above)
NSSa(As above) !
2 NSSas(Normal +Stimulator
+SA2cm fraction <50KD 20°%v/v)
NSSal(Normal +Stimulator
+SA2cm fraction >50KD 20°%v/v)
NSSaH (Normal --Stimulator
-■heat treated (+80°C ) SA2cm 20o%v/v )
NSM (Normal + stimulator j
+MIP-1-a 300 nq/ml)
TABLE 4.3; Summary of the conditions used to assay action of 
factors on a stem cell stimulator.
SA2JMB1 conditioned medium £12
For group 1 factors three replicate experiments were carried 
out. For group two factors six replicate experiments were 
carried out.
4(2.4.2) RESULTS
Table 4R.6.1 and figure G4.10 show the effect of exogenous 
factors in group 1 on the action of a stem cell stimulator.
There is a significant increase in the proportion of HPP- 
CFC(WEHI/L929) in S-phase in the presence of a stem cell 
stimulator as compared to the control. (Control 7.37%±4.57 I In 
the presence of stimulator 22.36% ± 2.26 where P<0.05 ) .
In the presence of 20%V/V SA2cm stimulator fails to induce a 
significant increase in the level of HPP-CFC DNA synthesis as 
compared to the control. ( 20% V/V SA2 5.82% ±6.52 where 
P>0.4). Thus SA2cm at this concentration prevents the action of 
stimulator on this cell population.
Similarly addition of stimulator to cells in the presence of. the 
fraction of SA2cm larger than IQKD fails to increase the level 
of DNA synthesis as compared to controls. ( 8.34%± 8.08 where 
P>0.4).
All other test factors fail to inhibit the action of a stem cell 
stimulator with the proportion of the cell population in DNA
synthesis raised in all instances. There is thus a significant 
increase in the level of DNA synthesis as compared to the 
control .(P<0.05 in all cases).
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In this first set of test conditions only 20%V/V SA2cm or 
20%V/V SA2cm > lOKD were able to alter the action of a stem 
cell stimulator.
Table 4R.6.2 and figure G4.11 show the effect of exogenous 
factors on the action of a stem cell stimulator. There is a 
significant increase in the proportion of HPP-CFC(WEHI/L929) 
in S-phase in the presence of a stem cell stimulator. (Control 
13.08 %±4.13 / In the presence of stimulator 24.77%±4.10 
where P<0.05 ) .The addition of stimulator in the presence of 
20%v/v SA2cm failed to increase the level of DNA synthesis as 
compared to the control (7.51% ±3.31 where P>0.05). Thus 
20%V/V SA2cm is able to inhibit the action of a stem cell 
stimulator on this population.
The addition of MIP-l-a, 20%V/V heat treated SA2cm or the 
fraction of SA2cm smaller than 50KD cannot mimic this 
response. There is a statistically significant increase in the level 
of DNA synthesis as compared to the control in all cases. 
(P<0.05 )
Treatment of cultures with stimulator in the presence of the 
fraction of SA2cm greater than 50KD failed to increase the level 
of DNA synthesis seen as compared to the control. (9.49%±4.05 
where P>0.05).
Thus whole SA2cm and a fraction of SA2cm larger than 50KD at 
concentrations of 20%V/V are able to inhibit the action of a 
stem cell stimulator on this cell population. The other activities 
assayed fail to mimic this response.
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TABLE 4R.6.1; The effect of a variety of factors on the action 
of a stem cell stimulator.
CONDITION PROPORTION HPP-CFC IN 
S-PHASE(%)
±STANDARD ERROR
N (Normal)
7.37+4.57
14.52
-1.14
8.73
NS (Normal +Stimulator)
22.36±2.26
0.01<p<0.05
25.00
17.86
24.22
NSSa(Normal + stimulator
5.82±6.52
P>0.4
+20%v/v SA2cm) 13.87
-7.08
10.67
NSIL-3 (Normal + stimulator +
18.25 + 6.81
0.1<P<0.375
80U/ml IL-3) 31.87
11.76
11.11
NSW(Normal + stimulator
24.01±8.75
0.05<P<0.1
+10%V/A WEHIcm) 29.55
6.86
35.63
NSSas(Normal + Stimulator
26.61±4.87
0.01<P<0.025
+SA2cm fraction < 10KD 20%v/v) 23.97
19.82
36.05
NSSal(Normal +Stimulator
8.34+8.08
P>0.4
+SA2cm fraction >10KD 20%v/v) 24.32 
-1.67
2.36
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TABLE 4R.6.2: The effect of SA2cm or SA2cm fractions(<or 
>50KD) or heat treated SA2cm or MIP-1-a on the action of a stem cell 
stimulator.
CONDITION PROPORTION 
S-PHASE(%) 
± STANDARD
HPP-CFC
ERROR
13.08 + 4.13
N (As above) 16.33
14.49
26.61
13.08
-4.72
12.72
24.77+4.10
NS(As above) 0.025<P<0.05
33
29.92
26.43
15.97
12.15
37.16
7.51±3.13
NSSa(As above) 0.1<P<0.375
11.34
7.59
20.18
5.74 
-1 .69
1.92
NSSas(Normal +StimuIator
+SA2cm fraction <50KD 20%v/v)
18.91+4.48
0.005<P<0.01
30.21
12.33
29.51
22.58
1.52
17.33
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9.49+4.05
NSSal(Normal +Stimulator 0.1<P<0.375
+SA2cm fraction >50KD 20%v/v) 13.64
16.54
22.11
5.43
-5.56
4.76
NSSaH (Normal +Stimulator
28.03±3.00
0.1<P<0.375
+heat treated (+80°C ) SA2cm 20%v/v ) 35.04
28.57
29.85
19.00
19.59
36.11
NSM (Normal 4- stimulator
18.79±3.13
0.1<P<0.375
+MIP-1-a300 ng/ml) 27.76
25.61
21.21
20.62 
-6.06
23.60
In all cases N=6
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FIGURE G4.11: The proportion HPP-CFC(WEHI/L929) from 
NBM in S-phase(%) after eretreatmebtt with a stem cell 
stimulator in the presence or absence of various factors.
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4D: DISCUSSION
4D1: The effect of SA2cm on colony formation in semi­
solid agar culture by a variety of NBM cell populations
The pattern of colony formation resulting from the addition of 
varying concentrations of SA2cm to LPP-CFC populations is 
complex. Alone it has limited colony stimulating ability in 7 
day cultures. At concentrations of 20%v/v it is able to support 
proliferation of progenitor cells. In the case of GM-CFC 
stimulated with GM-CSF or L929cm there is a statistically 
significant increase in the level of colony formation with 2, 5,
10 and 20% SA2cm. The first striking point about this increase 
is that it is large and apparently titratable (For GM-CSF, control 
100%, against 2% SA2cm 134%± 8.8 and 20% SA2cm 220.7+41).
A similar increase is seen with L929cm (M-CSF). Thus SA2cm 
contains an activity which is significantly enhancing colony 
formation, presumably by synergistic interaction, with these 
factors. Interestingly in the case of WEHIcm ( lL-3) stimulated 
colony formation, there is no statistically significant increase in 
colony formation as compared to controls. Where recombinant 
lL-3 has been used there is a statistically significant increase 
only with 20% SA2cm ( Control 100%, against 138%±9.6). Also 
this increase in the level of colony formation is not as large as 
that seen for GM-CSF or L929 cm. Thus in this case SA2cm 
contains an activity which has been only slightly effective in 
increasing the level of colony formation as compared to 
controls. As both of these particular assays were stimulated
SA2JMB1 conditioned medium
with IL-3 then the assumption was that SA2cm may itself 
contain IL-3, or an IL-3 like activity, or an activity which did 
not synergise with lL-3. The result in which 20% SA2cm 
enhanced the level of lL-3 stimulated colony formation was 
confusing. It could be explained if the activity did not synergise 
with lL-3 or if the recombinant lL-3 used to stimulate assays 
was in fact at sub-optimal levels. Thus at 20%V/V, the SA2cm 
supplied sufficient lL-3 to optimise levels. The fact that 
recombinant lL-3 had been titrated prior to assay and 8OU 
shown to be maximally stimulatory, should discount this 
possibility. If this particular activity were actually some other 
factor present at low levels but nevertheless at sufficient 
concentration in 20%V/V to be synergistic with lL-3 then this 
may explain the result. This is not an unlikely scenario, 
consider the multi-factorial nature of conditioned medium such 
as WEHIcm. Although largely a source of lL-3 it undoubtedly 
contains other factors which "improve " the colony formation 
seen as compared to that seen with lL-3 alone. SA2cm could in 
addition to lL-3 or an lL-3 like activity also contain an activity 
which improves colony formation in conjunction with lL-3. 
Interestingly there is no increase in the level of colony 
formation with WEHI cm. Is such a secondary activity present 
in this SA2cm. ? The fact that GM-CSF and L929 are both 
synergistic with low levels of this cm would seem to suggest 
that if it is, it is likely to be independent of the lL-3 like 
activity.
HPP-CFC
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The pattern of colony formation resulting from these cultures 
appears to support the assumptions made above. In cultures 
stimulated with GM-CSF+M-CSF or IL-l+M-CSF there is a 
statistically significant increase in the level of colony formation 
in the presence of SA2cm as compared to controls. Notably this 
is a large increase. With 20% SA2cm it is almost double the 
level seen in the control. (For IL-l+M-CSF control: 100%, against 
20%SA2cm: 213%±33.58). Where lL-3 is present in cultures
(IL-3+M-CSF or IL-1+IL-3+M-CSF ) in some cases there is an 
increase in the level of colony formation, however, it is not 
large. (For 1L-3+M-CSF control :100%, against 20%SA2cm: 
104.33%±1.33; For 1L-1+1L-3+M-CSF control :100%, against 
20% SA2cm: 119%±7.94). The arguments used to explain the 
pattern of colony formation seen in GM-CFC cultures would 
thus also seem to apply here. The cultures which lack lL-3 may 
be receiving it from SA2cm and as a consequence actually 
stimulating more primitive HPP-CFC populations to colony 
formation. Those cultures already stimulated with lL-3 may be 
receiving some secondary factor from SA2cm. Notably where 
cultures were stimulated with WEHlcm+L929cm (essentially 
lL-3 +M-CSF +ubkbfwb factors ) there is no alteration in the 
level of colony formation as compared to controls.
4D2: The effect of SA2cm on DNA. synthesis in various 
NBM derived cell populations.
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This assay was essentially an assay of the manner in which a
Leukaemic conditioned medium might perturb normal
haematopoiesis. Could factors associated with this particular
leukaemia directly interact with cells to alter their cell cycle 
status ?
SA2cm has not significantly altered the level of cycling in 
normal GM-CFC (WEHIcm), HPP-CFC (WEHlcm+L929cm) or 
cycling HPP-CFC (WEHlcm+L929cm). It has thus not acted as a 
direct inhibitor or stimulator of DNA synthesis in these 
populations. In addressing the significance of this finding a 
number of points are worth considering. Firstly two major 
bodies of work on inhibitory activities associated with 
leukaemias.
The first of these " leukaemia associated inhibitory activity" 
(LIA) was identified as an S-phase specific inhibitory activity 
against normal GM-CFC (Broxmeyer et al, 1978; Bognacki et al, 
1981; Broxmeyer et al 1981). It was produced by bone marrow 
spleen and blood cells from patients with acute and chronic 
myeloid leukaemia. Importantly this activity was not detected 
in normal patients and at significantly reduced levels in 
remission cases. (Broxmeyer et al, 1979). With molecular 
weight originally localised to 55KD. It has subsequently been 
reported to be monocyte-macrophage derived acidic isoferritin 
(Broxmeyer et al, 1981; Broxmeyer et a I, 1982). Ferritin is a 
large molecule in the molecular weight range of 55KD which 
can be separated into isoforms differing in charge and size. 
Acidic isoferratins are thought to be composed mainly of so 
called H sub-units. Having identified LIA as acidic isoferratin it
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was shown that it could be detected in normal bone marrow 
and blood cells belonging only to the mononucleur phagocytic 
lineage. This suggests that they may have a role to play in 
normal GM-CFC proliferation regulation. (Broxmeyer et al, 
1982; Broxmeyer et al, 1983) LTBMC cultures were also shown 
to endogenously produce acidic isoferritin (Oblonet et al, 1983). 
Lilu et al (1983 ) also implicate acidic isoferratin in the 
negative proliferation of BFU-E and GEMM-CFC interestingly 
noting that purified acidic isoferratin is active where LIA is not 
. Does this suggest that in some way LIA is a slightly modified 
acidic isoferratin ? Sala et al (1986) could not demonstrate a 
role for acidic isoferritins as a regulator of GM-CFC in vitro in 
mice. Broxmeyer et al (1989) demonstrated that in vivo in mice 
recombinant human H-subunit isoferratin decreased cycling 
rates and absolute numbers of haematopoietic progenitors 
(GM-CFC, BFU-E and GEMM-CFC).
A second inhibitory activity " leukaemia associated inhibitor" 
(LAI) has also been shown to suppress normal granulopoiesis 
in vitro. (Olofsson and Olsson, 1980a; Olofsson and Olsson, 1980 
b; Olofsson and Olsson 1980 c; Olofsson and Sallerfors, 1987). It 
is produced by human acute or chronic myeloid Leukaemic 
cells and the human promyelocytic cell line HL60 (Oloffson and 
Olsson, 1980a). Normal cells failed to produce detectable levels. 
It has been identified as a heat stable glycoprotien with 
apparent molecular weight of 500KD but with biological 
activity residing in a sub-unit of 150-170KD. It reversibly 
inhibits the normal cycling of human GM-CFC stimulated to 
colony formation with 10% human placenta conditioned
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medium as a source of growth factor. Leukaemic cells are 
insensitive to this regulation. (Olofsson and Olsson, 1980b). As 
with LIA, it has seemed likely that LAI may in fact be 
produced in normal haematopoietic tissue with a potential role 
in the regulation of normal granulopoiesis. (Olofsson et al, 
1984). This was largely due to the fact that LAI producer cells 
-characterised as non-phagocytic, non-adherent, non T, non B, 
Fc receptor +ve cells were found within the non-phagocytic 
Fc+ve compartment of nofmal ceUs. Impoflantry they are 
different cells to those producing LIA (Olofsson et al, 1984).
It is conceivably that both of these inhibitory activities 
represent normal inhibitors, possibly with subtly different 
roles, locally active and subject to degradation out with that 
environment. In leukaemia they may be over produced, 
perhaps in some slightly modified manner.
In this work no granulopoiesis inhibiting effect is observed. 
There are potentially a number of explanations for this. Firstly 
there are differences between the protocols used here and 
those used in the work of the groups discussed above. 
Specifically these relate to the killing agent and the factors 
used to stimulate colony formation. The former of these should 
certainly be discountable as ARA-C is a routinely used killing 
agent. The possibility that the populations being assayed are 
slightly different should certainly not be dismissed. However 
the ability of LIA to inhibit a broad spectrum of progenitor • cell 
populations suggests that such an activity should be seen in 
these cultures. It may be that although these factors represent 
one manner in which a Leukaemic cell population may
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manifest its proliferative advantage there may well be others. 
The fact that SA2cm can actually enhance colony formation 
within certain GM-CFC cell cultures is strongly supportive of
this notion.
LAI and LIA remain untested on the more primitive HPP 
populations. However SA2cm has no direct effect on the level 
of cell cycling in a population of HPP cells. On this basis it can 
be assumed that SA2cm does not manifest its inhibitory 
activity by production of some of the known inhibitors 
discussed in the introduction. For example MIP-l-a, which is 
known to be active in the inhibition of CFU-A cycling. As 
discussed HPP and CFU-A are thought to closely related and 
thus it would seem that MIP-l-a is not the relevant activity 
unless it is complexed and thus inactive in vitro. TGF-p, a 
highly conserved plieotrophic protein known to promote a 
three to five fold increase in the number and size of GM-CFC 
colonies, initially seems a potential candidate. (Keller et al, 
1990). However TGF-p is known to be a direct inhibitor of 
primitive haematopoietic cells similar in action to MIP-l-a. 
(Maltman et al, 1993; Bradley et al, 1991; Hampson et al, 1990; 
Migdalska et al, 1990). The pentapeptide pEEDCK is another 
haematopietic inhibitory activity. Oxidation of the cysteine thiol 
groups within pEEDCK leads to the formation of a disulphide 
bridged homodimer (pEEDCK2) which is a stimulator of in vitro 
and in vivo haematopoiesis (Paukovits et al 1991). pEEDCK has 
been shown to prevent the post chemotherapy proliferation of 
haematopoiesis stem cells CFU-S (Paukovits et al 1990) and 
thus to prevent the recruitment of CFU-S. This may seem a
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good candidate for a potential inhibitory activity however it is 
noted not only to be an active inhibitor of CFU-S but also GM- 
CFC. This would seem to rule out this particular factor. As 
outlined in discussions on LIF the assay system used in this 
thesis is limited in that only 1 population is studied. As 
discussed for LIA and LAI it is conceivably that inhibitors may 
act to regulate subtly different cell populations. It may be that 
any inhibitory activity is missed in this aasay ss^ste^e^.
This Leukaemic cell conditioned medium was not acting via 
known inhibitory molecules which have a direct action on the 
cycling of stem or progenitor cells. Could it work like AcSDKP? 
Could it be AcSDKP?
4D3: The interaction of SA2cm with a stem cell
s t i m u lato r
20%V/V SA2cm blocks the action of a stem cell stimulator on a 
population of HPP-CFC. This is an extremely important finding 
for a number of reasons. Firstly it confirms the finding that 
SA2cm does not manifest Leukaemic suppression via any of the 
agents discussed above. Secondly it initially opens up the 
possibility that the inhibitory activity may be AcSDKP. This 
seems unlikely however as AcSDKP is noted to inhibit the i n 
vitro growth of human progenitor cells (GM-CFC/BFU-E and 
CFU-E (Anagnostou et al 1991). SA2cm is clearly not inhibitory 
for GM-CFC. This finding also indicates that the conditioned 
medium contains both an inhibitory and a stimulatory activity. 
The question which immediately springs to mind is "are they
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the same activity?". This is certainly possible. Consider pEEDCK 
and the action of IL-lb on human LTBMC (Marley et al 1992). 
Only with identification of these activities will it be possible to 
answer this question. Similarly the precise action of the 
inhibitory activity is unknown. Does it block receptors ? Does it 
degrade stimulator ? Does it interfere with gene transcription 
following stimulator activation of cells ? Identification of the 
activity/iss would help to resolve these questions.
The fact that this activity appears to be different from any of 
the other inhibitory activities outlined suggests that it is either 
a new activity or an activity such as AcSDKP expressing only 
part of its inhibitory potential.
4D4: SA2cm as a source of IL-3
SA2cm appears to have a colony stimulating activity very like 
that of IL-3. The above studies provide indirect evidence in 
support of this. Initially the observation that IL-3 could 
support the proliferation of an IL-3 dependent cell line seemed 
strongly indicative of the presence of IL-3 in the medium. By 
filtering the medium such that small molecules could be 
removed from it (or substantially diluted ) it seems clear that 
this activity is localised to a fraction > lOKD. (25% SA2cm 
>10KD: 32073cpm±9167, against, 25%SA2cm < lOKD:
262cpm±101). The molecular weight of IL-3 is 28KD with 
possible variation due to the level of glycosylation (Farrar et al 
1989). It can stimulate the proliferation and differentiation of 
pluripotent haematopoietic stem cells as well as progenitor
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cells (Miyjima et al 1993). Coupled with the antibody studies it 
seems likely that IL-3 is present in the SA2cm and more-over 
is the activity responsible for the stimulation of colony 
formation seen in these cultures. Could IL-3 be the factor 
responsible for Inhibition ? There appears to be no precedent 
for such a possibility given that the inhibition is not 
attributable to toxicity.
4D5: SA2cm as a source of a stem cell inhibitor.
In the first series of these experiments it is clear that whole 
SA2cm blocks the action of a stem cell stimulator. The fraction 
of SA2cm larger than lOKD is similarly inhibitory whilst the 
fraction lower than lOKD fails to block the initiation of DNA 
synthesis. This suggests that the inhibitory activity is larger 
than lOKD or a smaller molecule at such a high concentration 
that even following significant dilution it is still a potent 
inhibitory molecule. The results for IL-3 and WEHIcm are less 
conclusive. Clearly they do not inhibit to the same extent as 
either whole SA2cm or SA2cm > lOKD. The results however do 
show that they significantly alter the action of the stimulator. 
The explanation for this finding is elusive. Firstly the degree of 
inhibition seen for WEHIcm and IL-3, different to that seen for 
SA2cm, could reflect the action of a molecule present at lower 
concentrations in WEHIcm. However where WEHIcm could 
possibly contain some inhibitory component it seems unlikely 
that recombinant IL-3 is a stem cell inhibitor. Not least because 
colony assay studies above show that IL-3 is at lower
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concentrations in SA2cm. Conclusive proof implicating IL-3 as
an inhibitory activity in this assay system would come if 
SA2cm were pre-treated with IL-3 antibodies and this medium 
then subsequently used to block the action of a stimulator.
The second test block in which the inhibitory activity is clearly 
demonstrated not to be heat stable supports the notion that the 
activity is attributable to a protein. The finding that the 
activity appears to reside in a fraction >50KD however suggests 
that it is unlikely to be IL-3 (Although this is a crude estimate 
of molecular weight and it is worth noting that in the early 
stages of molecular identification molecular weight is over­
estimated ). This later work confirms that the activity is not 
MIP-l-a which failed to block the action of a stem cell 
stimulator in these assays.
To resolve these problems a comprehensive identification
strategy would have to be undertaken.
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CONCLUSIONS: SA2JMB1 CM
The murine myeloid Leukaemic cell line SA2JMB1 can be used 
to generate a conditioned medium which has various
properties. Firstly this medium has limited colony stimulating 
abilities in 7 day semi-solid agar culture of NBM derived 
haematopoietic cells. In association with other factors it has a 
significant synergistic action with respect to the promotion of 
colony formation. Notably where IL-3 is present in cultures 
this synergistic activity is significantly reduced. Studies to 
determine the nature of this activity strongly suggest that it 
may be IL-3 as the activity was lost in cultures pre-treated 
with IL-3 antibodies. It is thus reasonable to conclude that 
SA2cm contains an activity which has functional similarities to 
IL-3. At least one of these functions can be inhibited by 
antibodies to IL-3.
A second activity blocks the action of a stem cell stimulator on 
a population of HPP-CFC. The nature of this activity has not 
been determined but it seems susceptible to heat treatmentt, 
larger than 50KD and thus probably independent of the activity 
synergising to enhance the level of colony formation. Several of 
the known inhibitory activities have been compared to this 
activity and it seems reasonable to conclude that this is a new 
activity .Identification of this adiiriiy would require a 
comprehensive identification protocol. Such a strategy could 
entail:
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lysis of Leukaemic cells, concentration of lysate and production 
of fractions using either centricon microconcentrators or
sephadex beads;
assay of concentrated fractions for stimulator blocking activity ; 
active fractions assayed for affinity for Concanavilin A 
sepharose, susceptibility to periodate treatmentt, protease 
digestion and resistance to heating ;
active fractions run on SDS-polyacrylamide gel electrophoresis., 
subsequent quantification of protein levels present in bands, 
and assay for the presence of lysate.
From the work in this thesis it is possible to speculate as to 
how this particular leukaemia may interact with normal 
haematopoiesis.
The leukaemia could actually be peomofinb the proliferation of 
white blood cells through the IL-3 tike activity. Howevee as the 
proliferation of more primitive cells is signalled to reconstitute 
decreased levels of more mature cells, the inhibitory activity 
prevents their proliferation. The balance of hematopoiesis is 
perturbed. Meanwhile the Leukaemic cells gain a proliferative 
advantage proliferating unchecked, filling the marrow with 
useless blasts .(Diagram 21)
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